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ABSTRACT 
Sally K. Head 
THE EFFECT OF OMEGA-3 FATTY ACIDS ON AIRWAY INFLAMMATION, 
HYPERPNEA-INDUCED BRONCHOCONSTRICTION, AND AIRWAY SMOOTH 
MUSCLE CONTRACTILITY IN ASTHMA 
Asthma, a chronic inflammatory disease of the airways, affects nearly 25 million 
Americans.  The vast majority of these patients suffer from exercise-induced 
bronchoconstriction (EIB), a complication of asthma.  Although traditionally treated 
pharmacologically, nutritional strategies provide a promising alternative for managing 
EIB as the prevalence of asthma may be due in part to changes in diet.   
Our objective was to determine the effects of novel nutritional strategies on 
hyperpnea-induced bronchoconstriction (HIB) in asthmatic individuals.  HIB uses rapid 
breathing to identify EIB in a research or clinical setting.  Fish oil, a combination of the 
omega-3 fatty acids eicosapentaenoic acid (EPA) and docsahexaenoic acid (DHA), has 
been shown to be effective in suppressing EIB.  However, its use in combination with 
other nutritional supplements, the optimal fish oil formula, and its effect on smooth 
muscle contractility have not been fully explored. 
An in vivo study (study 1) was conducted in individuals with both asthma and HIB 
to determine whether a combination of fish oil and vitamin C was more effective than 
either one alone in alleviating HIB.  Pulmonary function was significantly improved with 
both fish oil and the combination treatment but not with vitamin C alone.  In study 2, 
individuals with both asthma and HIB were supplemented with DHA alone since the 
optimal formula for fish oil has yet to be ascertained; previous in vitro studies have 
suggested DHA may be the more potent omega-3 fatty acid in fish oil.  However, no 
significant changes in pulmonary function or airway inflammation were seen with DHA 
supplementation. 
v 
For study 3, canine airway smooth muscle tissue was treated with fish oil to 
determine the in vitro effect of fish oil on smooth muscle contractility.  Acute treatment 
with fish oil relaxed smooth muscle strips that had been contracted with acetylcholine or 
5-hydroxytryptamine.  These minor relaxations in smooth muscle tension with fish oil 
may represent significant changes at the level of the smaller airways. 
These studies have confirmed that fish oil represents a viable treatment modality 
for asthmatic individuals with EIB and suggest that fish oil may influence airway smooth 
muscle contractility. 
Timothy D. Mickleborough, Ph.D., Chair 
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CHAPTER 1 
INTRODUCTION 
Asthma  
   Epidemiology of Asthma 
  Asthma is a chronic inflammatory disease of the airways characterized by 
recurrent wheezing, breathlessness, chest tightness, and coughing (87). The hallmark 
features of asthma are airway inflammation, airway hyperresponsiveness, and airway 
narrowing (90).  In 2009, 24.6 million Americans reported having asthma with 60% of 
those 5-17 years of age missing at least one day of school and 34% of those over 18 
years of age missing at least one day of work due to asthma symptoms; this translated 
to 10.5 million missed school days and 14.2 missed work days (6).  Moreover, around 
6% in each of the above age groups reported being limited in their activity due to asthma 
symptoms (6).  In 2007, asthma was reportedly responsible for $19.7 billion in direct and 
indirect healthcare costs annually; this includes $6.2 billion spent on prescription drugs 
for treating asthma (1).  Since asthma is a multifaceted disease, patients often need 
multiple medications to optimally control their symptoms.  Combination therapies 
targeting the acute and chronic symptoms of asthma are increasingly prescribed since 
monotherapy is often inadequate (31).  Appropriate asthma treatment and management 
is thus an important issue due to the substantial burden asthma has placed on American 
society in terms of lost productivity and healthcare costs.   
   Airway Smooth Muscle Contractility 
 As airway narrowing and hyperresponsiveness are key features of asthma, 
airway smooth muscle contraction is an important mechanism.  Consequently, 
medications that relax airway smooth muscle and thus dilate the airways are among the 
most widely prescribed treatments for asthma.  These include long- and short-acting β2-
agonists, such as salmeterol and albuterol, respectively. 
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Smooth muscle contraction (figure 1-1) involves membrane depolarization with 
subsequent calcium release.  Calcium binds to calmodulin which activates myosin light 
chain kinase to phosphorylate myosin, the thick filament in muscle.  Phosphorylated 
myosin binds actin, the thin filament in muscle, to produce contraction.  Smooth muscle 
relaxation occurs with the reuptake of calcium and de-phosphorylation of myosin by 
myosin light chain phosphatase. 
 
Figure 1-1.  Mechanism of smooth muscle contraction.  Following cell membrane 
depolarization, the calcium (Ca2+) concentration increases.  Myosin light chain kinase 
(MLCK), whose activation depends on calcium, phosphorylates myosin.  This allows 
myosin to bind with actin to produce smooth muscle contraction.  Myosin light chain 
phosphatase (MLCP) dephosphorylates myosin to cause relaxation. 
 
Airway smooth muscle contractility has been shown to be dependent on the 
overlying epithelium.  Epithelial functions include creating a barrier between the airways 
and the external environment as well as secreting many factors (48).  Epithelial 
secretions include arachidonic acid metabolites involved in airway smooth muscle tone, 
mucus secretion, and inflammation (48).  Nitric oxide, growth factors involved in 
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respiratory tissue repair, and proinflammatory cytokines that recruit inflammatory cells to 
the airways are also released by the epithelium (48).  It has been shown in animal 
models that in vitro airway smooth muscle sensitivity to contractile agonists is increased 
with the epithelium removed (3, 15).  This is important to note as it is known that the 
epithelium is damaged or denuded in the airways of asthmatics (48).  Although it is thus 
likely that this contributes to airway hyperresponsiveness, it is still not clear whether the 
epithelial abnormalities are a cause or an effect of asthma (48). 
   Airway Inflammation 
  The other key feature of asthma is airway inflammation, which can occur acutely 
or chronically, and is the target for many other asthma medications.  In fact, guidelines 
for managing asthma tend to concentrate on treating airway inflammation (18).  Acute 
inflammation in asthma includes both an early and a late phase.  In the early phase, 
mast cells and macrophages in the airways are activated and release proinflammatory 
mediators such as histamine, leukotrienes, prostaglandins, and reactive oxygen species 
(18).  Six to nine hours later, the late phase begins as cytokines released by the mast 
cells in the early phase recruit eosinophils, basophils, neutrophils, and macrophages to 
the airways (18).  Chronic inflammation in asthma is characterized by activated T-cells, 
eosinophils, mast cells, macrophages, epithelial cells, fibroblasts, and bronchial smooth 
muscle cells in the airways (18).  The eosinophils in particular secrete proinflammatory 
mediators, cytotoxic mediators, and cytokines which cause many of the features of 
asthma, including mucus secretion, smooth muscle contraction, epithelial shedding, and 
airway hyperresponsiveness (18).  
  Various treatment strategies are used to treat the inflammation associated with 
asthma.  Since the symptoms of wheezing and shortness of breath result from acute 
inflammation, β2-agonists used to dilate the airways can also be used to treat the effects 
of acute inflammation (18).  Medications, such as cromolyn and nedocromil, that 
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stabilize mast cells to reduce their early phase secretions are also used to treat 
inflammation.  Medications that target the proinflammatory products are routinely 
prescribed as well.  These include enzyme inhibitors, such as zileuton, an inhibitor of 5-
lipoxygenase (the enzyme involved in leukotriene production), and leukotriene receptor 
antagonists, such as montelukast and zafirlukast. 
   Non-Invasive Markers of Airway Inflammation 
 Non-invasive methods of assessing the adequacy of disease management can 
be useful clinically.  In addition to changes in pulmonary function and symptoms, the 
degree of airway inflammation can demonstrate how effective a particular treatment 
regimen is (58).  Exhaled breath condensate and exhaled nitric oxide can each be 
measured non-invasively to assess airway inflammation in asthma.   
  Exhaled breath condensate (EBC) pH has been shown to be correlated with 
airway inflammation (93).  Asthmatics tend to have a lower EBC pH (19).  The acidic pH 
likely stems from neutrophil and eosinophil products, such as myeloperoxidase and 
eosinophil peroxidase, reacting with hydrogen peroxide upon their release to form acids 
and increase the concentration of hydrogen ions in the airways (19).  Markers in EBC 
can also be measured to evaluate airway inflammation.  These markers include 
inflammatory mediators as well as 8-isoprostane, a marker of oxidative stress (19).  8-
Isoprostane is produced by free radical oxidation of arachidonic acid; its concentration is 
increased in asthmatics reflecting increased levels of oxidative stress (67). 
 The fraction of exhaled nitric oxide (FENO) has been shown to be higher in 
asthmatics than in healthy individuals (78).  This is thought to be due to the elevated 
activation of inducible nitric oxide synthase (iNOS), whose expression can be increased 
by proinflammatory cytokines and oxidants (18, 58).  It has also been shown that FENO 
levels are increased in subjects with exercise-induced bronchoconstriction as compared 
to those without it (29). 
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Exercise-Induced Bronchoconstriction 
Exercise-induced bronchoconstriction (EIB) is a complication of asthma that 
affects 80-90% of people with asthma (87).  EIB is characterized by symptoms of 
wheezing, reduced exercise tolerance, chest pain, cough, stomachache, and sore throat 
occurring during or after exercise that lasts at least five minutes (87).  EIB is clinically 
diagnosed based on the change in the volume of air exhaled in the first second of a 
forced exhalation (FEV1) before and after exercise; it is specifically defined as at least a 
10% post-exercise drop in FEV1 (12).  EIB is important to consider as it can deter 
individuals with asthma from being physically active (43).  Moreover, EIB suggests that 
an individual’s asthma is not being adequately managed (49).  Consequently, EIB testing 
can be used to evaluate asthma therapies (49).    
   Pathophysiology of Exercise-Induced Bronchoconstriction 
Currently, there are two major schools of thought on the pathogenesis of EIB, the 
hyperosmolarity theory and the airway re-warming theory.  According to the 
hyperosmolarity theory, the airway surface liquid becomes hypertonic due to water loss 
during exercise; the ensuing hyperosmolar environment in the airway cells results in the 
release of proinflammatory mediators that cause bronchoconstriction (90).  Alternatively, 
the less widely accepted airway re-warming theory suggests that hyperventilation during 
exercise cools the airway surface cells such that their post-exercise re-warming causes 
the surrounding bronchiolar vessels to dilate; this leads to hyperemia with fluid exudation 
and proinflammatory mediator release, which subsequently causes bronchoconstriction 
(90).   
Bronchoprovocation Tests to Diagnose Exercise-Induced Bronchoconstriction 
   Exercise Testing 
 Exercise is the actual stimulus for EIB that individuals will encounter outside of 
the laboratory or doctor’s office.  However, the standard exercise protocol for diagnosing 
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EIB requires patients to breathe dry air while exercising for 6-8 minutes at 85-95% of 
their maximal heart rate (8).  Therefore, in addition to the need for large and expensive 
equipment, not all patients or subjects can complete an exercise protocol (8). 
  Sport-specific testing is a variation of exercise testing that is important for 
athletes who regularly perform at the standard exercise protocol level (55).  In this case, 
the testing protocol is based on the physical demands of a particular sport; however, by 
testing the athlete in his or her workout environment, the ambient conditions cannot be 
standardized, which may affect the test’s ability to reliably elicit bronchoconstriction (55).  
   Methacholine Challenge 
 Methacholine is a parasympathomimetic drug that causes bronchoconstriction 
(76).  This widely used method of bronchoprovocation involves the patient inhaling 
progressively increasing doses of aerosolized methacholine.  There are two different 
protocols wherein the patient is instructed to inhale the methacholine with either normal 
tidal volume breaths or deep inhalations (76).  The patient is deemed to exhibit bronchial 
hyperresponsiveness if the dose of methacholine that causes a 20% decline in FEV1 
from the pre-challenge value is less than 4.0 mg/ml (76).  Importantly, a negative test 
excludes asthma in a symptomatic patient (76); however, a positive test is not specific 
for asthma (8).  A large number of false positive tests have been reported in athletes 
(55).  Moreover, a negative methacholine challenge test does not exclude EIB (8).   
   Mannitol Challenge 
 Mannitol has only recently been approved by the Food and Drug Administration 
in the United States although it has been used regularly as a bronchoprovocation test in 
other countries (8).  A standardized mannitol test kit provides progressively increasing 
doses of mannitol in a dry-powder form for patients to inhale (55).  The osmotic gradient 
that subsequently develops across the airways leads to the release of inflammatory 
mediators that promote bronchoconstriction (8, 55).  The test is considered positive for 
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bronchial hyperresponsiveness if the patient demonstrates a 15% or greater decrease in 
his or her baseline FEV1 at a dose less than 635 mg; alternatively, the test is also 
considered positive if the patient exhibits a 10% or greater decrease in FEV1 between 
two consecutive doses of mannitol (10).  Unfortunately, the mannitol challenge test is no 
more sensitive than the methacholine challenge test for identifying EIB (11).   
   Eucapnic Voluntary Hyperventilation 
  In a research or clinical setting, EIB can be readily identified with a test involving 
hyperpnea, or rapid breathing (9). This test, known as eucapnic voluntary 
hyperventilation (EVH), requires subjects or patients to breathe cold, dry air at a high 
rate for six minutes (figure1-2) (9). The rate is approximately 85% of the individual’s 
maximal voluntary ventilation and is estimated by multiplying the FEV1 at rest by 30 (9). 
EVH is the bronchoprovocation strategy recommended by the International Olympic 
Committee to identify athletes with EIB (9).  It has been shown that changes in FEV1 
following EVH are comparable to those seen following cold air exercise (81). 
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Figure 1-2.  Eucapnic voluntary hyperventilation challenge.  Eucapnic voluntary 
hyperventilation (EVH) is a surrogate exercise challenge recommended by the 
International Olympic Committee for identifying exercise-induced bronchoconstriction. 
Subjects are asked to breathe at 85% of their maximal voluntary ventilation estimated by 
multiplying their FEV1 at rest by 30 (9). 
 
Pharmacotherapy for Exercise-Induced Bronchoconstriction 
  Several classes of medications are typically prescribed to prevent EIB.  In 
general, these drugs either target bronchoconstriction or airway inflammation.  To 
alleviate bronchoconstriction acutely or chronically, either short- or long-acting β2-
agonists are typically prescribed, respectively.  These agonists act at β2-adrenergic 
receptors on the bronchial smooth muscle to promote bronchodilation (43).  Short-acting 
β2-agonists, especially albuterol, are most often prescribed as “rescue inhalers” for 
treating acute asthma exacerbations and preventing EIB (85).  However, β2-agonists, 
such as formoterol, that have both a short response time and longer duration of 
effectiveness may be more practical.  It has been shown that although albuterol and 
formoterol were both able to prevent EIB within fifteen minutes of administration, 
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albuterol provided bronchoprotection for four hours while formoterol’s bronchoprotection 
lasted twelve hours (85).   
Since β2-agonists do not affect the inflammation associated with asthma, other 
types of drugs are often prescribed as well (43).  Corticosteroids reduce inflammation 
over time by inhibiting the production of proinflammatory prostaglandins, leukotrienes, 
and cytokines as well as by upregulating β-receptor transcription, which enhances 
responsiveness to β2-agonists (43).  As such, they are typically prescribed in 
combination with a β2-agonist rescue inhaler to reduce EIB symptoms since they cannot 
alleviate an asthma attack themselves.  It has been shown that inhaled corticosteroid 
therapy begins to offer protection against EIB after one week; its effectiveness improves 
with increased doses and duration of treatment (91). 
Drugs that specifically target leukotrienes have repeatedly demonstrated the 
capability to control EIB (23, 49, 81, 89, 93).  Anti-leukotriene medications either inhibit 
leukotriene synthesis (e.g. zileuton) or bind to leukotriene receptors to reduce the action 
of leukotrienes (e.g. montelukast) (43).  Leff et al. (49) demonstrated that during a 12-
week course of treatment with the leukotriene receptor antagonist montelukast, subjects 
with mild asthma and EIB showed a significant reduction in EIB as compared to placebo.  
Similarly, Rundell et al. (81) showed that montelukast could diminish EIB after a single 
dose in most but not in all of the subjects with EIB. 
Although pharmacotherapy can thus manage asthma and EIB, patients have 
heterogeneous responses to these medications (27).  This may be due in part to the 
variable nature of asthma; however, since patients with clinically similar disease can 
have different responses, it is also likely due to genetic variation affecting the drugs’ 
actions (27).  Furthermore, medications typically have side effects.  Side effects for 
asthma medications range from muscle tremors and hoarseness to cardiotoxicity and 
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neurotoxicity (43).  Therefore, asthma patients may try alternative approaches to 
pharmacological treatment. 
Diet and Asthma 
 Because conventional asthma medications do not always offer optimal 
protection, there is interest in finding novel therapeutic strategies (23).  Dietary strategies 
are important to consider because changes in nutrition may have contributed to the 
increase in the prevalence of asthma (30).  Anecdotally, the rise in asthma in developed 
countries has coincided with a shift in diet to less fresh fruit, green vegetables, and fish 
(34).  In general, a low intake of antioxidants has been linked to the increase in asthma 
in Western societies, and specifically, it has been shown that adults with asthma have 
lower levels of plasma ascorbic acid (vitamin C) compared to healthy, non-asthmatic 
adults (66).  Sodium intake is also related to increased airway hyperresponsiveness 
(34); in non-asthmatic subjects with EIB, a high salt diet exacerbated post-exercise 
changes in pulmonary function whereas a low salt diet improved post-exercise changes 
in pulmonary function (37).  Furthermore, the American diet features a 10:1 ratio of 
omega-6 to omega-3 fatty acids whereas the World Health Organization recommends a 
3:1 or 4:1 ratio (41).  In contrast, it has been shown that Eskimos, who consume large 
amounts of omega-3 fatty acids compared to the typical Western diet, have a lower 
incidence of inflammatory diseases (40).  Thus, a proinflammatory diet may be 
contributing to the rise in asthma cases (57).  
  Since multiple medications are often needed to effectively control symptoms (31), 
the inclusion of nutritional supplements in asthma management may reduce the amount 
of medication someone with asthma requires.  Our laboratory has shown that both fish 
oil and the leukotriene receptor antagonist montelukast similarly reduce airway 
inflammation and protect against HIB (93).  Thus, nutritional supplements could reduce 
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reliance on asthma medications, which can have dangerous side effects, diminished 
efficacy over time, or may be banned for use in athletic competition (36).  
   Omega-3 Polyunsaturated Fatty Acids 
  Fish oil, a combination of the omega-3 polyunsaturated fatty acids (PUFAs) 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), has been used to 
alleviate the symptoms of asthma.  It works through the competition of omega-3 PUFAs 
with omega-6 PUFAs for enzymes in the production of different sets of leukotrienes and 
prostaglandins; the omega-3 PUFA products have less proinflammatory activity as 
compared to the omega-6 PUFA products (figure 1-3) (60).   
 
Figure 1-3.  Competing pathways for omega-3 and -6 polyunsaturated fatty acids.  
Omega-3 and -6 polyunsaturated fatty acids compete for the 5-lipoxygenase and 
cyclooxygenase enzymes to produce leukotrienes and prostaglandins with different 
proinflammatory potentials.  The omega-3 products, which are not as proinflammatory as 
the omega-6 products, trigger less bronchoconstriction than the omega-6 products. 
 
  12 
 The digestion and absorption of fish oil is a complex issue.  The longer carbon 
chain length of the omega-3 PUFAs has raised concerns that they may not be as readily 
hydrolyzed and absorbed as other fatty acids (70).  Furthermore, the double bond 
position in omega-3 PUFAs may affect which digestive enzymes are most important, 
which may impede the rate of initial lipolysis (70).  Nevertheless, this early delay is 
probably inconsequential given that fat digestion is normally a long process.  Once 
hydrolyzed, omega-3 PUFAs can form chylomicrons and enter the circulation via the 
lymphatic system similar to other long chain fatty acids (70).  Chylomicrons containing 
omega-3 fatty acids are hydrolyzed as efficiently as other chylomicrons (71); the 
released fatty acids are subsequently incorporated by nearby tissues (70).  The 
complexity of fish oil digestion arises when the different forms are considered.  
Commercial fish oil often contains ethyl derivatives of the omega-3 PUFAs in an effort to 
enhance their concentration (5).  The ethyl derivatives are not as well absorbed as their 
triglyceride counterparts found naturally in fish (28).  However, fish oil supplements can 
also be processed such that the triglyceride structure is retained.  Because the 
manufacture of fish oil has not been standardized, various types are available 
commercially (5).  This may contribute to inconsistent findings between studies. 
The literature shows conflicting results concerning the effectiveness of fish oil in 
treating asthma which may be due to experimental design differences in fish oil dose, 
treatment period, continued medication use, and bronchoprovocation strategy (13, 17, 
57, 59, 61, 68, 96).  Nevertheless, our laboratory has consistently shown that fish oil 
significantly prevents EIB (61, 62, 93).  In 2006, Mickleborough et al. (61) investigated 
the effect of three weeks of fish oil supplementation on EIB in adults with asthma.  
Compared to taking a placebo, fish oil reduced the change in post-exercise pulmonary 
function to below the threshold for EIB in these subjects.  Likewise, Tecklenburg-Lund et 
al. (93) showed that three weeks of supplementation with fish oil or the leukotriene 
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receptor antagonist medication montelukast (Singulair®) decreased the change in 
pulmonary function following eucapnic voluntary hyperventilation, a surrogate exercise 
challenge that involves rapid breathing.  The post-challenge FEV1 changes were similar 
for fish oil and montelukast in these adult subjects with asthma and EIB.  Thus, fish oil is 
an effective means of reducing EIB.   
   Docosahexaenoic Acid (DHA)                                   
  There is no consensus on which component of fish oil, EPA or DHA, is the more 
potent contributor to the positive effects seen with supplementation (86).  Knowing this 
would allow for the optimization of the fish oil formula for clinical and research purposes.  
To date, studies comparing EPA and DHA have focused on markers of inflammation and 
immune function, not airway responsiveness.  Results from these comparative studies, 
which include in vivo studies in humans and mice as well as in vitro studies on human 
macrophage cells, do not agree as to which omega-3 PUFA is more potent (47, 64, 86, 
98).  Kew et al. (47) compared the effect of chronic supplementation with either EPA-rich 
fish oil, DHA- rich fish oil, or placebo on immune function in healthy, non-asthmatic 
adults.  They determined that DHA suppressed T-cell activation while other immune 
function markers were not affected by either EPA or DHA.  
DHA promotes health in many physiological systems, including the central 
nervous and cardiovascular systems, in addition to alleviating various types of 
inflammatory diseases (41).  The mechanism of action for DHA relieving inflammation is 
likely through its metabolite protectin D1 (figure 1-4) (52).  Discovered by Serhan et al. 
(84), protectins are chemical mediators that actively resolve inflammation by reducing 
proinflammatory signaling.  In this study, novel DHA products were isolated from murine 
exudates in mice injected with DHA during an inflammatory response.  Human microglial 
cells involved in neural tissue host defense and inflammation were incubated with the 
novel DHA products; as a result, tumor necrosis factor-α (TNF-α)-induced cytokine 
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production was inhibited indicating that the novel products were anti-inflammatory.  
Although there have been no human studies on airway responsiveness following 
supplementation with DHA alone, Levy et al. (52) analyzed protectin D1 levels in 
asthmatic patients.  They found that compared to three healthy volunteers, four patients 
having an acute asthma exacerbation had significantly lower levels of protectin D1 in 
their exhaled breath condensate.  Levy et al. (52) also examined protectin D1 in a 
mouse model for airway hyperresponsiveness.  Compared to mice injected with saline, 
mice injected with protectin D1 30 minutes prior to an aerosol challenge had less 
bronchoalveolar lavage fluid inflammation as measured by reduced eosinophils, airway 
mucus, and proinflammatory leukotrienes and prostaglandins.  Bronchoconstriction 
following exposure of the mice to increasing concentrations of inhaled methacholine was 
also decreased.  In these experiments, lung tissue was removed from some mice and 
homogenized following sensitization and aerosol challenge.  When DHA was added ex 
vivo, the protectin D1 concentration increased significantly suggesting that DHA can be 
converted to protectin D1 by respiratory tissues during airway inflammation.  Thus, since 
respiratory DHA levels are reduced in diseases featuring airway inflammation, such as 
asthma, increasing DHA levels through supplementation should increase the availability 
of protectin D1 to alleviate airway inflammation and bronchoconstriction (52).  
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Figure 1-4.  EPA and DHA produce resolvins and protectins.  Eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA) are metabolized by cyclooxygenase-2 to 
produce resolvins and protectins, rescpectively.  These metabolites have anti-
inflammatory activity. 
 
   Antioxidants 
 Reactive oxygen species (ROS) are produced by normal cellular metabolism.  
They are physiologically important yet toxic to cell structure and function if not properly 
regulated by antioxidant defenses (35).  ROS can cause airway epithelial damage and 
inflammation; they may have an important role in the pathophysiology of asthma since 
their production is enhanced in asthmatics (15).  Moreover, patients with asthma have 
been documented to have reduced concentrations of antioxidants such as vitamin C and 
carotene (66).  This imbalance between excess ROS and lack of antioxidants leads to 
oxidative stress, which occurs with chronic inflammation (35).  Oxidative stress in 
asthma can be resolved by restoring the balance between ROS and antioxidants, either 
by inhibiting ROS production or by increasing antioxidant availability (80).   
  Vitamin C is the major antioxidant in the lung’s pulmonary protective lining (18).  
Its antioxidant activity includes direct scavenging of ROS (3).  Vitamin C may also affect 
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arachidonic acid metabolism and the cyclooxygenase pathway.  It can change 
prostaglandin synthesis from the bronchoconstrictor PGF2 to the bronchodilator PGE2 
(88).  Using a 2-week 1500 mg/day protocol, our laboratory showed that vitamin C 
supplementation reduces exercise-induced airway narrowing and inflammation in 
asthmatic subjects with EIB (94).   
   Combination of Nutritional Supplements 
 Since asthma is known to be a multifaceted disease that often requires multiple 
medications for optimal management, it is likely that a combination of nutritional 
supplements will be more effective in alleviating symptoms and protecting against 
asthma than any one supplement alone (26).  For example, ROS are thought to be just 
one contributor to the development of asthma (80) while it has been shown that the 
leukotriene pathway only accounts for up to 50-60% of EIB (81).  It is thus possible that 
addressing both of these contributors could lead to better asthma management though 
nutrition.   
Furthermore, there is a possible additive effect with the combination of vitamin C 
and fish oil as both substances affect arachidonic acid metabolism.  ROS cause 
increased 5-lipoxygenase activity, an enzyme involved in the lipoxygenase pathway of 
arachidonic acid metabolism; individuals with asthma have enhanced lipid peroxidation 
in their airways (16).  ROS-induced lipid peroxidation of cell membrane phospholipids 
releases arachidonic acid which subsequently forms proinflammatory prostaglandins and 
leukotrienes (figure 1-5) (15).  The omega-3 PUFAs in fish oil compete with the more 
proinflammatory omega-6 PUFAs, including arachidonic acid, in the cyclooxygenase and 
lipoxygenase pathways resulting in the increased production of less proinflammatory 
prostaglandins and leukotrienes (figure 1-6) (63).  Fish oil treatment has been shown to 
alter cell membrane phospholipid content such that the concentration of arachidonic acid 
is reduced (61).  The effect of the combination of fish oil and antioxidant supplements on 
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HIB and airway inflammation in adults with asthma has not been studied.  Biltagi et al. 
(17) found that a combination of fish oil, vitamin C, and zinc, which is a cofactor in 
prostaglandin synthesis, was more effective than any one supplement alone in treating 
children with moderately persistent asthma.  It is important to now study the effect of 
combining fish oil with another nutritional supplement in adults with asthma as the 
disease process of childhood asthma is different from that in adults (45). 
 
Figure 1-5.  Site of action for antioxidant supplementation.  Reactive oxygen 
species and oxidative stress increase the lipid peroxidation of cell membranes which 
results in an increased concentration of arachidonic acid, a precursor for 
proinflammatory leukotrienes and prostaglandins.  Antioxidants, which combat reactive 
oxygen species and reduce oxidative stress, may decrease this part of the pathway in 
asthmatics leading to less bronchoconstriction. 
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Figure 1-6.  Site of action for fish oil supplementation.  The omega-3 
polyunsaturated fatty acids in fish oil produce prostaglandins and leukotrienes that are 
less proinflammatory than their omega-6 fatty acid counterparts.  Fish oil 
supplementation thus increases this pathway to reduce bronchoconstriction.  
 
Omega-3 Fatty Acids and Smooth Muscle Contractility 
  Conflict exists in the current literature regarding the association between the 
exposure to fish oil or one of its components and smooth muscle contractility.  Both 
vascular and airway smooth muscle have been studied with vascular smooth muscle 
having received more attention.  
   Vascular Smooth Muscle  
More extensive research has been dedicated to fish oil’s effect on vascular 
smooth muscle due its use in reducing cardiovascular disease.  Since vascular and 
airway smooth muscle tissue differ physiologically, results from these studies cannot be 
assumed to hold true for airway smooth muscle tissue.  Nevertheless, Yanagisawa et al. 
(101) showed that EPA acutely relaxes pre-contracted rabbit and cat aortic rings in an 
endothelium-dependent manner.  Similarly, Engler et al. (32) showed that EPA acutely 
relaxes pre-contracted rat aortic rings in a concentration-dependent manner that is 
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abolished with a cyclooxygenase inhibitor and/or an ATP-sensitive K+ channel inhibitor.  
This result suggests that EPA exerts its relaxing effect through the production of K+ 
channel-activating prostaglandins. However, these results conflict with their earlier 
research (30) that showed EPA- and DHA-induced relaxations of pre-contracted rat 
aortic rings were not affected by cyclooxygenase or lipoxygenase inhibitors. Thus, they 
had suggested that their action on the vessel wall may be more important than 
prostaglandin production.  Engler et al. (33) also suggested this in an earlier study where 
DHA relaxed rat aortic rings at baseline tension and after pre-contraction.  Because 
washouts failed to diminish the relaxation response, Engler et al. (33) proposed that 
DHA may have been incorporated which would increase cell membrane fluidity and 
change enzyme and receptor activities at the membrane; however, this was not 
measured.  
   Airway Smooth Muscle 
  It has been shown that fish oil diminishes airway inflammation in asthma (64, 98, 
105), which can in turn reduce bronchoconstriction; however, its impact on airway 
smooth muscle is not as well-defined.  Although airway inflammation is significant in 
asthma, airway narrowing is of the utmost concern clinically (44).  Thus, determining fish 
oil’s impact on airway smooth muscle contractility is important.  Few studies have 
addressed this issue.  Hichami et al. (39) determined that adding free (non-conjugated) 
DHA to a tissue bath relaxes guinea pig bronchial smooth muscle basal tone whereas 
adding other diacylglycerols causes contraction.  They concluded that the fatty acid 
structure affects its modulation of airway smooth muscle tone through its activation of 
protein kinase C and smooth muscle contraction.  Interestingly, DHA failed to cause a 
relaxation in tissue pre-contracted with carbamylcholine, which differs from the Engler et 
al. (33) study where DHA was able to relax pre-contracted rat aortic rings.  Although not 
a study on fish oil, Abeywardena et al. (4) tested the contractility of airway smooth 
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muscle obtained from guinea pigs chronically fed a diet rich in olive, canola, or safflower 
oil.  Although lipid analysis of the tissue showed an overall increase in omega-3 PUFAs 
with the canola oil diet as compared to the other two diets, there was no significant 
change in airway contractility.  However, this does not rule out a possible association 
between fish oil incorporation and reduced smooth muscle contractility because there 
was not a significant change in EPA or DHA composition with any of the diets as has 
been shown in the lung tissue of mice chronically fed fish oil (102).  Furthermore, the 
results of these studies must be interpreted in the context that guinea pig airway smooth 
muscle basal tone is modulated by local prostaglandin production (74), which itself is 
known to be affected by fish oil exposure.  In a study on human tissue, Morin et al. (20) 
showed that the EPA metabolite 17(18)-epoxyeicosatetraenoic acid relaxes non-
stimulated bronchial smooth muscle tissue that has an initial load applied and following 
contraction with methacholine; K+ channels may be involved as this was inhibited with K+ 
channel blockers.  The results were similar following 48-hour incubation in TNF-α to 
induce airway hyper-responsiveness.  Despite some experiments on tissues incubated 
with fish oil, Morin et al. (69) did not evaluate omega-3 PUFA incorporation. 
  The existence of an acute or chronic effect of fish oil or one of its components on 
airway smooth muscle contractility is thus unclear.  Should an association exist, the 
reason for reduced airway smooth muscle contractility with fish oil may be a decrease in 
the formation of proinflammatory omega-6 PUFA products as a result of less arachidonic 
acid content in smooth muscle cell membranes, an increase in omega-3 PUFA content 
in smooth muscle cell membranes to compete for common enzymes, or an alteration in 
cell membrane properties, such as fluidity and enzyme function, from increased omega-
3 PUFA content.  
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Summary and Proposed Experimental Aims 
  Asthma is a chronic disease that may require multiple medications for adequate 
management (26), and oftentimes, a considerable burden of disease will nevertheless 
remain unaddressed (27).  Importantly, prescription medications account for over a third 
of the healthcare costs attributed to asthma (1).  Consequently, asthmatics have sought 
out alternative non-pharmacological treatments to replace or supplement their current 
treatment regimen (95).  Nutritional supplements have been investigated as an 
alternative strategy since changes in diet may be partially responsible for the prevalence 
of asthma (34). 
  The vast majority of asthmatics exhibit EIB, with estimates as high as 90% (87).  
For the most part, EIB has been treated pharmacologically (60).  However, several 
nutritional strategies, such as fish oil or vitamin C supplementation and salt-reduction, 
have recently been shown to be effective in preventing EIB (61, 62, 93, 94).  This shows 
promise for reducing reliance on asthma medications that may have side effects, show 
decreased effectiveness with chronic use, or not be allowed for athletic competitions 
(60). 
  Despite the encouraging results to date with fish oil, several important questions 
surrounding fish oil remain unanswered.  First, the ability of fish oil to work in conjunction 
with traditional medications or other nutritional supplements has just begun to be 
explored (93).  Although it has been shown that the combination of fish oil, zinc, and 
vitamin C is more effective in improving moderate asthma in children than taking fish oil 
alone (17), the effect of taking fish oil with another nutritional supplement in adults with 
asthma is unknown.  This is important to study because improvement in pulmonary 
function in asthmatics with EIB beyond that attained with fish oil is physiologically 
possible.  Mickleborough et al. (61) have demonstrated that fish oil supplementation 
reduced the percent change in FEV1 to below the diagnostic threshold for EIB, but 
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further improvement is possible as the normal response to exercise is dilation of the 
airways such that the post-exercise percent change in FEV1 is zero or positive.  
Additionally, it is estimated that blocking the leukotriene pathway, as with fish oil, offers a 
50-60% reduction in bronchoconstriction in EIB suggesting that one or more pathways 
are responsible for the remaining portion (81).  Furthermore, since the diverse nature of 
asthma is better managed with several pharmacologic agents, it is possible that more 
than one nutritional supplement may be necessary for optimal treatment. 
   Second, the optimal formula for fish oil has yet to be ascertained.  It is not known 
which omega-3 fatty acid in fish oil is more potent (86).   Although Levy et al. (52) have 
recently demonstrated that the DHA metabolite protectin D1 decreases airway 
inflammation and bronchoconstriction in a mouse model, treating EIB with DHA 
supplements has not been attempted in human subjects.  Finally, several studies have 
indicated that fish oil treatment is associated with a reduction in inflammation (64, 98, 
105); however, there is not a clear indication in the literature whether fish oil treatment is 
similarly associated with reduced airway smooth muscle contractility (39, 69), which, 
along with airway inflammation, is largely responsible for the symptoms of asthma.  
Further research on fish oil and airway smooth muscle contractility is thus necessary.          
  Our objective is to determine the effects of novel nutritional strategies on 
hyperpnea-induced bronchoconstriction (HIB) and airway inflammation in asthmatic 
individuals.  HIB uses rapid breathing to identify EIB in a research or clinical setting (9). 
We will also explore airway smooth muscle as a target of fish oil’s action to explain its 
effectiveness as a therapeutic agent. The central hypothesis is that nutritional 
supplementation with omega-3 polyunsaturated fatty acids effectively controls HIB and 
airway inflammation.  The secondary hypothesis is that omega-3 fatty acid treatment 
involves reduced arachidonic acid content and increased EPA and DHA content in 
smooth muscle cell membranes with an associated decrease in the airway smooth 
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muscle responsiveness to a contractile agonist.  These hypotheses will be tested in 
studies investigating the following specific aims (figure 1-7): 
1. Determine the effect of fish oil and antioxidant supplementation and their 
combination on hyperpnea-induced bronchoconstriction (HIB) and airway 
inflammation in asthmatic individuals.  Previous work has shown that fish oil 
and the antioxidant vitamin C individually reduce EIB (59, 61, 94).  It is 
hypothesized that fish oil and vitamin C supplementation taken in isolation will be 
effective in attenuating HIB and airway inflammation and that the two treatments 
combined will confer even greater protection than either intervention alone.    
2. Determine the effects of docosahexaenoic acid (DHA), a component of fish 
oil, on hyperpnea-induced bronchoconstriction (HIB) and airway 
inflammation in asthmatic individuals.  The DHA component of fish oil may 
effectively manage asthma and prevent HIB as suggested by an in vitro study 
where pure DHA was more potent than eicosapentaenoic acid (EPA) in relieving 
inflammation (98).  It is hypothesized that DHA supplementation will diminish HIB 
and airway inflammation as compared to placebo. 
3. Determine whether fish oil is associated with a reduction in the contractility 
of canine tracheal smooth muscle.  Asthma is characterized by airway 
narrowing due to airway smooth muscle contraction.  Research on fish oil and 
airway smooth muscle tissue contractility is limited.  It is hypothesized that fish oil 
treatment of tracheal smooth muscle tissue will be associated with a decrease in 
its contractility.  
 The proposed research builds upon our previous findings.  Our laboratory has 
shown that fish oil and vitamin C supplementation each effectively alleviate EIB.  Despite 
improvements in pulmonary function with these supplements, there is still unaddressed 
disease that may be minimized with a combination of the supplements.  Furthermore, 
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since it has been shown that fish oil is an effective treatment for EIB, we will begin to 
determine the optimal formula for fish oil by supplementing with pure DHA only.  Lastly, 
exploring the effect of fish oil incubation on airway smooth muscle contractility will be a 
step toward reducing the current confusion on this matter in the literature.  This project is 
a key step in the practice of evidence-based medicine since it will provide scientific 
support for using fish oil to treat asthma and will attempt to provide a rationale for its 
effectiveness.  The combination treatment study will afford answers about 
complementary mechanisms involved in the development of HIB.   Overall, a major 
benefit of this research will be that it will continue the effort to offer alternative treatment 
options to traditional asthma medications.   
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Figure 1-7.  Proposed mechanism of how omega-3 fatty acids reduce airway 
inflammation and constriction in hyperpnea-induced bronchoconstriction.  We 
propose that omega-3 fatty acids in the form of fish oil or pure DHA reduce 
bronchoconstriction through associated decreases in inflammation and smooth muscle 
contractility.  The proposed mechanism also indicates where vitamin C may act to have 
an additive effect with fish oil.  
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CHAPTER 2 
THE EFFECT OF FISH OIL, VITAMIN C, AND THEIR COMBINATION 
ON HYPERPNEA-INDUCED BRONCHOCONSTRICTION IN 
ADULTS WITH ASTHMA 
Abstract 
Background: Asthma is a multi-faceted disease that often includes exercise-induced 
bronchoconstriction (EIB).  Hyperpnea-induced bronchoconstriction (HIB) has been 
shown to reliably detect EIB.  Previous research has demonstrated that individual 
nutritional supplements, such as fish oil and vitamin C, alleviate EIB. 
Purpose: Determine whether the combination of fish oil and vitamin C supplementation 
offers increased protection against HIB over either one alone.   
Methods: Fourteen subjects (18 to 29 years) with asthma and HIB participated in a 
randomized, double-blind, parallel group trial consisting of two treatment periods in 
which subjects first received either active fish oil (n = 7) or vitamin C supplements (n = 7) 
for 3 weeks.  After a 2-week washout period, all subjects received both active fish oil and 
vitamin C for 3 weeks.  Subjects visited the laboratory following an initial 2-week run-in 
phase and after each supplementation phase for a total of three visits.  
Bronchoprovocation was elicited with eucapnic voluntary hyperventilation (EVH), a 
surrogate exercise challenge involving rapid breathing (hyperpnea).  Pulmonary function, 
fraction of exhaled nitric oxide (FENO), and exhaled breath condensate pH were 
measured pre- and post-EVH.  Subjects recorded daily symptoms, peak expiratory flow, 
and bronchodilator use throughout the study.   
Results: Post-EVH pulmonary function measures significantly improved with fish oil and 
the combination treatment of fish oil and vitamin C while airway inflammation was 
affected by vitamin C supplementation as well as by the combination treatment of fish oil 
and vitamin C. 
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Conclusions: Although previous research has shown that either fish oil or vitamin C can 
reduce bronchoconstriction and airway inflammation on their own, the variable 
responses obtained in this study suggest that for subjects not reaping the full benefits 
from either supplement alone, a combination of fish oil and vitamin C may be more 
effective.  
Introduction 
 Nearly 25 million Americans have asthma, a chronic inflammatory disease 
featuring airway inflammation, hyperresponsiveness, and narrowing (6, 90).  A 
complication of this disease that affects up to 90% of asthmatics is exercise-induced 
bronchoconstriction (EIB) (87).  EIB is specifically defined as a 10% or greater decrease 
in a person’s forced expiratory volume in one second (FEV1) following a bout of exercise 
lasting at least five minutes (12, 87).   
Because EIB suggests that an individual’s asthma is not being adequately 
managed, it is important to test for clinically to evaluate the effectiveness of asthma 
therapies (49).  Rapid breathing, or hyperpnea, can be used in place of exercise to 
provoke bronchoconstriction; the eucapnic voluntary hyperventilation (EVH) challenge is 
currently recommended by the International Olympic Committee to identify athletes with 
EIB (9).  Moreover, since it has been previously shown that the changes in FEV1 
following the EVH challenge are comparable to those seen following cold air exercise, 
hyperpnea-induced bronchoconstriction (HIB) is a reliable indicator of EIB (81). 
Traditional pharmacologic approaches to managing asthma do not always 
provide optimal protection (27).  This may be due to patients’ variable responses to 
medications or side effects of the drugs, including reduced efficacy with chronic use.  
Thus, patients may seek out alternatives to asthma medications.  Since it has been 
suggested that the prevalence of asthma is related to dietary factors such as a high ratio 
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of omega-6:omega-3 polyunsaturated fatty acids (PUFAs) or a low antioxidant intake, 
numerous nutritional strategies have been tried (41, 66).   
Of these nutritional strategies, fish oil supplementation is a promising approach.  
Fish oil is composed of the omega-3 PUFAs eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA).  It is thought that fish oil reduces bronchoconstriction by 
competing with the proinflammatory omega-6 PUFA pathway (60).  Both omega-6 and 
omega-3 PUFAs produce leukotrienes and prostaglandins via the 5-lipoxygenase and 
cyclooxygenase enzymes, respectively; however, the omega-3 products are less 
proinflammatory than the omega-6 products and thus cause less bronchoconstriction 
(60).  Fish oil supplementation has been shown to effectively reduce EIB in elite athletes 
without concurrent asthma (62) as well as in adults with asthma (61).  It has also been 
determined that fish oil and the leukotriene receptor antagonist montelukast (Singulair®) 
each prevent HIB to a similar extent (93). 
  As it has been shown that adults with asthma have lower levels of plasma 
ascorbic acid (vitamin C) compared to healthy, non-asthmatic adults (66), vitamin C 
supplementation has been tried as another nutritional approach to managing asthma.  
The mechanism supporting vitamin C supplementation is related to its antioxidant role.  
Asthmatics have enhanced production of reactive oxidant species (ROS), which can 
damage airway epithelium and cause airway inflammation (14, 35).  To reduce this 
oxidative stress, increased concentrations of antioxidants are needed to regulate the 
ROS (38).  In a recent meta-analysis investigating vitamin C as a treatment for asthma, 
Kaur et al. (46) determined that vitamin C has demonstrated only limited effectiveness 
although this may be due to the incongruent protocols for supplementation and 
bronchoprovocation among the current literature.  Nevertheless, Tecklenburg et al. (94) 
showed that a two-week, 1500 mg/day regimen of pharmaceutical grade vitamin C 
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significantly reduced exercise-induced narrowing and inflammation in adults with asthma 
and EIB.    
 Given that asthma is known to be a multi-faceted disease and that 
pharmacological treatment often includes multiple medications, it is likely that a 
nutritional approach incorporating multiple nutrients will be more effective than any one 
nutritional supplement alone (26).  In addition to simultaneously addressing different 
aspects of the disease, combining nutritional supplements may have an additive effect 
as well.  Specifically, fish oil and vitamin C both affect arachidonic acid metabolism, 
which is a component of the omega-6 PUFA pathway.  As previously mentioned, the 
omega-3 PUFAs EPA and DHA in fish oil compete with the omega-6 PUFA arachidonic 
acid for common enzymes to produce mediators with less proinflammatory activity (63).  
Furthermore, it had been demonstrated that fish oil supplementation increases the 
concentration of EPA and DHA in the cell membrane phospholipid bi-layer while 
reducing that of arachidonic acid (61).  This is important as it has been shown that 
asthmatics have increased ROS-induced lipid peroxidation of cell membranes in their 
airways (16).  Thus, by reducing ROS activity via an increase in the antioxidant 
concentration with vitamin C supplementation while decreasing the availability of 
arachidonic acid-derived mediators through an alteration of the cell membrane content 
and through competition for enzymes with fish oil supplementation, vitamin C and fish oil 
may work together to alleviate asthma.       
 The purpose of this study is to determine whether the combination of fish oil and 
vitamin C supplementation offers increased protection against HIB over either one alone.  
We will test the hypothesis that fish oil and vitamin C supplementation taken in isolation 
will be effective in the attenuation of HIB and airway inflammation and that the two 
treatments combined will confer even greater protection. 
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Methods 
Subjects.  Fourteen subjects (8 male, 6 female) between the ages of 18-29 years 
with both physician-diagnosed asthma and hyperpnea-induced bronchoconstriction 
(HIB) were recruited from a university and community setting.  Subjects were evaluated 
for HIB at the first laboratory test in order to only include mild to moderate asthmatics.  
This was determined by a resting forced expiratory volume in one second (FEV1) greater 
than 60% of the predicted value based on age, height, weight, and sex (76) as well as at 
least a 10% decrease in the FEV1 following a surrogate exercise challenge used to 
diagnose EIB (9).  Subjects were not allowed to take asthma maintenance medications 
during the study other than their prescribed short-acting β2-agonists (e.g. albuterol) to be 
used ad libitum except for six hours prior to reporting to the laboratory for testing.  One 
subject stopped taking ADVAIR DISKUS® (fluticasone propionate and salmeterol) with 
his doctor’s written permission for four weeks before starting the study (61); no other 
subjects were taking asthma maintenance medications at the time of enrollment.  
Furthermore, subjects could not be taking nutritional supplements containing vitamin C 
or fish oil at the time of enrollment or during the study.  Subjects were instructed to limit 
their fish consumption to one meal per week and to avoid vitamin C rich foods for the 
duration of the study.  Exclusion criteria for the study included pregnancy or a history of 
diabetes, hypertension, hyperlipidemia, bleeding disorders, delayed clotting time, or 
seizures. 
This investigation was approved by the Indiana University Institutional Review 
Board (protocol # 0910000751) and was registered as a clinical trial with clinicaltrials.gov 
(study # NT01057615).  Informed consent was obtained from all subjects prior to their 
enrollment.  A control group of healthy, non-asthmatic subjects was not included in this 
study design as it has previously been reported that fish oil supplementation does not 
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significantly affect pulmonary function or inflammatory mediators in individuals without 
asthma or EIB (62).     
Study Design.  This study (figure 2-1) was conducted as a randomized, double-
blind, parallel group trial consisting of two treatment periods in which subjects first 
received either active fish oil or ascorbic acid for 3 weeks.  After a 2-week washout 
period, all subjects received both active fish oil and ascorbic acid for 3 weeks.  Subjects 
came to the laboratory for testing following a 2-week run-in phase at the beginning of the 
study and after each supplementation phase for a total of three visits.   
 
Figure 2-1.  Schematic of study design.  Subjects entered the study on their normal 
diet.  Following a 2-week run-in period, subjects completed a placebo-controlled parallel 
group trial consisting of two 3-week supplementation periods separated by a 2-week 
washout phase.  Subjects were first supplemented with either 1500 mg of vitamin C or 
fish oil composed of 3.2 g eicosapentaenoic acid (EPA) and 2.0 g docosahexaenoic acid 
(DHA).  All subjects received both vitamin C and fish oil for the second supplementation 
period.  
 
Subjects entered the study on their normal diet and were randomly divided, but 
matched by sex, into one of two groups.  Following their first laboratory test, subjects 
received either [1] vitamin C capsules containing a total of 1500 mg of pharmaceutical 
grade ascorbic acid (NOW Foods, Bloomingdale, IL) per day and placebo fish oil 
capsules containing soybean oil (n = 7) or [2] placebo vitamin C capsules containing 
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sucrose and active fish oil capsules (Nordic Naturals, Watsonville, CA) containing a total 
of 3.2 g EPA and 2.0 g DHA per day (n = 7).  Subjects were supplemented for 3 weeks 
(61, 62) and then returned to the laboratory for a second test.  Subjects then underwent 
a 2-week washout period where they did not take any capsules (61, 62).  After the 
washout, all subjects (n = 14) took both active vitamin C and fish oil for 3 weeks.  At the 
end of this treatment phase, all subjects returned to the laboratory for testing. 
Subjects were not aware of when they received placebo treatments.  An 
independent investigator having no contact with subjects and no involvement in data 
collection or analysis used a computerized random number generator 
(http://www.randomizer.org/form.htm) to create the randomization sequence which was 
stratified by sex with a 1:1 allocation using a fixed random blocks size of two.  The active 
fish oil and ascorbic acid capsules were identical in appearance to their respective 
placebo counterpart.  Identical packages of capsules were numbered by the 
independent investigator.  After the principal investigator obtained the subject’s consent, 
the independent investigator was asked to provide the allocation assignment for the 
subject.  A list of subject number and randomized allocation number was kept 
confidential by the independent investigator and only revealed to the principal 
investigator after data collection and initial data analysis were completed.    
Subjects reported to the laboratory having abstained from exercising for 24 hours, 
having caffeine for 8 hours, and using their short-acting β2-agonist for 6 hours (93).  
They performed the same tests during each visit.  Bronchoprovocation was elicited with 
eucapnic voluntary hyperventilation (EVH), a surrogate exercise challenge.  Prior to and 
following EVH, markers of inflammation and pulmonary function were measured.  In 
between laboratory visits, each subject was instructed to record his or her daily peak 
expiratory flow, short-acting β2-agonist (albuterol) usage, and symptoms in log books 
submitted at each visit.  Two 24-hour dietary recalls were conducted during each phase 
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of the study to gauge any changes in nutrient intake over the course of the study.  
Compliance with supplementation was assessed by counting the pills returned by the 
subjects at their second and third laboratory tests. 
 Eucapnic Voluntary Hyperventilation.  Bronchoprovocation was provided by the 
eucapnic voluntary hyperventilation (EVH) challenge, which requires subjects to breathe 
cold, dry air at a rapid rate.  While wearing nose clips, subjects were asked to breathe 
through a non-rebreathing two-way valve (Hans Rudolph, Inc., Kansas City, MO) 
connected to a reservoir bag continually filled with 21% oxygen, 5% carbon dioxide, and 
balance nitrogen from a compressed gas tank containing less than 3 mg H2O.L-1 air (93).  
Subjects were instructed to breathe for 6 minutes at 85% of their maximal voluntary 
ventilation as estimated by thirty times their resting FEV1 (9).  In order to verify the 
ventilatory rate, a flow sensor measured ventilation (Vmax 22 Metabolic Measurement 
Cart, SensorMedics, Yorba Linda, CA) (81).   
 Pulmonary Function Tests.  Pulmonary function was measured pre-EVH and 
post-EVH at 5, 10, 15, and 20 minutes using a calibrated computerized 
pneumotachograph spirometer (Vmax 22 Metabolic Measurement Cart, SensorMedics, 
Yorba Linda, CA) (93).  In accordance with American Thoracic Society (ATS) 
recommendations, each subject performed three acceptable spirograms, of which the 
largest and second largest forced vital capacity (FVC) and FEV1 values did not vary by 
more than 0.15 L (65).  The largest value of each was recorded.  Values for forced 
expiratory flow at 25-75% of the FVC (FEF25-75%) were recorded from the trial with the 
greatest sum of FVC and FEV1 (65).  The bronchoconstrictor response to EVH was also 
determined as the area under the curve of the percentage fall in post-exercise FEV1 
plotted against time for 20 minutes, using trapezoidal integration (93). 
  Fraction of Exhaled Nitric Oxide.  Before and 30 minutes following EVH 
challenge, online measurement of the fraction of exhaled nitric oxide (FENO) was 
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recorded using a restricted exhaled breath protocol (NOA 280i Nitric Oxide Analyzer, 
Accurate NO Breath Kit, Thermal Mass Flowmeter, NO Analysis Software Version 3.21, 
Sievers Instruments, Boulder, CO) (93).  American Thoracic Society guidelines were 
followed (2).  Accordingly, subjects were instructed to inhale maximally to their total lung 
capacity and immediately exhale against expiratory resistance at a rate of 50 ± 10 mL/s 
for at least 6 seconds to produce a nitric oxide plateau lasting at least 3 seconds; real 
time feedback was provided visually on a computer screen.  Subjects performed this 
maneuver while wearing nose clips with at least 30 seconds of rest between each trial 
(93).  The FENO was recorded as the mean of three exhalations with the individual FENO 
values within 10% of the mean FENO (2).     
 Exhaled Breath Condensate.  Exhaled breath condensate (EBC) was collected 
pre-EVH and post-EVH at 0-10 minutes (93) according to American Thoracic Society 
and European Respiratory Society recommendations (42).  Subjects were instructed to 
breathe normally into a non-rebreathing valve attached to a condensing chamber 
(ECoScreen, Viasys Healthcare-Jaeger, Germany) for 10 minutes while wearing nose 
clips (93).  This condensing chamber maintains an internal temperature of -20 ˚C to 
immediately freeze the exhaled breath sample during collection (93).  The pH of the non-
deaerated EBC was measured within 5 minutes of collection (Orion 2 Star pH benchtop 
meter, ROSS™ Glass Combination Micro pH electrode, Thermo Fisher Scientific, Inc., 
Beverly, MA).   
 Symptoms and Short-Acting β2-Agonist Usage.  Subjects were instructed to rate 
their symptoms by filling out a symptom diary every day throughout the study.  This diary 
adapted from Santanello et al. (83) contained four questions about daytime symptoms 
with a seven point scale and one question about nighttime symptoms with a four point 
scale.  Symptom scores were calculated for each subject by averaging the mean score 
from each day (83). 
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 Subjects recorded their short-acting β2-agonist use in log books provided to 
them.  Subjects were instructed to mark down the number of puffs taken per day 
throughout the study. 
 Peak Flow Measurements.  Electronic peak flow meters (PiKo-1, Ferraris 
Medical, Louisville, CO) were given to subjects to measure their morning and evening 
peak expiratory flow throughout the study.  Subjects were instructed to perform the 
maneuver by inhaling fully to their total lung capacity and then exhaling forcefully 
through the flow meter according to manufacturer instructions.  Subjects were instructed 
to record the best of three trials upon waking and before going to bed.  
 Nutrient Intake.  To evaluate nutrient intake during the study, 24-hour dietary 
recalls were conducted for each subject using the nutrition data system for research 
(NDSR) dietary assessment computer program from the University of Minnesota.  
Subjects were called twice during each phase of the study to be interviewed about what 
food and beverages they consumed in the previous 24-hour period.  These calls were 
made unannounced so that subjects could not change their eating habits in anticipation 
of the interview.  
 Data Analysis.  A power analysis of data collected by our laboratory was used to 
determine the number of subjects.  In separate studies, our laboratory tested pulmonary 
function in asthmatics receiving fish oil or ascorbic acid supplements (93, 94).  Based on 
the maximum percent drop in FEV1 following an exercise challenge in these subjects, it 
was determined with the aid of the G*Power3.0.5 program (Universität Kiel, Germany) 
that a minimum of seven subjects per group would be needed to show a significant 
difference between baseline and post-supplementation pulmonary function with a power 
of 0.80.  Since it was hypothesized that the combination would be more effective than 
either alone, it was expected that fewer subjects would be needed to show a significant 
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difference.  Thus, this study should be sufficiently powered with seven subjects per 
group. 
 Data was analyzed with SPSS version 18.0 statistical software (SPSS Inc., 
Chicago, IL).  Pairwise comparisons were made using dependent t-tests to assess 
changes between baseline, each supplement, or the combination of supplements for 
each group of subjects in the parallel study design.  A Bonferroni adjustment was made 
to the p-value to account for the multiple t-tests.  Thus, for this set of analyses, 
significance was held at p < 0.016.  This strategy for statistical analysis was undertaken 
in order to avoid a large type II error wherein the null hypothesis would be accepted 
when it is actually false; a repeated measures ANOVA with Tukey’s post-hoc would be 
too conservative for the small sample size (n = 6 or 7) in this study.  An independent t-
test was used to determine whether the groups of subjects were significantly different 
from each other at the pre-supplementation test.  Where the groups were not 
significantly different from each other, the subjects were pooled in order to examine the 
overall effect of the combination of treatments compared to pre-supplementation values 
with dependent t-tests.  Significance was held at p < 0.05 for these analyses.  Repeated 
measures analysis of variance (ANOVA) was used to assess nutrient intake and at-
home measurements during the four phases of the study (run-in phase, one treatment 
phase, washout phase, and combination of treatments phase).  Mauchley’s test was 
conducted to determine if sphericity was violated; if it was, a Greenhouse-Geisser 
adjustment was used.  Where a significant F-ratio was found (p < 0.05), Tukey’s post-
hoc test was used to isolate differences in group means.  Significance was held at p < 
0.05.  Repeated measures ANOVA with a Tukey’s post-hoc was chosen here because 
the additional measurement under analysis for this set of measurements would increase 
the number of dependent t-tests to six and thus lower the p-value for significance to 
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0.008 with a Bonferroni adjustment; this would increase the risk of committing type I 
error.  The data is reported as mean ± standard error of the mean.  
Results 
 Subjects.  One subject reported gastrointestinal symptoms with supplementation; 
these symptoms subsided with increased water consumption.  The subjects’ 
measurements at the pre-supplementation laboratory visit were considered their 
baseline values (table 2-1).  There were no significant differences within (p > 0.016) or 
between (p > 0.05) the two groups of subjects in terms of resting pulmonary function 
among the three laboratory tests.  However, one subject’s post-eucapnic voluntary 
hyperventilation (EVH) pulmonary function progressively worsened from the pre-
supplementation test to the one treatment test to the combination treatment test.  Since 
this was in contrast to the response of the rest of the subjects, this subject was deemed 
a “non-responder” and the subject’s data was removed from analysis.  Descriptive 
statistics of the baseline characteristics were thus recalculated for the remaining 13 
subjects who responded positively to treatment (table 2-2).  The mean percent predicted 
values for resting pulmonary function for each group were not significantly different (p > 
0.016) among the three laboratory tests (tables 2-3, 2-4).  A summary of the results for 
the main dependent variables with means for each group as well as for all 13 subjects 
encapsulates the treatment effects (tables 2-5, 2-6, 2-7). 
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Males 8 
Females 6 
Age, yr (range) 22.1  ± 0.8 (18-29) 
Height, m 1.74 ± 0.47 
Weight, kg 77.1 ± 20.6 
BMI, kg/m2 24.9 ± 6.7 
Morning Peak Flow, L/min 420.0 ± 38.1 
Evening Peak Flow, L/min 426.1 ± 37.8 
FEV1/FVC 77.68 ± 2.25 
Percent Predicted FVC, % 102.1 ± 3.8 
Percent Predicted FEV1, % 96.6 ± 3.6 
Table 2-1.  Baseline characteristics of the subjects at their first (pre-
supplementation) laboratory visit.  The values are averages of all the subjects who 
completed the protocol and are reported as mean ± standard error of the mean.  BMI, 
body mass index; FEV1, forced expiratory volume in one second; FVC, forced vital 
capacity 
 
Males 8 
Females 5 
Age, yr (range) 22.2  ± 0.9 (18-29) 
Height, m 1.75 ± 0.49 
Weight, kg 79.3 ± 22.0 
BMI, kg/m2 25.4 ± 7.1 
Morning Peak Flow, L/min 430.2 ± 39.6 
Evening Peak Flow, L/min 435.6 ± 39.5 
FEV1/FVC 77.78 ± 2.43 
Percent Predicted FVC, % 103.4 ± 3.8 
Percent Predicted FEV1, % 97.9 ± 3.6 
Table 2-2.  Baseline characteristics of the “responders” at their first (pre-
supplementation) laboratory visit.  The values are averages of the 13 subjects who 
responded positively to treatment and upon whom data analysis was performed.  The 
values are reported as mean ± standard error of the mean.  BMI, body mass index; 
FEV1, forced expiratory volume in one second; FVC, forced vital capacity 
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Pre-
Supplementation Fish Oil Fish Oil + Vitamin C 
FVC 105.46 ± 7.69 102.70 ± 7.16 104.64 ±  8.21 
FEV1 99.20 ± 6.80 94.93 ± 5.73 99.13 ± 6.82 
FEF25-75% 81.93 ± 9.54 76.17 ± 9.37 79.95 ± 10.03 
Table 2-3.  Resting pulmonary function of the subjects in the Fish Oil Group.  
These subjects (n=6) received fish oil supplements for the first treatment phase.  There 
were no significant differences in the resting pulmonary function values among pre-
supplementation, the fish oil treatment, and the combination treatment prior to the 
eucapnic voluntary hyperventilation challenge.  The pulmonary function values are 
expressed as percentages of the subjects’ predicted values based on age, height, 
weight, and sex.  They are reported as mean ± standard error of the mean.  FVC, forced 
vital capacity; FEV1, forced expiratory volume in one second; FEF25=75%, forced 
expiratory flow at 25-75% of the FVC 
 
 
 
 
  
Pre-
Supplementation Vitamin C Fish Oil + Vitamin C 
FVC 101.65 ± 3.19 102.96 ± 4.36 101.76 ± 3.79 
FEV1 96.84 ± 3.97 101.82 ± 3.05 100.36 ± 3.03 
FEF25-75% 81.99 ± 10.06 91.03 ± 8.72 92.81 ± 8.71 
Table 2-4.  Resting pulmonary function of the subjects in the Vitamin C Group.  
These subjects (n=7) received vitamin C supplements for the first treatment phase.  
There were no significant differences in the resting pulmonary function values among 
pre-supplementation, the vitamin C treatment, and the combination treatment prior to the 
eucapnic voluntary hyperventilation challenge.  The pulmonary function values are 
expressed as percentages of the subjects’ predicted values based on age, height, 
weight, and sex.  They are reported as mean ± standard error of the mean.  FVC, forced 
vital capacity; FEV1, forced expiratory volume in one second; FEF25=75%, forced 
expiratory flow at 25-75% of the FVC 
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Variable 
Pre-
Supplementation Fish Oil 
Fish Oil +  
Vitamin C 
Post-EVH max drop 
FVC (L) 0.53 ± 0.10 0.24 ± 0.05 * 0.25 ± 0.06 
Post-EVH max drop 
FEV1 (L) 0.72 ± 0.11 0.39 ± 0.08 * 0.43 ± 0.13 
Post-EVH max drop 
FEF25-75% (L/s) 1.07 ± 0.21 0.58 ± 0.13 0.63 ± 0.13 
Post-EVH max % 
drop FVC 9.79 ± 2.13 4.49 ± 1.03 * 4.43 ± 0.97 
Post-EVH max % 
drop FEV1 17.29 ± 1.98 9.94 ± 1.90 * 10.19 ± 3.35 
Post-EVH max % 
drop FEF25-75% 28.33 ± 3.33 18.43 ± 4.52 17.75 ± 3.26 
AUC FEV1 202.72 ± 12.18 112.36 ± 30.26 91.21 ± 49.03 
Pre-EVH Exhaled 
Breath Condensate 
pH 6.92 ± 0.13 7.18 ± 0.11 6.85 ± 0.12 
Post-EVH Exhaled 
Breath Condensate 
pH 6.85 ± 0.08 7.22 ± 0.08 6.68 ± 0.18 
Pre-EVH FENO 33.5 ± 7.0 41.4 ± 9.5 31.0 ± 4.7 
Post-EVH FENO 32.8 ± 8.4 36.1 ± 7.8 27.8 ± 4.9 
Table 2-5.  Summary of the treatment effects in the Fish Oil Group at each 
laboratory visit.  These subjects (n = 6) received fish oil for the first treatment phase 
and both fish oil and vitamin C for the second treatment phase.  Values are reported as 
mean ± standard error of the mean.  FVC, forced vital capacity; FEV1, forced expiratory 
volume in one second; FEF25=75%, forced expiratory flow at 25-75% of the FVC; AUC 
FEV1, area under the curve of the percent change in FEV1, FENO, fraction of exhaled 
nitric oxide; *, significantly different from pre-supplementation 
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Variable 
Pre-
Supplementation Vitamin C 
Fish Oil + 
Vitamin C 
Post-EVH max drop 
FVC (L) 0.63 ± 0.20 0.56 ± 0.27 0.18 ± 0.08 
Post-EVH max drop 
FEV1 (L) 0.88 ± 0.19 0.76 ± 0.32 0.34 ± 0.09 * 
Post-EVH max drop 
FEF25-75% (L/s) 1.29 ± 0.20 1.23 ± 0.39 0.71 ± 0.17 * 
Post-EVH max % 
drop FVC 12.07 ± 2.94 9.98 ± 4.39 3.29 ± 1.50 * 
Post-EVH max % 
drop FEV1 23.48 ± 4.50 18.03 ± 7.05 8.64 ± 2.14 
Post-EVH max % 
drop FEF25-75% 39.28 ± 6.08 32.73 ± 10.45 18.45 ± 3.73 * 
AUC FEV1 346.99 ± 81.61 232.63 ± 106.22 103.41 ± 36.11 
Pre-EVH Exhaled 
Breath Condensate 
pH 7.05 ± 0.11 6.94 ± 0.09 6.91 ± 0.08 
Post-EVH Exhaled 
Breath Condensate 
pH 7.10 ± 0.11 7.06 ± 0.09 7.20 ± 0.10 † 
Pre-EVH FENO 89.7 ± 44.9 82.7 ± 38.9 66.1 ± 19.6 
Post-EVH FENO 65.8 ± 26.9 72.6 ± 39.3 † 54.8 ± 18.0 † 
Table 2-6.  Summary of the treatment effects in the Vitamin C Group at each 
laboratory visit.  These subjects (n = 7) received vitamin C for the first treatment phase 
and both fish oil and vitamin C for the second treatment phase.  Values are reported as 
mean ± standard error of the mean.  FVC, forced vital capacity; FEV1, forced expiratory 
volume in one second; FEF25=75%, forced expiratory flow at 25-75% of the FVC; AUC 
FEV1, area under the curve of the percent change in FEV1, FENO, fraction of exhaled 
nitric oxide; *, significantly different from pre-supplementation; †, post-EVH value 
significantly different from the pre-EVH value at the same laboratory visit 
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Variable 
Pre-
Supplementation Fish Oil + Vitamin C 
Post-EVH max drop 
FVC (L) 0.58 ± 0.11 0.21 ± 0.05 * 
Post-EVH max drop 
FEV1 (L) 0.81 ± 0.11 0.38 ± 0.07 * 
Post-EVH max drop 
FEF25-75% (L/s) 1.19 ± 0.14 0.67 ± 0.10 * 
Post-EVH max % drop 
FVC 11.02 ± 1.82 3.82 ± 0.90 * 
Post-EVH max % drop 
FEV1 20.62 ± 2.65 9.36 ± 6.68 * 
AUC FEV1 280.39 ± 47.46 97.78 ± 28.57 * 
Pre-EVH Exhaled 
Breath Condensate pH 6.98 ± 0.08 6.88 ± 0.07 
Pre-EVH FENO 63.7 ± 24.8 49.9 ± 11.5 
Post-EVH FENO 50.6 ± 15.2 42.3 ± 10.4 † 
Table 2-7.  Summary of the treatment effects for all subjects at the pre-supplement 
and combination treatment tests.  Data from the Fish Oil and Vitamin C groups were 
pooled for variables in which the subjects were not significantly different from each other 
(n = 13).  Values are reported as mean ± standard error of the mean.  FVC, forced vital 
capacity; FEV1, forced expiratory volume in one second; FEF25=75%, forced expiratory 
flow at 25-75% of the FVC; AUC FEV1, area under the curve of the percent change in 
FEV1, FENO, fraction of exhaled nitric oxide; *, significantly different from each other 
 
 
 Pulmonary Function.  At the initial laboratory test, subjects who would receive 
fish oil during the first supplementation period (Fish Oil Group) showed a mean 
maximum drop in post-EVH FEV1 of 0.72 ± 0.11 L or 17.29 ± 1.98% of their resting 
FEV1.  Subjects who would receive vitamin C during the first supplementation period 
(Vitamin C Group) showed a mean maximum drop in post-EVH FEV1 of 0.88 ± 0.19 L or 
23.48 ± 4.50% of their resting FEV1.  Since there was no significant difference in the pre-
supplementation FEV1 values between the Fish Oil Group and Vitamin C Group (p > 
0.05), the subjects were pooled to determine the overall effect of the combination 
treatment.  Thus, the maximum volume and percent changes in FEV1 were significantly 
  43 
lower (p < 0.05) with the combination treatment (0.42 ± 0.08 L, 11.36 ± 2.63%) as 
compared to pre-supplementation (0.77 ± 0.11 L, 19.92 ± 2.55%) (figures 2-2, 2-3).   
 
 
Figure 2-2.  The maximum drop in FEV1 volume for all subjects at the pre-
supplementation and combination treatment tests following the eucapnic 
voluntary hyperventilation challenge.  The maximum post-challenge change in the 
volume of the FEV1 was significantly reduced with the combination treatment.  Error bars 
represent standard error of the mean.  FEV1, forced expiratory volume in one second; *, 
significantly different from each other 
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Figure 2-3.  The maximum percent drop in FEV1 for all subjects at the pre-
supplementation and combination treatment tests following the eucapnic 
voluntary hyperventilation challenge.  The maximum post-challenge percent change 
in FEV1 was significantly reduced with the combination treatment.  Error bars represent 
standard error of the mean.  FEV1, forced expiratory volume in one second; *, 
significantly different from each other 
  
 When examined in isolation, subjects in the Fish Oil Group demonstrated 
significant differences (p < 0.016) in their FEV1 values between pre-supplementation and 
fish oil treatment.  The maximum volume and percent changes in FEV1 (figures 2-4, 2-5) 
were significantly reduced (p < 0.016) with fish oil (0.39 ± 0.07 L, 10.80 ± 1.82%) as 
compared to pre-supplementation (0.66 ± 0.11 L, 16.36 ±1.92%).  However, there were 
no significant differences (p > 0.016) between the combination treatment (0.50 ± 0.13 L, 
14.07 ± 4.80%) and pre-supplementation or between the combination treatment and the 
fish oil treatment.   
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Figure 2-4.  The maximum drop in FEV1 volume for the Fish Oil Group at each 
laboratory test.   The maximum drop in the post-eucapnic voluntary hyperventilation 
challenge was significantly reduced with fish oil supplementation compared to pre-
supplementation for these subjects (n = 6).  There were no significant changes between 
pre-supplementation and the combination treatment or between the fish oil treatment 
and the combination treatment.   Error bars represent standard error of the mean.  FEV1, 
forced expiratory volume in one second; *, significantly different from each other 
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Figure 2-5.  The maximum percent drop in FEV1 for the Fish Oil Group at each 
laboratory test.  There was a significant decrease in the maximum percent drop in the 
post-eucapnic voluntary hyperventilation FEV1 with the fish oil treatment compared to 
pre-supplementation (n = 6).  There was not a significant change between pre-
supplementation and the combination treatment or between the fish oil treatment and the 
combination treatment.   Error bars represent standard error of the mean.  FEV1, forced 
expiratory volume in one second; *, significantly different from each other 
 
  In contrast, the subjects in the Vitamin C Group only showed a significant change 
in FEV1 on the combination treatment as compared to pre-supplementation.  The mean 
maximum drop in post-EVH FEV1 significantly decreased (p < 0.016) with the 
combination treatment (0.34 ± 0.09 L) compared to pre-supplementation (0.88 ± 0.19 L) 
(figure 2-6).  There was not a significant change (p > 0.016) in the maximum percent 
drop in post-EVH FEV1 between the combination treatment (8.64 ± 2.14%) and pre-
supplementation (23.48 ± 4.50%) (figure 2-7).  
 
Also, as a group, there were no 
significant differences (p > 0.016) between the combination treatment and the vitamin C 
treatment (0.76 ± 0.32 L, 18.03 ± 7.05%) or between the vitamin C treatment and pre-
supplementation.   
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Figure 2-6.  The maximum drop in FEV1 volume for the Vitamin C Group at each 
laboratory test.  The maximum drop in the post-eucapnic voluntary hyperventilation 
challenge was significantly reduced with the combination treatment of fish oil and vitamin 
C compared to pre-supplementation for these subjects (n = 7).  There were no significant 
changes between pre-supplementation and the vitamin C treatment or between the 
vitamin C treatment and the combination treatment.  Error bars represent standard error 
of the mean.  FEV1, forced expiratory volume in one second; *, significantly different from 
each other 
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Figure 2-7.  The maximum drop in FEV1 volume for the Vitamin C Group at each 
laboratory test.  There was not a significant change in the maximum percent drop in the 
post-eucapnic voluntary hyperventilation FEV1 among the pre-supplementation, vitamin 
C, and the combination treatment (n = 7).   Error bars represent standard error of the 
mean.  FEV1, forced expiratory volume in one second 
 
  Since exercise-induced bronchoconstriction is defined as a post-exercise drop in 
FEV1 of at least 10% and most often occurs between 5 to 15 minutes following exercise, 
it is important to examine the effects of treatment on this response in hyperpnea-induced 
bronchoconstriction.  The Fish Oil Group and Vitamin C Group were not significantly 
different (p > 0.05) from each other in terms of the percent change in FEV1 at any of the 
time points; thus, the subjects were pooled to evaluate the overall effect of the 
combination treatment compared to pre-supplementation.  The percent drop in FEV1 was 
significantly reduced (p < 0.05) with the combination treatment at 5, 10, 15, and 20 
minutes post-EVH (figure 2-8).  Additionally, the area under the FEV1 curve for the 20 
minutes following EVH (AUC0-20) was significantly reduced (p < 0.05) with the 
combination treatment (97.78 ± 28.57) as compared to pre-supplementation (280.40 ± 
47.46) (figure 2-9).  
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Figure 2-8.  The mean percent change in FEV1 volume for all subjects for 20 
minutes following the eucapnic voluntary hyperventilation (EVH) challenge.  At 
each of the post-EVH time points tested, the percent change in FEV1 was significantly 
lower with the combination treatment compared to pre-supplementation (n = 13). Error 
bars represent standard error of the mean.  FEV1, forced expiratory volume in one 
second; *, significantly different from pre-supplementation 
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Figure 2-9.  The area under the FEV1 curve for the 20 minutes following EVH 
(AUC0-20) for all subjects.  The bronchoconstrictor response, as measured by the AUC0-
20, was significantly reduced with the combination treatment compared to pre-
supplementation (n = 13).  Error bars represent standard error of the mean.  FEV1, 
forced expiratory volume in one second; *, significantly different from each other 
 
  For the Fish Oil Group, the percent drop in FEV1 was significantly reduced (p < 
0.016) at 5 minutes post-EVH with the combination treatment compared to pre-
supplementation (figure 2-10).  There were no significant differences (p > 0.016) in 
AUC0-20 among the pre-supplementation (202.72 ± 12.18), fish oil treatment (112.36 ± 
30.26), and combination treatment (91.21 ± 49.03) tests (figure 2-11). 
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Figure 2-10.  The mean percent change in FEV1 volume for the Fish Oil Group for 
20 minutes following the eucapnic voluntary hyperventilation (EVH) challenge.  At 
five minutes post-EVH, the percent change in FEV1 was significantly lower with the 
combination treatment compared to pre-supplementation (n = 6).  There were no other 
significant differences at any other time points.  Error bars represent standard error of 
the mean.  FEV1, forced expiratory volume in one second; *, significantly different pre-
supplementation 
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Figure 2-11.  The area under the FEV1 curve for the 20 minutes following EVH 
(AUC0-20) in the Fish Oil Group.  There were no significant differences in the AUC0-20 
among the pre-supplementation, fish oil treatment, and combination treatment tests (n = 
6).  Error bars express standard error of the mean.  FEV1, forced expiratory volume in 
one second 
 
  The Vitamin C Group did not demonstrate any significant changes (p > 0.016) in 
the percent drop in FEV1 at any of the post-EVH time points among the three laboratory 
tests (figure 2-12).  Furthermore, there were no significant changes (p > 0.016) in the 
AUC0-20 among the pre-supplementation (346.98 ± 81.61), vitamin C treatment (232.63 ± 
106.22), and combination treatment (103.41 ± 36.11) laboratory tests (figure 2-13). 
0
50
100
150
200
250
AUC0-20
Pre-Supplementation
Fish Oil
Fish Oil + Vitamin C
  53 
 
Figure 2-12.  The mean percent change in FEV1 volume for the Vitamin C Group for 
20 minutes following the eucapnic voluntary hyperventilation (EVH) challenge.  
There were no significant changes in the post-EVH percent change in FEV1 at any of the 
times points tested among the three laboratory visits for these subjects (n = 7).  Error 
bars express standard error of the mean.  FEV1, forced expiratory volume in one second 
 
 
 
 
 
-30
-25
-20
-15
-10
-5
0
0 5 10 15 20
% Change in 
FEV1
Time (minutes post-EVH challenge)
Pre-Supplementation
Vitamin C
Fish Oil + Vitamin C
Threshold for 
Hyperpnea-Induced 
Bronchoconstriction
  54 
 
Figure 2-13.  The area under the FEV1 curve for the 20 minutes following EVH 
(AUC0-20) in the Vitamin C Group.  There were no significant differences in the AUC0-20 
among the pre-supplementation, vitamin C, and combination treatment laboratory tests 
(n = 7).  Error bars express standard error of the mean.  FEV1, forced expiratory volume 
in one second 
 
 At the pre-supplementation lab test, the Fish Oil Group had a mean maximum 
drop in post-EVH FVC of 0.53 ± 0.10 L or 9.79 ± 2.13% of their resting FVC while the 
Vitamin C Group had a mean maximum drop in post-EVH FVC of 0.63 ± 0.20 or 12.07 ± 
2.94% of their resting FVC.  The groups were not significantly different (p > 0.05).  The 
groups were thus pooled to determine the effect of the combination treatment on FVC.  
The maximum volume and percent changes in FVC were significantly lower (p < 0.05) 
with the combination treatment (0.22 ± 0.05 L, 4.11 ± 0.89%) as compared to pre-
supplementation (0.55 ± 0.11 L, 10.35 ± 1.81%) (figures 2-14, 2-15).   
 
0
50
100
150
200
250
300
350
400
450
500
AUC0-20
Pre-Supplementation
Vitamin C
Fish Oil + Vitamin C
  55 
 
Figure 2-14.  Maximum drop in FVC following the eucapnic voluntary 
hyperventilation challenge for all subjects.  The maximum post-challenge drop in 
FVC was significantly reduced with the combination treatment compared to pre-
supplementation (n = 13).  Error bars express standard error of the mean.  FVC, forced 
vital capacity; *, significantly different from each other 
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Figure 2-15.  Maximum percent drop in FVC following the eucapnic voluntary 
hyperventilation challenge for all subjects.  The combination treatment significantly 
decreased the maximum percent drop in FVC as compared to pre-supplementation (n = 
13).  Error bars express standard error of the mean.  FVC, forced vital capacity; *, 
significantly different from each other 
 
 The fish oil treatment alone significantly improved the FVC in the Fish Oil Group.  
After taking fish oil, these subjects demonstrated significant reductions (p < 0.016) in 
both the maximum volume (0.23 ± 0.05 L) and percent changes (4.56 ± 0.88%) in their 
post-EVH FVC values compared to pre-supplementation (0.46 ± 0.11 L, 8.64 ± 2.14%) 
(figures 2-16, 2-17).  However, there were no significant differences (p > 0.016) between 
the combination treatment (0.25 ±0.05 L, 4.94 ± 0.96%) and pre-supplementation or 
between the combination treatment and the fish oil treatment.   
-14.00
-12.00
-10.00
-8.00
-6.00
-4.00
-2.00
0.00
Maximum % 
Drop in FVC
Pre-Supplementation
Fish Oil + Vitamin C
*
*
  57 
 
Figure 2-16.  Maximum drop in FVC following the eucapnic voluntary 
hyperventilation challenge for the Fish Oil Group.  The maximum drop in FVC was 
significantly reduced with the fish oil treatment compared to pre-supplementation (n = 6).  
There were no significant differences between pre-supplementation and the combination 
treatment or between the fish oil treatment and the combination treatment.  Error bars 
express standard error of the mean.  FVC, forced vital capacity; *, significantly different 
from each other 
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Figure 2-17.  Maximum percent drop in FVC following the eucapnic voluntary 
hyperventilation challenge for the Fish Oil Group.  The fish oil treatment significantly 
decreased the maximum drop in FVC as compared to pre-supplementation (n = 6).  
There were no significant differences between pre-supplementation and the combination 
treatment or between the fish oil treatment and the combination treatment.Error bars 
express standard error of the mean.  FVC, forced vital capacity; *, significantly different 
from each other 
 
Although the vitamin C treatment alone did not significantly alter the FVC of the 
Vitamin C Group compared to pre-supplementation, the combination treatment was 
effective.  There was not a significant change (p > 0.016) in the maximum post-EVH 
FVC volume with the combination treatment (0.18 ± 0.08 L) compared to pre-
supplementation (0.63 ± 0.20 L) or to the vitamin C treatment (0.56 ± 0.27 L) (figure 2-
18). However, the mean maximum percent drop in post-EVH FVC was significantly lower 
(p < 0.016) with the combination treatment (3.29 ± 1.50%) than at pre-supplementation 
(12.07 ± 2.94%) (figure 2-19).   
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Figure 2-18.  Maximum drop in FVC following the eucapnic voluntary 
hyperventilation challenge for the Vitamin C Group.  There were no significant 
changes in the maximum drop in FVC among the pre-supplementation, vitamin C 
treatment, or combination treatment laboratory tests (n = 7).  Error bars express 
standard error of the mean.  FVC, forced vital capacity 
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Figure 2-19.  Maximum percent drop in FVC following the eucapnic voluntary 
hyperventilation challenge for the Vitamin C Group.  The maximum percent drop in 
FVC was significantly decreased with the combination treatment compared to pre-
supplementation (n = 7).  There were no significant differences between pre-
supplementation and the vitamin C treatment or between the vitamin C treatment and 
the combination treatment.  Error bars express standard error of the mean.  FVC, forced 
vital capacity; *, significantly different from each other 
 
 The Fish Oil Group had a mean maximum drop in post-EVH FEF25-75% of 1.07 ± 
0.21 L/s or 28.33 ± 3.33% of their resting FEF25-75% at the first laboratory test.  The 
Vitamin C Group had a mean maximum drop in post-EVH FEF25-75% of 1.29 ± 0.20 L/s or 
39.28 ± 6.08% of their resting FEF25-75% at the first laboratory test.  Although the groups 
did not significantly differ in the change in flow rate (p > 0.05), the groups were 
significantly different at some time points when this value was expressed in terms of a 
percentage of the resting FEF25-75% (p < 0.05).  Therefore, only the data on the change in 
flow rate was pooled for the subjects to determine the effect of the combination 
treatment on FEF25-75%.  The maximum flow rate change in FEF25-75% was significantly 
lower (p < 0.05) with the combination treatment (0.72 ± 0.11 L/s) as compared to pre-
supplementation (1.15 ±  0.14 L/s) (figure 2-20). 
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Figure 2-20.  Maximum percent drop in FEF25-75% following the eucapnic voluntary 
hyperventilation challenge for all subjects.  The combination treatment significantly 
reduced the maximum drop in FEF25-75% as compared to pre-supplementation (n = 13).  
Error bars express standard error of the mean.  FEF25-75%, forced expiratory flow at 25-
75% of the forced vital capacity; *, significantly different from each other 
 
 The Fish Oil Group did not demonstrate any significant differences (p > 0.016) in 
the maximum drop in FEF25-75% in terms of flow rate or percent change among the pre-
supplementation (1.00 ± 0.19 L/s, 28.08 ± 2.82%), fish oil treatment (0.56 ± 0.11 L/s, 
19.16 ± 3.89), and combination treatment (0.73 ± 0.15 L/s, 24.49 ± 7.27%) laboratory 
visits (figures 2-21, 2-22).  However, while on the combination treatment, the Vitamin C 
Group had a mean maximum drop in post-EVH FEF25-75% that was significantly reduced 
(p < 0.016) in terms of the change in flow rate (0.71 ± 0.17 L/s) and the change in the 
percentage of the resting value (18.45 ± 3.73%) in comparison to pre-supplementation 
(1.29 ±  0.20 L/s, 39.28 ±  6.08%) (figures 2-23, 2-24).  There were no significant 
differences (p > 0.016) in the post-EVH FEF25-75% between the combination treatment 
and the vitamin C treatment (1.23 ± 0.39 L/s, 32.73 ± 10.45%) or between the vitamin C 
treatment and pre-supplementation.   
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Figure 2-21.  Maximum drop in FEF25-75% following the eucapnic voluntary 
hyperventilation challenge for the Fish Oil Group.  There were no significant 
changes in the maximum drop in FEF25-75% among the pre-supplementation, fish oil 
treatment, and combination treatment laboratory tests (n = 6).  Error bars express 
standard error of the mean.  FEF25-75%, forced expiratory flow at 25-75% of the forced 
vital capacity 
 
  
 
 
-1.40
-1.20
-1.00
-0.80
-0.60
-0.40
-0.20
0.00
Maximum 
Drop in 
FEF25-75%(L/S)
Pre-Supplementation
Fish Oil
Fish Oil + Vitamin C
  63 
 
Figure 2-22.  Maximum percent drop in FEF25-75% following the eucapnic voluntary 
hyperventilation challenge for the Fish Oil Group.  There were no significant 
differences in the maximum percent drop in FEF25-75% among the three laboratory visits 
(n = 6).   Error bars express standard error of the mean.  FEF25-75%, forced expiratory 
flow at 25-75% of the forced vital capacity 
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Figure 2-23.  Maximum drop in FEF25-75% following the eucapnic voluntary 
hyperventilation challenge for the Vitamin C Group.  The combination treatment 
significantly reduced the maximum drop in FEF25-75% as compared to pre-
supplementation (n = 7).  There were no significant differences between pre-
supplementation and the vitamin C treatment or between the vitamin C treatment and 
the combination treatment.  Error bars express standard error of the mean.  FEF25-75%, 
forced expiratory flow at 25-75% of the forced vital capacity; *, significantly different from 
each other 
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Figure 2-24.  Maximum percent drop in FEF25-75% following the eucapnic voluntary 
hyperventilation challenge for the Vitamin C Group.  The maximum percent drop in 
FEF25-75% was significantly decreased with the combination treatment compared to pre-
supplementation (n = 7).  There were no significant changes between pre-
supplementation and the vitamin C treatment or between the vitamin C treatment and 
the combination treatment.  Error bars express standard error of the mean.  FEF25-75%, 
forced expiratory flow at 25-75% of the forced vital capacity; *, significantly different from 
each other 
 
  Fraction of Exhaled Nitric Oxide.  There were no significant differences (p > 0.05) 
between the Fish Oil Group and the Vitamin C Group for either the pre-or post-EVH 
fraction of exhaled nitric oxide (FENO); therefore, the groups were again pooled to 
determine overall differences between pre-supplementation and the combination 
treatment.  There were no significant differences (p > 0.05) between the pre-EVH FENO 
values at the combination treatment test (58.2 ± 13.5 ppb) compared to the pre-
supplementation test (67.0 ± 23.2 ppb) or between the post-EVH FENO values at the 
combination treatment test (48.2 ± 11.2 ppb) compared to the pre-supplementation test 
(53.3 ± 14.3 ppb).  Moreover, there was not a significant difference (p > 0.05) between 
the pre- and post-EVH values at the pre-supplementation test; the mean change score 
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between the values was -13.1 ± 10.2 ppb.  However, the post-EVH FENO was 
significantly lower (p < 0.05) than the pre-EVH FENO with the combination treatment; the 
mean change score between the values was -7.6 ± 2.1 ppb (figure 2-25). 
 
  
Figure 2-25.  The fraction of exhaled nitric oxide (FENO) pre- and post-eucapnic 
voluntary hyperventilation (EVH) challenge for all subjects.  The post-EVH FENO 
was significantly decreased from the pre-EVH FENO at the combination treatment test 
but not at the pre-supplementation test (n = 13).  There were no significant differences in 
the pre-EVH FENO or in the post-EVH FENO between the pre-supplementation and 
combination treatment laboratory tests.  Error bars express standard error of the mean.  
*, significantly different from each other 
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  The Fish Oil Group did not show any significant changes (p > 0.016) in pre-FENO 
with either the fish oil treatment (41.4 ± 9.5 ppb) or the combination treatment (31.0 ± 4.7 
ppb) as compared to each other or to the pre-supplementation value (33.5 ± 7.0) (figure 
2-26).  Also, the Fish Oil Group did not have any significant changes (p > 0.016) in post-
FENO among pre-supplementation (32.8 ± 8.4 ppb), fish oil treatment (36.1 ± 7.8 ppb), 
and combination treatment (27.8 ± 4.9 ppb).  The mean change scores between pre- 
and post-EVH FENO were -0.7 ± 2.4 ppb at pre-supplementation, -5.3 ± 4.2 ppb at the 
fish oil treatment test, and -3.2 ± 1.5 ppb at the combination treatment test.  In contrast, 
the Vitamin C Group demonstrated a significant decrease (p < 0.016) in the post-EVH 
FENO as compared to the pre-EVH FENO with both the vitamin C treatment and the 
combination treatment (figure 2-27).  The mean change scores between pre- and post-
EVH FENO were -23.8 ± 18.5 ppb at pre-supplementation, -10.1 ± 2.5 ppb at the vitamin 
C treatment test, and -11.3 ± 3.1 ppb at the combination treatment test.  However, there 
were no significant changes (p > 0.016) between pre-EVH FENO values at the vitamin C 
treatment test (82.7 ± 38.9 ppb) compared to the pre-supplementation test (89.7 ± 44.9 
ppb) or at the combination treatment test (66.1 ± 19.6 ppb) compared to the pre-
supplementation test.  There were also no significant changes (p > 0.016) in the post-
EVH FENO values among the pre-supplementation test (65.8 ± 26.9 ppb), vitamin C 
treatment test (72.6 ± 39.3 ppb), and combination treatment test (54.8 ± 18.0 ppb). 
 
  68 
 
Figure 2-26.  The fraction of exhaled nitric oxide (FENO) pre- and post-eucapnic 
voluntary hyperventilation (EVH) challenge for the Fish Oil Group.  There were no 
significant changes in FENO for the Fish Oil Group (n = 6).  Error bars express standard 
error of the mean.   
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Figure 2-27.  The fraction of exhaled nitric oxide (FENO) pre- and post-eucapnic 
voluntary hyperventilation (EVH) challenge for the Vitamin C Group.  The post-EVH 
FENO was significantly lower than the pre-EVH FENO at the vitamin C treatment and 
combination treatment tests but not at the pre-supplementation test (n = 7).  There were 
no significant differences in the pre-EVH or post-EVH FENO values among the three 
laboratory tests. Error bars express standard error of the mean.  *, significantly different 
from the pre-EVH value at the same laboratory test 
 
 
 Exhaled Condensate Breath pH.  Although the Fish Oil Group and the Vitamin C 
Group were not significantly different (p > 0.05) in the pre- or post-EVH exhaled breath 
condensate (EBC) pH at the pre-supplementation test, the groups were significantly 
different (p < 0.05) in the post-EVH EBC pH at the combination treatment test.  Thus, the 
groups were not pooled to examine the overall effect of the combination treatment on the 
EBC pH. 
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 The Fish Oil Group’s pre-EVH EBC pH did not significantly change (p > 0.016) 
among the pre-supplementation (6.92 ± 0.32), fish oil treatment (7.18 ± 0.10), and 
combination treatment tests (6.85 ± 0.11).  However, their post-EVH EBC pH was 
significantly increased (p < 0.016) with the fish oil treatment (7.22 ± 0.08) as compared 
to the combination treatment (6.68 ± 0.17) (figure 2-28).  There were no significant 
differences (p > 0.016) between the pre-supplement value (6.85 ± 0.07) and the fish oil 
treatment value or the combination treatment value.   
 
 
 
Figure 2-28.  Exhaled breath condensate (EBC) pH pre- and post-eucapnic 
voluntary hyperventilation (EVH) challenge for the Fish Oil Group.  There were no 
significant changes in the pre-EVH EBC pH values among the laboratory tests (n = 6).  
The post-EVH EBC pH values were significantly different from each other at the fish oil 
treatment and combination treatment laboratory tests.  Error bars express standard error 
of the mean. *, significantly different from each other   
 
6.00
6.20
6.40
6.60
6.80
7.00
7.20
7.40
Pre-Supplementation  Fish Oil  Fish Oil + Vitamin C
pH Pre-EVH
Post-EVH
*
*
  71 
  Six out of the seven subjects in the Vitamin C Group provided adequate EBC 
samples to test the pH at all three lab tests.  This group did not show any significant 
changes (p > 0.016) in the pre-EVH EBC pH among the pre-supplementation (7.05 ± 
0.11), vitamin C treatment (6.94 ± 0.09), and combination treatment (6.91 ± 0.21) tests.  
There were also no significant changes (p > 0.016) in the post-EVH EBC pH among the 
pre-supplementation (7.10 ± 0.11), vitamin C treatment (7.06 ± 0.09), and combination 
treatment (7.20 ± 0.10) tests for the Vitamin C Group (figure 2-29).   
 
 
Figure 2-29.  Exhaled breath condensate pH pre- and post-eucapnic voluntary 
hyperventilation (EVH) challenge.  There were no significant differences in the pre-
EVH or post-EVH EBC pH values among the pre-supplementation, vitamin C treatment, 
and combination treatment laboratory tests (n = 6).  Error bars express standard error of 
the mean.   
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 Symptoms and Short-Acting β-Agonist Usage.  During the run-in phase, first 
treatment phase, washout phase, and combination treatment phase, subjects recorded 
their daytime symptoms and nighttime symptoms using a symptom diary (83).  They also 
reported their short-acting β-agonist usage by recording the number of puffs taken each 
day.  The Fish Oil Group’s daytime symptom score decreased throughout the study 
phases from 1.13 ± 0.18 during the run-in phase, to 0.90 ± 0.18 during the fish oil 
treatment phase, to 0.79 ± 0.17 during the washout phase, and to 0.76 ± 0.15 during the 
combination treatment phase; the washout and combination treatment phases were both 
significantly lower (p < 0.05) than the run-in phase (figure 2-30).  The Vitamin C Group 
did not exhibit any significant changes (p > 0.05) in the daytime symptom score between 
any of the study’s phases (run-in phase: 1.63 ± 0.25, vitamin C treatment phase: 1.21 ± 
0.27, washout phase: 1.50 ± 0.25, combination treatment phase: 1.52 ± 0.27).  Neither 
the Fish Oil Group nor the Vitamin C Group demonstrated significant changes (p > 0.05) 
in the nighttime symptom score among the run-in phase (Fish Oil Group: 0.10 ± 0.09, 
Vitamin C Group: 0.21 ± 0.08), one treatment phase (Fish Oil Group: 0.04 ± 0.04, 
Vitamin C Group: 0.05 ± 0.05), washout phase (Fish Oil Group: 0.00 ± 0.00, Vitamin C 
Group: 0.15 ± 0.08), and combination treatment phase (Fish Oil Group: 0.00 ± 0.00, 
Vitamin C Group: 0.14 ± 0.08).  Furthermore, neither group had a significant difference 
(p > 0.05) in their short-acting β-agonist usage from the run-in phase (Fish Oil Group: 
0.38 ± 0.30 puffs per day, Vitamin C Group: 0.84 ± 0.65 puffs per day), to the one 
treatment phase (Fish Oil Group: 0.04 ± 0.03 puffs per day, Vitamin C Group: 0.58 ± 
0.48 puffs per day), to the washout phase (Fish Oil Group: 0.08 ± 0.04 puffs per day, 
Vitamin C Group: 0.38 ± 0.32 puffs per day), and to the combination treatment phase 
(Fish Oil Group: 0.08 ± 0.04 puffs per day, Vitamin C Group: 0.37 ± 0.24 puffs per day) 
(figures 2-31, 2-32).   
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Figure 2-30.  Daily symptom scores for the Fish Oil Group and Vitamin C Group 
during each of the study’s phases.  The Fish Oil Group’s daytime symptom score was 
significantly lower during the washout and combination treatment phases than during the 
pre-supplementation phase (n = 6).  There were no significant differences in the daily 
symptom scores among the pre-supplementation, one treatment, washout, and 
combination treatment study phases for the Vitamin C Group (n = 7).  Error bars express 
standard error of the mean.  *, significantly different from pre-supplementation   
 
 
 
 
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
2.00
Fish Oil Group Vitamin C Group
Daily 
Symptom 
Score
Pre-Supplementation
One Treatment
Washout
Combination Treatment
*
*
  74 
 
Figure 2-31.  Nightly symptom scores for the Fish Oil Group and Vitamin C Group 
during each of the study’s phases.  There were no significant changes in the nightly 
symptom scores among the four study phases for either the Fish Oil Group (n = 6) or the 
Vitamin C Group (n = 7).  Error bars express standard error of the mean.   
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Figure 2-32.  Average daily bronchodilator use for the Fish Oil Group and Vitamin 
C Group during each of the study’s phases.  There were no significant differences in 
the subjects’ bronchodilator use among the pre-supplementation, one treatment, 
washout, and combination treatment study phases for either the Fish Oil Group (n = 6) or 
the Vitamin C Group (n = 7).  Error bars express standard error of the mean.   
 
  Peak Flow Measurements.  Each subject used an electronic meter to measure 
his or her peak expiratory flow every morning and evening during the run-in phase, first 
treatment phase, washout phase, and combination treatment phase.  Although there 
were no significant differences (p > 0.05) in their morning peak flow measurements 
during the course of the study (figure 2-33), the Fish Oil Group exhibited a significant 
increase (p < 0.05) in their mean evening peak flow during the combination treatment 
phase (491.61 ± 62.44 L/min) as compared to the pre-supplementation phase (448.29 ± 
63.27 L/min) (figure 2-34).  The fish oil treatment phase (473.94 ± 67.80 L/min) and 
washout phase (480.28 ± 63.69 L/min) did not significantly differ (p > 0.05) from any of 
the other phases.  The Vitamin C Group did not demonstrate any significant changes (p 
> 0.05) in their morning or evening peak flow throughout the study.     
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Figure 2-33.  Morning peak expiratory flow values for the Fish Oil Group and 
Vitamin C Group during each of the study’s phases.  There were no significant 
differences in the morning peak flow values among the pre-supplementation, one 
treatment, washout, and combination treatment study phases for either the Fish Oil 
Group (n = 6) or the Vitamin C Group (n = 7).  Error bars express standard error of the 
mean.   
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Figure 2-34.  Evening peak expiratory flow values for the Fish Oil Group and 
Vitamin C Group during each of the study’s phases.  The Fish Oil Group 
demonstrated a significant increase in its mean evening peak flow with the combination 
treatment compared to pre-supplementation (n = 6).  There were no significant changes 
in the mean evening peak flow for the Vitamin C Group among the four study phases (n 
= 7).  Error bars express standard error of the mean.  *, significantly different from pre-
supplementation 
 
 
 Nutrient Intake.  Twenty-four hour dietary recalls were used to gauge each 
subject’s nutrient intake during the run-in phase, first treatment phase, washout phase, 
and combination treatment phase.  Neither the Fish Oil Group nor the Vitamin C Group 
significantly changed (p > 0.05) their nutrient intake among any of the study phases 
(table 2-8).   
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Energy 
(kcal) 
Total 
Fat (g) 
Total 
Carbohydrate 
(g) 
Total 
Protein 
(g) 
Total 
Dietary 
Fiber (g) 
Vitamin C 
(mg) 
Arachidonic 
Acid (g) EPA (g) DHA (g) 
Pre-Supplementation                     
Fish Oil Group Mean 3032.23 109.37 364.62 126.20 26.43 93.55 0.20 0.03 0.08 
  SEM 395.85 17.91 67.48 24.21 6.77 23.38 0.04 0.01 0.03 
Vitamin C Group Mean 2042.51 77.83 238.45 85.94 18.60 88.73 0.20 0.09 0.29 
  SEM 308.96 12.10 41.78 16.67 3.80 24.48 0.05 0.04 0.15 
    
One Treatment                     
Fish Oil Group Mean 2713.83 88.40 369.45 113.95 26.05 198.97 0.10 0.03 0.05 
  SEM 369.40 14.53 54.66 21.15 8.24 134.66 0.02 0.02 0.02 
Vitamin C Group Mean 2584.30 103.10 299.20 109.62 20.45 70.38 0.18 0.02 0.07 
  SEM 477.30 20.15 58.65 17.23 3.99 19.72 0.05 0.01 0.02 
    
Washout                     
Fish Oil Group Mean 2842.75 96.15 361.30 111.20 28.29 148.33 0.12 0.06 0.12 
  SEM 560.92 30.62 74.20 18.84 8.12 60.79 0.03 0.03 0.06 
Vitamin C Group Mean 1845.08 61.59 245.38 75.92 16.50 86.72 0.14 0.01 0.04 
  SEM 347.90 14.14 44.93 16.55 3.74 21.99 0.05 0.00 0.02 
    
Combination Treatment                     
Fish Oil Group Mean 3264.28 123.09 414.21 122.95 25.76 114.57 0.11 0.04 0.13 
  SEM 674.89 36.78 77.10 21.88 5.59 36.53 0.02 0.03 0.10 
Vitamin C Group Mean 2042.51 77.83 238.45 85.94 18.60 88.73 0.20 0.09 0.29 
  SEM 308.96 12.10 41.78 16.67 3.80 24.48 0.05 0.04 0.15 
Table 2-8.  Average intake amounts of selected nutrients for the Fish Oil Group and the Vitamin C Group.  There were no 
significant changes in diet for the Fish Oil Group (n = 6) or the Vitamin C Group (n = 7) among the four study phases as assessed by 
nutrient intake.  The average values for the intake of only selected nutrients are presented here.  SEM, standard error of the mean; 
EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid 
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Discussion 
 This study was undertaken to determine whether a combination of nutritional 
supplements would improve pulmonary function and airway inflammation to a greater 
extent than an individual nutritional supplement in adults with asthma and hyperpnea-
induced bronchoconstriction (HIB).  Based on previous research demonstrating the 
effectiveness of fish oil and vitamin C supplementation in attenuating exercise-induced 
bronchoconstriction (EIB), the combination of these supplements was tested (61, 62, 93, 
94).  We have demonstrated that pulmonary function was improved with both fish oil and 
the combination of fish oil and vitamin C but not with vitamin C alone.  Moreover, airway 
inflammation seems to have been affected by vitamin C supplementation as well as by 
the combination treatment of fish oil and vitamin C. 
 Pulmonary function was evaluated with spirometry before and after 
bronchoprovocation.  The forced expiratory volume in one second (FEV1) is the primary 
measure used in diagnosing EIB or HIB because it is known to be highly reproducible.  
The area under the curve of the percent change in FEV1 for a given time period (AUC20) 
represents the bronchoconstrictor response; it thus indicates the degree of airway 
narrowing and recovery following bronchoprovocation.  The forced vital capacity (FVC) 
represents the usable volume of air in the lungs.   The forced expiratory flow at 25-75% 
of the FVC (FEF25-75%) is a measure of constriction in the peripheral airways; it is these 
small, distal airways that are typically obstructed in asthma.   It was expected that these 
pulmonary function measures would improve with each supplement as based on 
previous research and to a greater degree with the combination of fish oil and vitamin C 
based on the proposed mechanism for an additive effect.  Significant improvements 
were seen with either fish oil alone or the combination of supplements but not with 
vitamin C alone.   
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These results for fish oil supplementation support previous research from our 
laboratory showing that fish oil alleviates airway narrowing in EIB and HIB (61, 62, 93).  
However, the lack of significant improvement in any of the pulmonary function measures 
with vitamin C supplementation is in disagreement with Tecklenburg et al. (94).  The 
discrepancy may be due to experimental differences between the studies.  Tecklenburg 
et al. (94) allowed subjects to continue freely using their prescribed asthma medications 
throughout the study except for in the hours to days before laboratory tests where use 
was restricted.  Furthermore, the method of bronchoprovocation differed from the current 
study as Tecklenburg et al. (94) used a sub-maximal treadmill exercise test instead of 
eucapnic voluntary hyperventilation (EVH).  Lastly, although the vitamin C supplement 
composition and daily dose were the same between the studies, the current study 
treated subjects for an additional week in order to match the treatment period required 
for fish oil.  As it known that some antioxidants, such as vitamin C, can become pro-
oxidant in large amounts, this difference in treatment periods may be important (75).  
Nevertheless, this study’s vitamin C results support the finding by Cohen et al. (22) that 
not all asthmatics with exercise-induced bronchoconstriction respond positively to 
vitamin C supplementation.  Cohen et al. (22) found that following a single 2000 mg 
dose of ascorbic acid, only nine of twenty asthmatic subjects had improved post-
exercise pulmonary function compared to placebo.  In the current study, four of the 
seven subjects in the Vitamin C Group had reduced decreases in their FEV1 values after 
the EVH challenge at the laboratory test following vitamin C supplementation.  In future 
nutritional studies, subjects should first be screened for vitamin C responsiveness to 
allow for a more homogeneous study population.   
The combination treatment significantly improved pulmonary function in 
comparison to pre-supplementation values for the Vitamin C Group as well as for all 
subjects overall.  However, a limitation of this study’s research design is that it cannot 
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determine whether fish oil is solely responsible for the overall significant improvements 
in pulmonary function between pre-supplementation and post-combination treatment 
values.  Because subjects in the Vitamin C Group demonstrated significant changes 
from pre-supplementation to the combination treatment but not between pre-
supplementation and the vitamin C treatment, it is not clear whether the improvement is 
due to the combination of fish oil and vitamin C or just due to fish oil.  Since the Fish Oil 
Group demonstrated significant improvement with fish oil alone, the post-combination 
treatment improvements in the Vitamin C Group may be due to these subjects being 
supplemented with active fish oil.  Nevertheless, although the lack of significant changes 
between all treatments makes it difficult to ascertain the effect of the combination 
treatment, improvements observed in individual subjects in both groups throughout the 
study suggest that the combination of fish oil and vitamin C may be effective in a subset 
of the asthma population.  
 Changes in airway inflammation were evaluated by measuring the fraction of 
exhaled nitric oxide (FENO) and exhaled breath condensate (EBC) pH.  These measures 
are recognized as indirect markers of airway inflammation.  It was anticipated that FENO 
would be decreased both pre-EVH and post-EVH with supplementation.  However, no 
significant changes were demonstrated in the pre-EVH or post-EVH FENO values with 
any of the treatments compared to pre-supplementation.  The lack of significant changes 
in FENO with vitamin C supplementation agrees with the results from Baumann et al. 
(16).  These researchers tracked changes in pre-EVH FENO in subjects with EIB who 
were supplemented with a placebo or undenatured whey protein, an antioxidant 
supplement, and determined that there were no significant changes in FENO.   However, 
fish oil supplementation not affecting the pre-EVH FENO in this study differs from 
Tecklenburg-Lund et al. (93) who showed a significant reduction in pre-EVH FENO with 
fish oil treatment.   
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The lack of changes in post-EVH FENO is supported by similar findings by 
Tecklenburg-Lund (92).  It was suggested that there were no significant changes in the 
post-EVH FENO among treatment with fish oil, the leukotriene-receptor antagonist 
montelukast (Singulair®), or the combination of the two as compared to pre-
supplementation because bronchoconstriction may limit the amount of nitric oxide that 
leaves the lungs during an exhalation (24).  Therefore, lower FENO values may be due 
to either reduced airway inflammation or nitric oxide being trapped in the inflamed 
airways of the lungs, which thus confounds the ability of the test to detect changes in 
airway inflammation as intended. 
Additionally, the pre- and post-EVH FENO values were compared for each 
laboratory test.  Overall, in all subjects, there was no significant change (p > 0.05) 
between the pre- and post-EVH FENO at the pre-supplementation test whereas the post-
EVH FENO was significantly lower (p < 0.05) than the pre-EVH FENO with the 
combination treatment, which could suggest either less airway inflammation or increased 
bronchoconstriction as previously mentioned.  In looking at the graph of this data (figure 
2-25), it appears that the large variability in the pre-supplementation measures are 
masking any significant changes.  ElHalawani et al. (29) demonstrated that a wide range 
of FENO values exist in subjects with EIB (median ± standard deviation, 23 ± 42.2 ppb) 
and without EIB (19.95 ± 18.47 ppb).  Moreover, examination of the change scores 
between pre- and post-EVH FENO at the pre-supplementation and combination 
treatment laboratory tests, indicates that there is a smaller decrease in FENO with the 
combination treatment (-7.6 ± 2.1 ppb) than at pre-supplementation (-13.1 ± 10.2 ppb), 
which suggests reduced airway inflammation with supplementation.  Thus, in this case, 
statistical significance or insignificance does not seem to appropriately reflect 
physiological significance.   
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Similarly, in the Vitamin C Group, there was no significant difference (p > 0.016) 
between pre- and post-EVH FENO at the pre-supplementation test.  However, the post-
EVH FENO was significantly lower (p < 0.016) than the pre-EVH at the vitamin C 
treatment test and combination treatment test despite smaller change scores (-10.1 ± 
2.5 ppb and -11.3 ± 3.1 ppb, respectively) compared to the pre-supplementation test     
(-23.8 ± 18.5 ppb).  In addition to the variability in the subjects’ pre-supplementation 
responses, the drastic improvement of one particular subject’s pre- and post-EVH FENO 
from 353.3 ppb and 221.8 ppb, respectively, at pre-supplementation, 311.3 ppb and 
305.7 ppb with the vitamin C treatment, and 169.0 ppb and 152.0 ppb with the 
combination treatment may have also impacted the detection of statistical significance.    
Since it has been shown that people with asthma have a lower EBC pH than 
healthy subjects, it was expected that nutritional supplementation would increase the 
EBC pH.  Because the Fish Oil Group and Vitamin C Group were significantly different 
from each other in terms of the EBC pH, the groups were not pooled to examine the 
overall effect of the combination of fish oil and vitamin C.  There were no significant 
differences in the pre-EVH EBC pH for either group among pre-supplementation, one 
supplement treatment (i.e. fish oil or vitamin C), and the combination treatment.  These 
results are in contrast to those obtained by Tecklenburg-Lund et al. (93) who showed 
that fish oil supplementation significantly improved the mean pre-EVH EBC pH.  
However, the post-EVH EBC pH was significantly greater with fish oil supplementation 
compared to the combination treatment in the Fish Oil Group.  This suggests that these 
subjects had better buffering capabilities with just fish oil than with vitamin C and fish oil.  
Since vitamin C did not improve EBC pH either singly or in combination with fish oil, it 
suggests that vitamin C supplementation does not improve the proinflammatory acidic 
environment of the airways in asthma and may impede fish oil’s positive effect on airway 
inflammation.   
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Subjects were asked to provide records of their morning and evening peak 
expiratory flow (PEF) measurements, short-acting β-agonist usage, and symptoms 
throughout the four phases of the study (run-in, one treatment, washout, and 
combination treatment phases).  It was expected that their PEF would increase while 
their short-acting β-agonist usage and symptoms would decrease throughout the study 
to illustrate improved asthma management with the nutritional supplements.  The Fish 
Oil Group demonstrated a significant increase in the evening PEF and a significant 
decrease in their symptoms with the combination treatment.  There were no significant 
changes seen in their short-acting β-agonist usage.  The Vitamin C Group did not 
demonstrate any significant changes in their PEF, symptoms, or short-acting β-agonist 
usage.   
It has been suggested that self-reported symptoms cannot reliably diagnose EIB 
(82).  However, Santanello et al. (83) have demonstrated that a symptom diary 
containing daytime and nighttime questions with scaled responses was reliable, valid, 
and responsive to changes in clinical trials where subjects also recorded their PEF and 
short-acting β-agonist usage, which is what subjects were asked to do in the current 
study.  This concordance between subjective symptoms and objective measurements 
was seen in this study as the decrease in the daytime symptom score for the Fish Oil 
Group on the combination treatment was accompanied by an increase in the evening 
PEF.  Although there was not a concurrent decrease in short-acting β-agonist usage, 
this should not discount the significance of the other results because the subjects in the 
current study reported low baseline short-acting β-agonist usage; overall, 5 of the 13 
analyzed subjects averaged 0 puffs per day while only 2 subjects averaged greater than 
1 puff per day during the pre-supplementation phase.  Because the significant decrease 
in the daytime symptom score for the Fish Oil Group during the washout phase was not 
accompanied by changes in either objective measure, this change may not be as 
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reliable.  Therefore, treatment phases of the study for which there was not a significant 
change in symptom score and PEF did not significantly improve the day-to-day control of 
asthma in these subjects. 
In conclusion, this study has confirmed the effectiveness of fish oil in preventing 
HIB with a 3-week regimen of 3.2 g of eicosapentaenoic acid (EPA) and 2.0 g of 
docosahexaenoic acid (DHA) per day.  Future studies should determine the optimal 
duration and formula for treatment with fish oil in order to best inform clinical 
recommendations to patients.  Additionally, this study has demonstrated that vitamin C 
supplementation as a therapy for HIB is not universally effective.  However, it can 
improve pulmonary function in a subset of patients.  Thus, in the future, studies 
assessing vitamin C supplementation should include an additional screening period to 
first identify asthmatics who respond to vitamin C supplementation.  This would help 
reduce variability in the subject population.  Due to the multi-faceted nature of asthma, 
studying the most homogenous population of subjects may be a necessary, though 
difficult, task to best assess treatment efficacy.  A vitamin C loading test could also be 
administered at the start of the study to determine the appropriate dose since individuals 
differ in the amount of vitamin C they absorb (97).  Furthermore, there was not an 
additive effect with fish oil and vitamin C as expected.  It is possible that subjects in both 
the Vitamin C and Fish Oil Groups who did not respond to vitamin C may have masked 
the potential additive effect.  Examination of individual subjects’ data reveals cases 
where the subject improved with one treatment and then improved further with the 
combination treatment.  These results encourage future research on combining 
nutritional supplements to treat HIB.  
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CHAPTER 3 
THE EFFECT OF THE OMEGA-3 POLYUNSATURATED FATTY ACID 
DOCOSAHEXAENOIC ACID (DHA) ON HYPERPNEA-INDUCED 
BRONCHOCONSTRICTION IN ADULTS WITH ASTHMA   
Abstract 
Background:  Hyperpnea, or rapid breathing, can be used to identify exercise-induced 
bronchoconstriction, which is a complication of asthma that has been shown to be 
attenuated by supplementation with fish oil.  An optimal formula for fish oil has not been 
determined although previous in vitro studies have suggested that docosahexaenoic 
acid (DHA) may be the more potent omega-3 fatty acid in fish oil in terms of reducing 
inflammation.  
Purpose: Determine whether supplementation with DHA can attenuate 
bronchoconstriction and airway inflammation in adults with asthma as compared to 
placebo. 
Methods:  Nine subjects (18-30 years) with asthma and hyperpnea-induced 
bronchoconstriction (HIB) participated in a randomized, double-blind, placebo-controlled 
crossover trial where they received either DHA or placebo capsules for 3 weeks.  
Following a 2-week washout phase, subjects then received the opposite supplement for 
3 weeks.  Subjects were tested in a laboratory following an initial 2-week run-in phase 
and after each supplementation phase.  At each laboratory test, bronchoprovocation was 
elicited with eucapnic voluntary hyperventilation (EVH), a surrogate exercise challenge 
involving rapid breathing (hyperpnea).  Prior to and following the EVH challenge, 
pulmonary function, fraction of exhaled nitric oxide (FENO), exhaled breath condensate 
pH, and the concentrations of 8-isoprostane and the DHA metabolites 17S-hydroxy-
docosahexaenoic acid and protectin D1 in exhaled breath condensate were measured.  
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Subjects submitted records of their daily symptoms, peak expiratory flow measures, and 
bronchodilator use at each laboratory visit.    
Results:  There were no significant changes in pulmonary function, FENO, exhaled 
breath condensate pH, the concentration of 8-isoprostane, or the concentrations of the 
DHA metabolites 17S-hydroxy-docosahexaenoic acid and protectin D1 with DHA 
supplementation. 
Conclusion:  The data indicate that supplementation with 4.0 g DHA for 3 weeks did not 
significantly attenuate HIB or airway inflammation in asthmatic subjects as compared to 
baseline or placebo.  Supplementation with eicosapentaenoic acid (EPA) should be 
similarly tested to determine if it is the more effective component of fish oil.   
Introduction 
 The Center for Disease Control recently reported that 8.2% of the United States 
population has asthma (6).  Exercise-induced bronchoconstriction (EIB) is an important 
complication of this chronic inflammatory disease of the airways as patients with asthma 
often report limitations in their physical activity (43).  Moreover, EIB is an indication that 
a patient’s current asthma treatment is inadequate (49).  Because asthma is a multi-
faceted disease, multiple medications targeting the acute and chronic symptoms are 
often prescribed (26).  Nearly a third of the estimated $19.7 billion in direct and indirect 
healthcare costs for asthma in 2007 stemmed from prescription medications (1).  
Therefore, there is a growing interest in non-pharmacological alternatives. 
 A nutritional approach is an appealing alternative as the prevalence of asthma 
has been linked to societal changes in diet, such as increased sodium intake along with 
decreased antioxidant and omega-3 polyunsaturated fatty acid (PUFA) intake (60).  
Moreover, dietary supplement use is already popular in both the general and asthmatic 
populations with approximately 50% in each group reporting use in the last month in a 
recent National Health and Nutrition Examination Survey (54).  It is thus important to 
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study these nutritional supplements and their effect on asthma in order to have a 
scientific basis upon which clinicians can recommend their proper and safe use. 
  Omega-3 PUFA supplementation is reportedly used by 6.7% of asthmatics (54).  
The omega-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic (DHA) are the 
primary components of fish oil.  Previous research has shown that supplementation with 
fish oil (3.2 g EPA and 2.0-2.2 g DHA per day for 3 weeks) reduces airway inflammation 
and EIB in elite athletes without asthma (62) and in adults with asthma (61).  The 
mechanism of action of the omega-3 PUFAs is thought to involve decreasing the 
availability of the more proinflammatory omega-6 PUFA products through competition for 
common enzymes (60).  The omega-3 PUFA products cause less bronchoconstriction 
than the omega-6 PUFA products (60). 
 The optimal fish oil formula, dose, and length of treatment period used for 
alleviating EIB has yet to be determined; this is partly due to the fact that there is no 
consensus as to which component of fish oil, EPA or DHA, is the more potent contributor 
to the positive effects seen with supplementation in asthma or EIB (86).  Although there 
have been several in vivo studies in humans and mice (47, 86) as well as in vitro studies 
on human macrophage cells (64, 98) comparing the anti-inflammatory effects of EPA 
and DHA, the existing research primarily focuses on markers of inflammation and 
immune function, not airway responsiveness.  This is a notable shortcoming of the 
available literature comparing EPA and DHA since airway responsiveness is clinically 
important for patients with asthma.  
  Studies by Serhan et al. (84) and Levy et al. (52) provide the principal support for 
DHA as the more potent ingredient in fish oil.  Serhan et al. (84) have demonstrated that 
a metabolite of DHA, now called protectin D1, can actively resolve inflammation by 
reducing proinflammatory signaling.  Applying this mechanism to in vivo murine studies, 
Levy et al. (52) have shown that injecting mice with protectin D1 decreased their 
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subsequent bronchoconstriction during a methacholine challenge.  Furthermore, Levy et 
al. (52) have demonstrated that adding DHA to the homogenized murine lung tissue ex 
vivo yielded a significant increase in the protectin D1 concentration, which suggests that 
DHA can be converted to its anti-inflammatory metabolite by respiratory tissues (52).  In 
addition, it was shown that during an asthma attack, patients had significantly lower 
levels of protectin D1 in their exhaled breath condensate as compared to healthy 
individuals (52).  Therefore, the next step is to determine whether asthmatics taking DHA 
supplements will increase their exhaled breath condensate concentration of protectin D1 
and thus experience less bronchoconstriction upon provocation. 
  The purpose of this study was to investigate whether DHA can attenuate 
hyperpnea-induced bronchoconstriction and airway inflammation in adults with asthma 
as compared to placebo.  It is hypothesized that DHA supplementation will attenuate 
hyperpnea-induced bronchoconstriction (HIB) and airway inflammation in asthmatic 
individuals as compared to placebo. 
Methods 
 Subjects.  Nine subjects (6 male, 3 female) between the ages of 18 to 30 years 
with physician-diagnosed asthma and exercise-induced bronchoconstriction (EIB) were 
recruited from a university setting.  Mild to moderate asthmatics were included based on 
their pulmonary function evaluated during their first laboratory test.  Each subject’s 
forced expiratory volume in one second (FEV1) was measured at rest and following 
eucapnic voluntary hyperventilation, a surrogate exercise challenge used to diagnose 
EIB (9).  Subjects who demonstrated a 10 to 50% change in their FEV1 from pre- to post-
challenge were classified as mildly to moderately asthmatic and permitted to continue in 
the study.  All subjects were allowed to continue to use their prescribed short-acting β2-
agonist (albuterol) throughout the study except for in the six hours before they reported 
to the laboratory for testing.  No other prescribed maintenance medications for asthma 
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were allowed during the study.  This required one subject to stop taking ADVAIR 
DISKUS® (fluticasone propionate and salmeterol) with the written permission of his 
physician for four weeks prior to beginning the study (61).  Exclusion criteria included 
current fish oil supplementation, pregnancy, or a history of seizures, diabetes, 
hypertension, hyperlipidemia, bleeding disorders, or delayed clotting time.  Subjects 
were asked to limit their fish consumption to one meal per week throughout the course of 
the study. 
  This study was approved by the Indiana University Institutional Review Board 
(protocol # 1005001346) and was registered as a clinical trial with clinicaltrials.gov 
(study # NCT01200446).  All subjects gave their informed consent before enrolling in the 
study.  Healthy, non-asthmatic subjects were not recruited to this study to act as a 
control group because it has been demonstrated that fish oil supplementation does not 
significantly change pulmonary function or inflammatory mediators in individuals without 
asthma or EIB (62). 
  Study Design.  This study (figure 3-1) was conducted as a randomized, double-
blind, placebo-controlled crossover trial where subjects received either active capsules 
containing 4.0 g of DHA (Martek Biosciences Corporation, Columbia, MD) (n = 5) or 
placebo capsules containing a corn and soy oil blend (n = 5) for 3 weeks. Following a 2-
week washout period, subjects who were given placebo capsules received active DHA 
capsules and subjects who were given active DHA capsules received placebo capsules 
for 3 weeks. 
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Figure 3-1.  Schematic of study design.  Subjects entered the study on their normal 
diet.  Following a 2-week run-in period, subjects completed a placebo-controlled 
crossover trial of two 3-week supplementation periods separated by a 2-week washout 
phase.  Subjects were supplemented with either 4.0 g of docosahexaenoic acid or 
placebo containing a mixture of corn and soy oils.  
 
  Subjects were enrolled while on their normal diet.  The order of supplementation 
was randomly assigned with the use of a computerized random number generator 
(http://www.randomizer.org/form.htm).  The randomization sequence was created using 
a fixed random block size of two to correspond to the two treatments (i.e. active and 
placebo).  The company supplying the active and placebo capsules delivered sealed pill 
bottles labeled with one of two material numbers.  The principle investigator was not 
informed which material number corresponded to each treatment until after data 
collection and initial data analysis was completed.  The active and placebo capsules 
were identical in appearance so that subjects were not aware of which treatment they 
received. 
  At each laboratory visit, subjects completed the same series of tests.  They 
reported to the laboratory having abstained from exercising for 24 hours, having caffeine 
for 8 hours, and using their short-acting β2-agonist for 6 hours (93).  Eucapnic voluntary 
hyperventilation (EVH) was the bronchoprovocation test used at each visit to the 
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laboratory.  Before and after EVH, inflammatory markers and pulmonary function were 
evaluated.  Food frequency questionnaires were employed to assess changes in diet 
between phases of the study.  Subjects were instructed to track their peak expiratory 
flow values, short-acting β2-agonist (albuterol) usage, and symptoms every day at home 
and to submit these records at each laboratory visit.  Compliance with supplementation 
was determined through pill counts of the bottles returned by each subject at the second 
and third laboratory visits. 
  Eucapnic Voluntary Hyperventilation.  Bronchoprovocation was provided by the 
eucapnic voluntary hyperventilation (EVH) challenge, which requires subjects to breathe 
cold, dry air at a rapid rate. While wearing nose clips, subjects were asked to breathe 
through a non-rebreathing two-way valve (Hans Rudolph, Inc., Kansas City, MO) 
connected to a reservoir bag continually filled with 21% oxygen, 5% carbon dioxide, and 
balance nitrogen from a compressed gas tank containing less than 3 mg H2O*L-1 air 
(93).  Subjects were instructed to breathe for 6 minutes at 85% of their maximal 
voluntary ventilation as estimated by thirty times their resting FEV1 (9).  In order to verify 
the ventilatory rate, a flow sensor measured ventilation (Vmax 22 Metabolic 
Measurement Cart, SensorMedics, Yorba Linda, CA) (81).   
 Pulmonary Function Tests.  Pulmonary function was measured pre-EVH and 
post-EVH at 5, 10, 15, and 20 minutes using a calibrated computerized 
pneumotachograph spirometer (Vmax 22 Metabolic Measurement Cart, SensorMedics, 
Yorba Linda, CA) (93).  In accordance with American Thoracic Society (ATS) 
recommendations, each subject performed three acceptable spirograms, of which the 
largest and second largest forced vital capacity (FVC) and FEV1 values did not vary by 
more than 0.15 L (65).  The largest value of each was recorded.  Values for the forced 
expiratory flow at 25-75% of the FVC (FEF25-75%) were recorded from the trial with the 
greatest sum of FVC and FEV1 (65).  The bronchoconstrictor response to EVH was also 
 94 
determined as the area under the curve of the percentage fall in post-exercise FEV1 
plotted against time for 20 min, using trapezoidal integration (93). 
  Fraction of Exhaled Nitric Oxide.  Before and 30 minutes following EVH 
challenge, online measurement of the fraction of exhaled nitric oxide (FENO) was 
recorded using a restricted exhaled breath protocol (NOA 280i Nitric Oxide Analyzer, 
Accurate NO Breath Kit, Thermal Mass Flowmeter, NO Analysis Software Version 3.21, 
Sievers Instruments, Boulder, CO) (93).  American Thoracic Society guidelines were 
followed (2).  Accordingly, subjects were instructed to inhale maximally to their total lung 
capacity and immediately exhale against expiratory resistance at a rate of 50 ± 10 mL/s 
for at least 6 seconds to produce a nitric oxide plateau lasting at least 3 seconds; real 
time feedback was provided visually on a computer screen.  Subjects performed this 
maneuver while wearing nose clips with at least 30 seconds of rest between each trial 
(93).  The FENO was recorded as the mean of three exhalations with the individual FENO 
values within 10% of the mean FENO (2).     
 Exhaled Breath Condensate.  Exhaled breath condensate (EBC) was collected 
from seven subjects (6 male, 1 female) pre-EVH and post-EVH at 0-10 minutes (93) 
according to American Thoracic Society and European Respiratory Society 
recommendations (42).  Subjects were instructed to breathe normally into a non-
rebreathing valve attached to a condensing chamber (ECoScreen, Viasys Healthcare-
Jaeger, Germany) for 10 minutes while wearing nose clips (93).  This condensing 
chamber maintained an internal temperature of -20 ˚C to immediately freeze the exhaled 
breath sample during collection (93).  The pH of the non-deaerated EBC was measured 
within 5 minutes of collection (Orion 2 Star pH benchtop meter, ROSS™ Glass 
Combination Micro pH electrode, Thermo Fisher Scientific, Inc., Beverly, MA).   
  The EBC samples were then stored at -80 ˚C until liquid chromatography 
analysis was performed.  Quantification of the DHA metabolites 17S-hydroxy-
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docosahexaenoic acid and protectin D1 as well as the oxidative stress marker 8-
isoprostane was performed using the QTRAP 4000 instrument (ABI Sciex, Foster City, 
CA).  A Dionex UltiMate 3000 LC system (Dionex Corporation, Sunnyvale, CA) 
consisting of a binary pump, a temperature-controlled autosampler maintained at 5 ˚C, 
and a column oven compartment maintained at 25 ˚C, was interfaced to an ESI Turbo V 
ion source of the triple quadrupole 4000 QTRAP instrument.  The samples (~200 µL) 
were lyophilized following the addition of 2 µL of 10 pg/µL of the internal standard (IS) 
docohexanoic acid d5 dissolved in 50:50 (v:v) methanol:H2O.  The samples were then 
re-suspended in 25 µL of 50:50 (v:v) methanol:H2O, and 20 µL were injected into the 
mass spectrometer.  Calibration curve solutions of all three metabolites at 
concentrations of 1, 5, 10, and 20 pg/µL containing the IS at a concentration of 0.8 pg/µL 
in each of the solutions were prepared starting from a working solution mixture 
containing all three metabolites at a concentration of 1 ng/µL in 50:50 (v:v) 
methanol:H2O.  The internal standard working solution had a concentration of 10 pg/µL.  
The analysis was performed in negative ion mode using a reversed-phase Acclaim® 
RSLC 120 C18 column (100 mm × 2.1 mm, 2.2 µm particle size, 120 A˚ diameter) from 
Dionex.  The flow rate was 150 µL/minute and mobile phase A consisted of 
methanol:water:acetic acid (65:35:0.01, v:v:v); mobile phase B was methanol.  The 
gradient conditions were from 0% B to 100% B from 8-30 minutes followed by 3 minutes 
at 100% B.  The total run time was 41 minutes.  The mobile phase and gradient 
conditions were similar to those used by Lu et al. (53)   
  The mass spectrometer was operated in negative ion multiple reaction 
monitoring (MRM) mode where the radiofrequency (rf) and direct current (dc) in both Q1 
and Q3 were jumped to transmit different precursor/product ion pairs.  The [M-H]¯  
precursor ions were used for all species monitored in this experiment.  The MRM 
transitions employed were 332/288 for docohexanoic acid-d5, 343/281 for 17S-hydroxy-
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docosahexaenoic acid, 375/140.9 for protectin D1, and 353/193 for 8-isoprostane.   The 
Turbo V ion source parameters were common to all analytes in the MRM method.  The 
capillary was operated at 4500 V, and the source temperature was set to 250 ˚C.  The 
curtain gas (N2) and collision gas (N2) settings were 10 psi; the nebulization gas setting 
was 40 psi and the vaporization gas setting was 50 psi.  A dwell time of 20 msec, a 
declustering potential (DP) of -78 V, and a collision energy (CE) value of -25 V were 
used. 
 Symptoms and Short-Acting β2-Agonist Usage.  Subjects were instructed to rate 
their symptoms by filling out a symptom diary everyday throughout the study.  This diary 
adapted from Santanello et al. (83) contained four questions about daytime symptoms 
with a seven point scale and one question about nighttime symptoms with a four point 
scale.  Daily symptom scores were calculated for each subject by averaging the mean 
score from each day (83). 
 Subjects recorded their short-acting β2-agonist use in log books provided to 
them.  Subjects were instructed to mark down the number of puffs taken per day 
throughout the study. 
 Peak Flow Measurements.  Electronic peak flow meters (PiKo-1, Ferraris 
Medical, Louisville, CO) were given to subjects to measure their morning and evening 
peak expiratory flow throughout the study.  Subjects were instructed to perform the 
maneuver by inhaling fully to their total lung capacity and then exhaling forcefully 
through the flow meter according to manufacturer instructions.  Subjects were instructed 
to record the best of three trials upon waking and before going to bed.  
 Nutrient Intake.  The GSEL version of food frequency questionnaires developed 
by the Nutrient Assessment Shared Resource (NASR) of the Fred Hutchinson Cancer 
Research Center (FHCRC) was used to evaluate subjects’ nutrient intake during the 
study.  Subjects were asked to complete a questionnaire at the end of each phase of the 
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study.  They were instructed to refer to their diet during the course of that particular 
phase of the study to answer the questions.  It has been previously demonstrated that 
food frequency questionnaires are a valid and reliable method of collecting dietary data 
(99). 
 Data Analysis.  A power analysis was conducted using data from our laboratory 
to determine the number of subjects needed for the present study (61).  Based on the 
maximal post-exercise drop in FEV1 (L) in asthmatics supplemented with fish oil, it was 
determined with the aid of the G*Power3.0.5 program that at least three subjects would 
be needed to achieve a power of 0.80.  Because the current study used DHA, which is a 
different fish oil formula, we recruited additional subjects with asthma.    
  Data was analyzed with SPSS version 18.0 statistical software (SPSS Inc., 
Chicago, IL). Repeated measures ANOVA assessed differences among pre-
supplementation, placebo, and DHA supplementation values at the laboratory tests as 
well as among the pre-supplementation, placebo, DHA supplementation, and washout 
phases for nutrient intake and the at-home measures.  Mauchley’s test was conducted to 
determine if sphericity was violated; if it was, a Greenhouse-Geisser adjustment was 
applied.  When a significant F-ratio was present (p < 0.05), Tukey’s post-hoc test was 
used to isolate differences in group means.  To determine the presence of a carry-over 
effect between the two treatment periods, a 2 x 2 cross-over trial split-plot ANOVA was 
conducted.  Significance was held at p < 0.05 for all statistical tests.  The data is 
presented as mean ± standard error of the mean. 
Results 
  Subjects.  There were no reported adverse effects with supplementation.  
According to the 2 x 2 cross-over design split-plot ANOVA, there was not a significant 
carry-over effect (p > 0.05) between the two treatment periods (figure 3-2).  The 
subjects’ measurements at the pre-supplementation laboratory visit were considered 
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their baseline values (table 3-1).  The subjects’ resting pulmonary function was not 
significantly different (p > 0.05) among the three laboratory visits (table 3-2).  A summary 
of the treatment effects for the main dependent variables demonstrates that there were 
no significant differences (p > 0.05) between DHA supplementation and placebo (table 
3-3). 
 
Figure 3-2.  Analysis of the treatment periods for a carry-over effect.  The mean 
forced expiratory volume in one second (FEV1) at 5 minutes post-eucapnic voluntary 
hyperventilation challenge for each group at each treatment period is shown.  There was 
not a significant (p > 0.05) carry-over effect between the treatment periods for the two 
groups.  Group 1 contains the subjects who received the placebo during the first 
treatment period and docosahexaenoic acid (DHA) supplements during the second 
treatment period (n = 5).  Group 2 contains the subjects who received DHA supplements 
during the first treatment period and the placebo during the second treatment period (n = 
4).     
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Males 6 
Females 3 
Age, yr (range) 22.36 ± 1.31 (18-30) 
Height, m 1.77 ± 0.02 
Weight, kg 75.77 ± 2.43 
BMI, kg/m2 24.17 ± 0.86 
Morning Peak Flow, L/min 467.68 ± 43.61 
Evening Peak Flow, L/min 483.17 ± 46.33 
FEV1/FVC 79.11 ± 3.44 
Percent Predicted FVC, % 110.89 ± 4.39 
Percent Predicted FEV1, % 103.65 ± 3.69 
Table 3-1.  Baseline characteristics of the subjects at their first (pre-
supplementation) laboratory visit.  Values are reported as mean ± standard error of 
the mean.  BMI, body mass index; FEV1, forced expiratory volume in one second; FVC, 
forced vital capacity 
 
 
 
 
  
Pre-Supplementation 
(%) 
Placebo  
(%) 
DHA  
(%) 
FVC 110.89 ± 4.39  108.59 ± 5.20  108.04 ± 4.08  
FEV1 103.65 ± 3.69  101.00 ± 4.14  103.01 ± 4.04  
FEF25-75% 90.67 ± 11.70  88.95 ± 9.56  91.16 ± 9.65  
Table 3-2.  Resting pulmonary function.  There were no significant differences in the 
resting pulmonary function of the subjects among the pre-supplementation, placebo, and 
docosahexaenoic acid (DHA) supplementation laboratory tests prior to the eucapnic 
voluntary hyperventilation challenge.  The pulmonary function values are expressed as 
percentages of the subjects’ predicted values based on age, height, weight, and sex.  
They are reported as mean ± standard error of the mean.  FVC, forced vital capacity; 
FEV1, forced expiratory volume in one second; FEF25-75%, forced expiratory flow at 25-
75% of the FVC 
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Variable 
Pre-
Supplementation Placebo DHA 
Post-EVH maximum drop 
FVC (L) 0.66 ± 0.06 0.55 ± 0.10 0.49 ± 0.12 
Post-EVH maximum drop 
FEV1 (L) 0.87 ± 0.11 0.69 ± 0.13 0.79 ± 0.18 
Post-EVH maximum drop 
FEF25-75% (L/s) 1.17 ± 0.30 0.91 ± 0.23 0.97 ± 0.30 
Post-EVH maximum % 
drop FVC 12.23 ± 1.43 10.49 ± 1.89 10.06 ± 2.77 
Post-EVH maximum % 
drop FEV1 21.07 ± 2.65 17.20 ± 3.27 17.27 ± 3.73 
Post-EVH maximum % 
drop FEF25-75% 31.56 ± 6.37 26.86 ± 5.93 26.85 ± 6.78 
AUC FEV1 296.69 ± 46.09 232.31 ± 56.23 251.69 ± 61.84 
Pre-EVH Exhaled Breath 
Condensate pH 6.86 ± 0.12 7.15 ± 0.04 6.86 ± 0.06 
Post-EVH Exhaled Breath 
Condensate pH 6.86 ± 0.09 6.96 ± 0.13 7.01 ± 0.19 
Pre-EVH FENO 73.02 ± 20.96 43.26 ± 9.42 68.96 ± 21.64 
Post-EVH FENO 63.50 ± 16.67 36.39 ± 8.36 * 59.87 ± 18.20 
Pre-EVH 8-Isoprostane 
Concentration (pg/µL) 3.08 ± 1.50  6.16 ± 2.12  4.48 ± 1.20 
Post-EVH 8-Isoprostane 
Concentration (pg/µL)  2.21 ± 1.67 3.47 ± 1.82 6.59 ± 3.71 
Pre-EVH Protectin D1 
Concentration (pg/µL) < 0  < 0   < 0   
Post-EVH Protectin D1 
Concentration (pg/µL)  < 0  < 0   < 0   
Pre-EVH 17S-hydroxy-
docosahexaenoic acid 
(pg/µL) < 0    < 0   < 0  
Post-EVH 17S-hydroxy-
docosahexaenoic acid 
(pg/µL) < 0    < 0   < 0  
Table 3-3.  Summary of the treatment effects.  Values are reported as mean ± 
standard error of the mean.  DHA, docosahexaenoic acid; EVH, eucapnic voluntary 
hyperventilation; FVC, forced vital capacity; FEV1, forced expiratory volume in one 
second; FEF25-75%, forced expiratory flow at 25-75% of the FVC; AUC FEV1, area under 
the curve of the percent change in FEV1; FENO, fraction of exhaled nitric oxide; *, 
significantly different from pre-supplementation 
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  Pulmonary Function.  At the pre-supplementation laboratory test, the mean 
maximum drop in FEV1 following the eucapnic voluntary hyperventilation (EVH) 
challenge was 21.07 ± 2.65%.  At the subsequent laboratory tests, the mean maximum 
drop in FEV1 remained greater than the diagnostic threshold of a 10% post-challenge 
decrease in FEV1; the mean maximum drop in FEV1 was not significantly different (p > 
0.05) among the pre-supplementation, placebo (17.20 ± 3.27%), and DHA 
supplementation (17.27 ± 3.73%) values (figure 3-3).  When examined as a change in 
volume, there were still no significant differences (p > 0.05) in the values for the 
maximum drop in FEV1 among the pre-supplementation (0.87 ± 0.11 L), placebo (0.69 ± 
0.13 L), and DHA supplementation (0.79 ± 0.18 L) tests (figure 3-4).   
 
 
Figure 3-3.  Maximum percent drop in FEV1 following the eucapnic voluntary 
hyperventilation challenge.  The mean maximum percent drop in FEV1 exceeded the 
diagnostic threshold for hyperpnea-induced bronchoconstriction (HIB) at all three 
laboratory visits.  There were no significant differences (p > 0.05) among pre-
supplementation, placebo, and DHA supplementation.   Error bars express standard 
error of the mean.  DHA, docosahexaenoic acid; FEV1, forced expiratory volume in one 
second 
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Figure 3-4.  Maximum drop in FEV1 following the eucapnic voluntary 
hyperventilation challenge.  There were no significant differences (p > 0.05) in the 
post-challenge FEV1 volumes at the three laboratory visits.  Error bars express standard 
error of the mean.  DHA, docosahexaenoic acid; FEV1, forced expiratory volume in one 
second 
 
Furthermore, there were no significant differences (p > 0.05) between maximal 
changes in FVC expressed as a percentage (figures 3-5) or as a volume (figures 3-6) for 
pre-supplementation (12.23 ± 1.43%, 0.66 ± 0.6 L), placebo (10.49 ± 1.89%, 0.55 ± 0.10 
L), and DHA supplementation (10.16 ± 2.77%, 0.49 ± 0.12 L).   
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Figure 3-5.  Maximum percent drop in FVC following the eucapnic voluntary 
hyperventilation challenge.  There were no significant differences (p > 0.05) between 
pre-supplementation, placebo, and docosahexaenoic acid (DHA) supplementation.  
Error bars express standard error of the mean.  FVC, forced vital capacity 
 
 
Figure 3-6.  Maximum drop in FVC following the eucapnic voluntary 
hyperventilation challenge.  There were no significant differences (p > 0.05) in the 
post-challenge FVC volumes at the three laboratory tests.  Error bars express standard 
error of the mean.  DHA, docosahexaenoic acid; FVC, forced vital capacity 
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There were also no significant differences (p > 0.05) in FEF25-75% in terms of 
percentages (figure 3-7) or flow rates (figure 3-8) among the pre-supplementation (31.57 
± 6.37%, 1.17 ± 0.30 L/s), placebo (26.86 ± 5.93%, 0.91 ± 0.23 L/s), and DHA 
supplementation (26.85 ± 6.78%, 0.97 ±0.30 L/s) laboratory tests. 
 
 
Figure 3-7.  Maximum percent drop in FEF25-75% following the eucapnic voluntary 
hyperventilation challenge.  There were no significant differences (p > 0.05) between 
pre-supplementation, placebo, and docosahexaenoic acid (DHA) supplementation.  
Error bars express standard error of the mean.  FEF25-75%, forced expiratory flow at 25-
75% of the forced vital capacity 
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Figure 3-8.  Maximum drop in FEF25-75% following the eucapnic voluntary 
hyperventilation challenge.  There were no significant differences (p > 0.05) in the 
post-challenge FEF25-75% flow rates at the three laboratory visits.  Error bars express 
standard error of the mean.  DHA, docosahexaenoic acid; FEF25-75%, forced expiratory 
flow at 25-75% of the FVC 
 
Additionally, no significant differences (p > 0.05) were found between pre-
supplementation, placebo, and DHA supplementation in terms of the post-eucapnic 
voluntary hyperventilation (EVH) percent changes in FEV1, FVC, or FEF25-75% at any of 
the time points tested (5, 10, 15, and 20 minutes post-EVH) (figures 3-9, 3-10, 3-11).   
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Figure 3-9.  The percent change in FEV1 at 5, 10, 15, and 20 minutes after the 
eucapnic voluntary hyperventilation challenge.  There were no significant differences 
(p > 0.05) between pre-supplementation, placebo, and docosahexaenoic acid (DHA) 
supplementation at any of the time points.  Error bars express standard error of the 
mean.  FEV1, forced expiratory volume in one second 
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Figure 3-10.  The percent change in FVC at 5, 10, 15, and 20 minutes after the 
eucapnic voluntary hyperventilation challenge.  There were no significant differences 
(p > 0.05) between pre-supplementation, placebo, and docosahexaenoic acid (DHA) 
supplementation at any of the time points.  Error bars express standard error of the 
mean.  FVC, forced vital capacity 
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Figure 3-11.  The percent change in FEF25-75% at 5, 10, 15, and 20 minutes after the 
eucapnic voluntary hyperventilation challenge.  There were no significant differences 
(p > 0.05) between pre-supplementation, placebo, and docosahexaenoic acid (DHA) 
supplementation at any of the time points.  Error bars express standard error of the 
mean.  FEF25-75%, forced expiratory flow at 25-75% of the FVC 
 
 Lastly, there were no significant differences (p > 0.05) between the values for the 
area under the curve of the percent change in FEV1 for the 20 minutes following EVH 
(AUC0-20) among the pre-supplementation (296.69 ± 46.09), placebo (232.31 ± 56.23), 
and DHA supplementation (251.69 ± 61.84) tests (figure 3-12). 
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Figure 3-12.  The area under the curve of the percent change in FEV1 for 20 
minutes (AUC0-20).  This measure represents the bronchoconstrictor response to the 
eucapnic voluntary hyperventilation challenge.  There were no significant differences (p 
> 0.05) in the AUC0-20 at the three laboratory visits.  Error bars express standard error of 
the mean.  DHA, docosahexaenoic acid; FEV1, forced expiratory volume in one second 
 
  Fraction of Exhaled Nitric Oxide.  The pre-EVH fraction of exhaled nitric oxide 
(FENO) was not significantly different (p > 0.05) between pre-supplementation (73.02 ± 
20.96 ppb), placebo (43.26 ± 9.42 ppb), and DHA supplementation (68.96 ±  21.64 ppb) 
(figure 3-13).  However, the placebo value for post-EVH FENO (36.39 ± 8.36 ppb) was 
significantly lower (p < 0.05) than the pre-supplementation value for post-EVH FENO 
(63.50 ± 16.67 ppb).  The post-EVH FENO following DHA supplementation (59.87 ± 
18.20 ppb) was not significantly different (p > 0.05) from either the pre-supplementation 
or placebo values. 
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Figure 3-13.  The fraction of exhaled nitric oxide (FENO) pre- and post-eucapnic 
voluntary hyperventilation (EVH) challenge.  There were no significant differences (p 
> 0.05) between the pre-EVH values from any of the laboratory visits.  The post-EVH 
FENO was significantly lower with the placebo treatment compared to the pre-
supplementation value.  The post-EVH FENO with docosahexaenoic acid (DHA) 
supplementation was not significantly different from pre-supplementation or placebo 
values. Error bars express standard error of the mean.  *, significantly different from 
each other 
 
 Exhaled Breath Condensate.  Seven subjects provided exhaled breath 
condensate samples at each of the laboratory tests.  Neither the pre- nor post-EVH 
exhaled breath condensate (EBC) pH values significantly changed (p > 0.05) among the 
pre-supplementation (pre-EVH: 6.88 ± 0.09, post-EVH: 6.82 ± 0.09), placebo (pre-EVH: 
7.09 ± 0.07, post-EVH: 6.93 ± 0.12), and DHA supplementation (pre-EVH: 6.90 ± 0.07, 
post-EVH: 7.02 ± 0.16) laboratory tests (figure 3-14).   
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Figure 3-14.  Exhaled breath condensate pH pre- and post-eucapnic voluntary 
hyperventilation (EVH) challenge.  There were no significant differences (p > 0.05) 
between the pre-EVH values or between the post-EVH values at any of the laboratory 
visits (n = 7).  Error bars express standard error of the mean.   
 
  For these seven subjects, EBC was also analyzed by liquid chromatography for 
the oxidative stress marker 8-isoprostane and the DHA metabolites protectin D1 and 
17S-hydroxy-docosahexaenoic acid at each laboratory test before and after the EVH 
challenge.  The concentration of 8-isoprostane did not significantly change among the 
three laboratory tests (figure 3-15).  The mean pre-EVH concentration of 8-isoprostane 
was 3.08 ± 1.50 pg/µL at the pre-supplementation test, 6.16 ± 2.12 pg/µL following 
placebo supplementation, and 4.48 ± 1.20 pg/µL following DHA supplementation.  The 
post-EVH concentration of 8-isoprostane was 2.21 ± 1.67 pg/µL at the pre-
supplementation test, 3.47 ± 1.82 pg/µL following placebo supplementation, and 6.59 ± 
3.71 pg/µL following DHA supplementation. 
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Figure 3-15.  Exhaled breath condensate 8-isoprostane concentration pre- and 
post-eucapnic voluntary hyperventilation (EVH) challenge.  8-isoprostane is a 
marker of oxidative stress.  There were no significant differences (p > 0.05) between the 
pre-EVH values or between the post-EVH values at any of the laboratory visits.  Error 
bars express standard error of the mean.   
 
The levels of protectin D1 and 17S-hydroxy-docosahexaenoic acid were too low 
for detection both pre- and post-EVH at each of the three laboratory tests.  Thus, the 
pre- and post-EVH concentration was < 0 pg/µL for each metabolite at all the laboratory 
tests. 
 Symptoms and Short-Acting β2-Agonist Usage.  Eight subjects returned their 
symptom diaries and logs of their bronchodilator usage for each phase of the study.  
There were no significant changes (p > 0.05) in the subjects’ daily symptom scores 
among the pre-supplementation (1.12 ± 0.24), placebo (0.66 ± 0.15), washout (0.74 ± 
0.13), and DHA supplementation (0.70 ± 0.14) phases (figure 3-16).  There were also no 
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significant changes (p > 0.05) in the subjects’ nightly symptom scores among the pre-
supplementation (0.17 ± 0.10), placebo (0.00 ± 0.00), washout (0.01 ± 0.01), and DHA 
supplementation (0.02 ± 0.02) phases (figure 3-17).  Moreover, the subjects did not 
significantly change (p > 0.05) their short-acting β2-agonist use during the course of the 
study (figure 3-18); the mean bronchodilator usage was 0.17 ± 0.05 puffs per day during 
pre-supplementation, 0.04 ± 0.02 puffs per day during the placebo phase, 0.03 ± 0.03 
puffs per day during the washout phase, and 0.10 ± 0.05 puffs per day during the DHA 
supplementation phase. 
 
 
Figure 3-16.  Daily symptom scores for each phase of the study.  There were no 
significant differences (p > 0.05) in the daily symptom scores between any of the four 
study phases.  Error bars express standard error of the mean.   
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Figure 3-17.  Nightly symptom scores for each phase of the study.  There were no 
significant differences (p > 0.05) in the nightly symptom scores between any of the four 
study phases.  Error bars express standard error of the mean.   
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Figure 3-18.  Bronchodilator usage during each phase of the study.  There were no 
significant differences (p > 0.05) in the subjects’ bronchodilator usage between any of 
the four study phases.  Error bars express standard error of the mean.   
 
 Peak Flow Measurements.  Eight subjects returned logs of their peak flow 
measurement data for all four phases of the study.  The at-home measurements of the 
morning peak expiratory flows were not significantly different (p > 0.05) among the pre-
supplementation (446.63 ± 43.31 L/min), placebo (464.12 ± 42.07 L/min), washout 
(463.19 ± 40.96 L/min), and DHA supplementation (468.92 ± 42.51 L/min) phases (figure 
3-19).  Also, the evening peak expiratory flow measurements were not significantly 
different (p > 0.05) among the pre-supplementation (456.37 ± 42.85 L/min), placebo 
(470.99 ± 42.80 L/min), washout (462.37 ± 46.72 L/min), and DHA supplementation 
(474.12 ± 47.91 L/min) phases (figure 3-20). 
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Figure 3-19.  Morning peak expiratory flow (PEF) during each phase of the study.  
There were no significant differences (p > 0.05) in the subjects’ morning PEF 
measurements among the four study phases.  Error bars express standard error of the 
mean.   
 
 
Figure 3-20.  Evening peak expiratory flow (PEF) during each phase of the study.  
There were no significant differences in the subjects’ evening PEF measurements 
among the four study phases.  Error bars express standard error of the mean.   
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Nutrient Intake.  Eight subjects completed a food frequency questionnaire for 
each phase of the study.  There were no significant changes (p > 0.05) in nutrient intake 
among the pre-supplementation, DHA, placebo, and washout phases (table 3-4). 
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Study Phase 
Total 
Grams 
Energy 
(kcal) 
Total 
Fat 
(g) 
Total 
Carbohydrate 
(g) 
Total 
Protein 
(g) 
Total 
Dietary 
Fiber 
(g) 
Arachidonic 
Acid (g) 
EPA 
(g) 
DHA 
(g) 
Pre-Supplementation 
  
Mean 3184.26 2602.13 98.00 316.77 110.87 25.52 0.19 0.02 0.05 
SEM 603.89 499.10 20.20 66.83 20.77 5.39 0.04 0.01 0.01 
DHA Supplementation 
  
Mean 2704.66 1894.00 65.31 236.91 81.56 20.19 0.17 0.02 0.06 
SEM 522.92 257.95 10.08 37.31 13.76 4.99 0.04 0.01 0.02 
Placebo 
Supplementation 
  
Mean 2891.81 2142.87 80.09 257.03 96.33 21.57 0.18 0.02 0.05 
SEM 568.02 401.92 16.67 46.44 20.26 4.10 0.05 0.01 0.01 
Washout 
  
Mean 2274.70 1655.35 61.54 188.71 69.62 14.44 0.16 0.02 0.07 
SEM 287.99 207.22 11.14 25.41 10.97 2.06 0.04 0.01 0.04 
Table 3-4.  Average intake amounts of selected nutrients.  There were no significant changes in diet for the subjects (n = 8) 
among the four study phases as assessed by nutrient intake.  The average values for the intake of selected nutrients are presented 
here.  SEM, standard error of the mean; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid 
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Discussion 
 Since it has been shown that fish oil effectively attenuates bronchoconstriction 
and airway inflammation (61, 62, 93), the main purpose of this study was to determine 
whether supplementation with docosahexaenoic acid (DHA), an omega-3 fatty acid 
found in fish oil, could reduce hyperpnea-induced bronchoconstriction (HIB) and airway 
inflammation in adults with asthma.  Using a placebo-controlled crossover design, the 
present study has shown that supplementation with 4.0 g of DHA per day for 3 weeks 
does not significantly alter pulmonary function, markers of airway inflammation, or DHA 
metabolite concentrations in comparison to placebo or baseline values in a group of nine 
adults with asthma. 
 There are several reasons why DHA supplementation may not have had a 
significant impact on the pulmonary function measures, inflammatory markers, or 
symptoms as anticipated.  First, it is possible that DHA supplementation simply cannot 
improve HIB on its own.  This may be because eicosapentaenoic acid (EPA) is the more 
important component of fish oil in terms of attenuating hyperpnea-induced 
bronchoconstriction and airway inflammation.  Although there is not a consensus in the 
literature whether EPA or DHA is the more potent component of fish oil, there is 
substantial evidence to support DHA’s effectiveness in reducing inflammation (41, 52, 
98, 103).  DHA administration has also been shown to reduce bronchial 
hyperresponsiveness in mice (52, 103).  Nevertheless, a recent study from 
Mickleborough et al. (64) showed that EPA was more effective than DHA in reducing 
inflammatory responses in lipopolysaccharide-stimulated macrophages.  This was in 
contrast to an earlier in vitro study from Weldon et al. (98) demonstrating that DHA 
decreased proinflammatory cytokine production to a greater extent than EPA in 
macrophages.  The discrepancy in the findings between these two studies may be 
explained by the different cell lines used for the experiments.  Weldon et al. (98) studied 
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THP-1 macrophages, a monocytic leukemia cell line, whereas Mickleborough et al. (64) 
studied human asthmatic alveolar macrophages, which suggests that their data may be 
more relevant to patients with asthma.   
Second, it is possible that our study design used an inappropriate dose or time 
course.  Because this was a novel application of DHA supplementation, we used the 3-
week time course that has been shown to be effective for fish oil supplementation and a 
4.0 g dose of DHA.  The duration of the washout phase was sufficient as there was not a 
significant carry-over effect between the treatment periods.  Since the exhaled breath 
condensate (EBC) concentration of the DHA metabolites protectin D1 and 17S-hydroxy-
docosahexaenoic acid did not increase with supplementation, it suggests that a higher 
dose of DHA would be necessary to have an effect.  Levy et al. (52) reported that there 
were only “trace amounts” of protectin D1 in the EBC of four adults during an acute 
exacerbation of their asthma.  In the current study, the concentrations of protectin D1 
and 17S-hydroxy-docosahexaenoic acid were not detectable at baseline, following 
placebo supplementation, or following DHA supplementation.  In addition to perhaps 
requiring a larger dose of DHA to produce significant changes in the DHA metabolites as 
hypothesized, a different method of supplementation may be necessary.  DHA 
supplementation was accomplished via oral intake of gel capsules as in previous fish oil 
studies.  However, murine studies demonstrating the effectiveness of DHA administered 
the omega-3 fatty acid via aerosol (103) or intravenously in its metabolite form (52).  
Thus, the efficacy of DHA may have been affected by the means of administration.   
  Third, the variability in our subject population was greater than expected.  There 
was no suitable data available on DHA supplementation in adults with asthma to use to 
determine an appropriate sample size.  Therefore, an a priori power analysis was 
conducted using data from Mickleborough et al.’s (61) study on fish oil supplementation 
in adults with asthma because it used a similar placebo-controlled crossover design.  
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Due to the large effect size in the Mickleborough et al. (61) study, it was determined that 
three subjects would be needed to show a significant reduction in the maximum drop in 
FEV1 volume with DHA supplementation compared to placebo.  However, we were 
unable to demonstrate a significant difference in this or any other pulmonary function 
measure in the nine subjects in the present study.  The coefficients of variation for the 
maximum drop in FEV1 volume for our subjects were 0.38 at pre-supplementation, 0.55 
with placebo, and 0.68 with DHA supplementation; in contrast, the coefficients of 
variation for the subjects in the Mickleborough et al. (61) study were 0.30 at pre-
supplementation, 0.23 with placebo, and 0.26 with fish oil supplementation.  Therefore, 
the subjects in the current study showed greater variability in their pulmonary function 
responses, and this may have impaired our ability to detect statistically significant 
differences between treatments.  
However, before concluding that pure DHA is not effective in alleviating HIB in 
asthmatic individuals, variations of the current study should be undertaken.  First, time 
course trials using different doses should be completed.  Additionally, a different route of 
administrating DHA should be attempted.  Although intravenous administration of DHA 
may be problematic in humans, aerosolized DHA may be a viable option (103).  
Furthermore, it would also be worthwhile to conduct a similar study using EPA instead of 
DHA.  Significant in vivo improvements in pulmonary function and airway inflammation 
with EPA supplementation in adults with asthma would indicate that EPA is the more 
potent component in fish oil and the optimization of a formula for omega-3 fatty acid 
supplementation in asthma could proceed.   
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CHAPTER 4 
THE ASSOCIATION BETWEEN FISH OIL TREATMENT OF ISOLATED CANINE 
TRACHEAL SMOOTH MUSCLE TISSUE AND THEIR CONTRACTILITY 
Abstract 
Background:  Fish oil supplementation has been shown to reduce exercise-induced 
bronchoconstriction.  However, the association between airway smooth muscle 
contractility and its exposure to fish oil or one of its components has received only 
limited attention in the literature.  
Purpose:  Determine whether fish oil exposure is associated with a reduction in the 
contractility of canine tracheal smooth muscle tissue.  
Methods:  Canine tracheal smooth muscle strips were exposed to fish oil, soybean oil 
(placebo), or control with vehicle media either chronically or acutely.  Contractility was 
measured in vitro before and after exposure.  Lipid analysis via gas chromatography was 
performed on select tissue samples to determine the incorporation of the omega-3 
polyunsaturated fatty acids in fish oil.  
Results:  Significant incorporation (p < 0.05) of the fish oil omega-3 fatty acids was 
evident following 24 hours of incubation in fish oil but not after 15 hours (p > 0.016).  
Following 4 hours of incubation in fish oil, there was a statistically significant (p < 0.016), 
though likely not physiologically significant, increase in DHA incorporation.  Smooth 
muscle contractility in response to acetylcholine was significantly elevated (p < 0.05) for 
tissues incubated for 15 hours in fish oil medium compared to those incubated in control 
with vehicle medium.  There were no significant changes (p > 0.05) in contractility or the 
effective dose (ED) 50 following incubation periods of 2, 4, and 24 hours.  Acute 
administration of fish oil significantly relaxed (p < 0.05) tissues contracted with either 10-6 
M acetylcholine or 10-6 M 5-hydroxytryptamine.   
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Conclusions:  These experiments suggest that fish oil exposure can be associated with 
changes in airway smooth muscle contractility.  Although there does not appear to be a 
relationship between airway smooth muscle contractility and the lipid profile of the tissue 
according to the current data, this may be due to differences in the experimental 
protocols at the time points tested; additional experiments to reconcile these differences 
may be necessary in the future.   
Introduction 
 Airway inflammation, narrowing, and hyperresponsiveness are the hallmark 
features of asthma (90).  Asthma pharmacotherapy typically targets either airway 
inflammation or airway narrowing.  Clinically, airway narrowing is the greater concern 
(44).  Therefore, addressing the impact of asthma treatment strategies on airway smooth 
muscle contractility is important. 
 Fish oil is a non-pharmacological alternative for treating asthma.  Recent studies 
have demonstrated that fish oil supplementation suppresses exercise-induced 
bronchoconstriction, which can be a complication of asthma (61, 62, 93).  The 
mechanism for fish oil’s effectiveness in this regard has not been fully elucidated.  It is 
generally thought that fish oil works through a reduction in airway inflammation via the 
competition of its omega-3 polyunsaturated fatty acids, eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), for enzymes also used by omega-6 polyunsaturated fatty 
acids.  Because the omega-3 fatty acids produce leukotrienes and prostaglandins that 
are less proinflammatory than those produced by the omega-6 fatty acids, less 
bronchoconstriction is consequently expected with fish oil supplementation (60).  
However, the impact of fish oil on the airway smooth muscle itself has only received 
modest attention. 
 Few studies have focused on the association between airway smooth muscle 
contractility and its exposure to fish oil or one of its components.  In an in vitro study 
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involving guinea pig bronchial smooth muscle, Hichami et al. (39) determined that acute 
administration of DHA reduced basal tone but not contractions with carbamylcholine.  
Moreover, Morin et al. (69) demonstrated that treatment with an EPA metabolite resulted 
in the relaxation of human bronchial smooth muscle tissue that had not been stimulated 
as well as following contraction of the tissue with methacholine.  By studying the effects 
of ion channel blockers on the changes in smooth muscle contractility elicited with 
omega-3 fatty acid exposure, these studies suggested that ion channels were involved 
(39, 69).  However, they did not address the possibility of the tissue’s responsiveness 
having been affected by omega-3 polyunsaturated fatty acid incorporation in the 
phospholipid bi-layer.   
 Although the existing literature contains additional studies on vascular smooth 
muscle treated with fish oil or one of its components, these findings cannot be assumed 
to hold true for airway smooth muscle due to the physiological differences between 
these tissue types.  Nevertheless, they are worth noting in that these studies have 
suggested that lipid incorporation of omega-3 fatty acids may affect smooth muscle 
contractility via an alteration in cell membrane properties, such as fluidity and enzyme 
function (33, 101).  While these studies did not measure lipid incorporation, in vivo 
human and mice studies involving fish oil supplementation have shown increased 
omega-3 fatty acid content in plasma phoshoplipids (47), neutrophils (47, 61), and lung 
tissue (102).   
 The purpose of this study is to determine whether fish oil exposure is associated 
with a reduction in the contractility of canine tracheal smooth muscle tissue.  The 
hypothesis is that the treatment of canine tracheal smooth muscle with fish oil will reduce 
arachidonic acid content and increase EPA and DHA content in smooth muscle cell 
membranes and will be associated with a decrease in the airway smooth muscle 
responsiveness to a contractile agonist.  
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Methods 
 Study Design.  Canine tracheal smooth muscle strips were exposed to fish oil, 
soybean oil (placebo), or control with vehicle media either chronically or acutely.  
Chronic exposure to the treatments ranged from 2 to 24 hours for the contractility 
experiments and from 4 hours to 6 days for the lipid analysis experiments while acute 
exposure to the treatments lasted 30 to 40 minutes.  Contractility was measured in vitro 
before and after exposure to the treatments. 
 Smooth Muscle Tissue Preparation.  All procedures involving animal tissues 
were performed in accordance with the guidelines of the Institutional Animal Care and 
Use Committee of the Indiana University School of Medicine.  Tracheal smooth muscle 
tissue was obtained as previously described (104).  Briefly, mongrel dogs were 
sacrificed by exsanguination following injection with sodium pentobarbital (30 mg/kg).  A 
section of the trachea was removed immediately and immersed in physiological saline 
solution (PSS) at 22 °C containing 110 mM NaCl, 3.4 mM KCl, 2.4 mM CaCl2, 0.8 mM 
MgSO4, 25.8 mM NaHCO3, 1.2 mM KH2PO4, and 5.6 mM glucose.  The canine tracheal 
smooth muscle tissue was excised from the trachea with the connective tissue removed 
and then cut into strips.  The tissue was subsequently placed in PSS at 37 °C in 25 ml 
organ baths aerated with 95% O2 and 5% CO2 to maintain a pH of 7.4.   
 Treatments.  Fish oil and soybean oil (Nordic Naturals, Watsonville, CA) were 
dissolved in a 0.5% by volume mixture of 1:1 ethanol and dimethyl sulfoxide (DMSO). 
Controls with vehicle were prepared with equivalent volumes of PSS (acute) or 
incubation media (chronic) dissolved in ethanol and DMSO.  Controls without vehicle 
were also used in each protocol.   
 Lipid Analysis.  To determine the extent of canine tracheal smooth muscle 
incorporation of fish oil during incubation periods of various lengths, cell membrane fatty 
acid content was analyzed via gas chromatography.  Following incubation at 37 °C and 
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5% CO2 in Dulbecco’s modified eagle medium (DMEM) with antibiotics in fish oil or 
control without vehicle for 1, 2, 4, and 6 days in a high dose (8 mM) of fish oil, the 
muscle strips were rinsed with PSS containing 1% bovine serum albumin to remove 
unincorporated lipids and then frozen with liquid nitrogen for storage.  Tissue samples 
from 4 hour and 15 hour incubations (see below for details) were also frozen with liquid 
nitrogen after contraction experiments were completed.  The samples were then stored 
at -80 °C before analysis. A modified protocol of Lepage and Roy’s (50, 51) one-step 
transesterification method developed by Xu et al. (100) for the optimal determination of 
fatty acid concentrations was employed.  Briefly, the internal standard tricosanoate-
methyl ester and methanol-benzene were added to the dried tissue samples; this 
mixture was vortexed, purged with nitrogen for 10 seconds, capped, and bathed in dry 
ice for 10 minutes.  Acetyl chloride was added, and then, the samples were transferred 
to room temperature until the reaction mixture melted.  The sample tubes were then 
placed on a 100 °C heating plate for 15 minutes, sonicated for 10 seconds, put back on 
the heating plate for 45 minutes, and cooled in an ice bucket.  To end the 
transesterification reaction and to allow the mixture to neutralize, a 6% K2CO3 solution 
was added slowly to the samples.  After the samples were centrifuged at 200 rpm for 10 
minutes at 25 °C, the benzene layer was removed and the remaining contents analyzed 
by split injection gas chromatography at 250 °C using the Shimadzu GC2010 system 
and RT-2560 column.  The equation C(GC) = A(FA) / A(IS) x C(IS), where  C(GC) is the 
concentration of the particular fatty acid, A(FA) is the peak area of the particular fatty acid, 
A(IS) is the peak area of the internal standard, and C(IS) is the concentration of the internal 
standard, was used to calculate the concentration of each fatty acid (100).  The percent 
contribution of arachidonic acid, EPA, and DHA to the smooth muscle sample’s total 
fatty acid composition was determined.   
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 Chronic Exposure to Fish Oil.  Contractility was measured as previously 
described (104).  Each strip was attached to a force transducer (Grass Technologies, 
West Warwick, RI) to measure force with the aid of the PolyVIEW program (Grass 
Technologies, West Warwick, RI).  The optimal length for muscle contraction was 
determined by progressively increasing the muscle’s length until the active isometric 
force elicited by 10-5 M acetylcholine (ACh) reached a maximum.  The tissue samples 
were maintained at the optimal length for 30 to 60 minutes without stimulation.  Using 
half-logarithmic doses from 10-9 M to 10-4 M, the active isometric force in response to 
ACh at the optimal muscle length was measured.   
  After the ACh dose-response contractions, the muscle strips were attached to 
metal mounts at their optimal lengths.  They were incubated at 37 °C and 5% CO2 in 
DMEM with antibiotics in fish oil, soybean oil, control with vehicle, or control without 
vehicle overnight (15 hours) or for 24 hours.  Following incubation, the muscle strips 
were rinsed in PSS containing 1% bovine serum albumin to remove the incubation 
media and then studied immediately.  The strips were placed at their optimal lengths in 
the same tissue baths as before to repeat the half-logarithmic dose response to ACh.  
  Shorter incubation periods of 2 and 4 hours were also evaluated.  For these time 
periods, the tissues were maintained in the tissue baths attached to the transducers and 
exposed to the treatments for the desired time period; a dose response curve to ACh 
was then repeated.  
Acute Exposure to Fish Oil.  Each strip was attached to a force transducer 
(Grass Technologies, West Warwick, RI) to measure force with the aid of the PolyVIEW 
program (Grass Technologies, West Warwick, RI).  The smooth muscle strips were 
contracted with 10-6 M acetylcholine (ACh) to achieve peak force.  After the tension 
reached a plateau, fish oil, soybean oil, control with vehicle, or control (sham) treatments 
were added to the tissue bath.  Tissues were evaluated for 30 to 40 minutes after the 
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treatments to determine whether there was a change in tension.  The percent relaxation 
was calculated for each smooth muscle strip. 
To assess the effect of a weaker contractile stimulus, the experiment was 
repeated with 10-7 M ACh.  In this experiment, the smooth muscle strips were first 
conditioned with 10-5 M ACh to determine the optimal length for each strip.  After this 
was determined, the agonist was washed out of the tissue baths and the tissue was 
contracted with 10-7 M ACh.  Once the tension reached a plateau, fish oil, soybean oil, or 
control with vehicle treatments were added to the tissue baths.  Tissues were evaluated 
for 30 to 40 minutes after the treatments, and the percent relaxation was calculated for 
each smooth muscle strip.  
Contractions with Other Agonists.  To determine whether the results would be 
affected by using a weaker contractile agonist, either prostaglandin F2 (PGF2) or 5-
hydroxytryptamine (5-HT) was administered to untreated canine tracheal smooth muscle 
strips attached to force transducers.  Since only 5-HT elicited contractions in the muscle 
strips, select experiments were repeated with 5-HT as the contractile agonist.  These 
experiments included the chronic exposure to fish oil for 4 and 24 hours as well as the 
acute exposure to fish oil.  Contractility was measured in the manner already described 
with two exceptions: half-logarithmic doses from 10-9 M to 10-4 M 5-HT were used in the 
chronic exposure experiment and 10-6 M 5-HT and 10-7 M 5-HT were used in the acute 
exposure experiment after peak force with 10-5 M ACh had been achieved.    
 Data Analysis.  Statistical analysis was performed with SPSS version 18.0 
statistical software (SPSS Inc., Chicago, IL).   
For the lipid analysis, the composition of EPA, DHA, and arachidonic acid were 
each calculated as a percent of the total fatty acid composition of the tissues.  The 
percentages reflect the mean of the smooth muscle strips that received the same 
treatment for a particular length of time.  Independent t-tests were used to determine 
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differences between tissues incubated in fish oil or control media at each time point (1, 
2, 4, and 6 days).  Significance was set at p < 0.05.  Independent t-tests were also used 
to determine differences between tissues incubated in fish oil medium and soybean oil, 
control with vehicle, or control media for 4 hours or 15 hours.  A Bonferroni adjustment of 
the p-value was made to correct for the three sets of independent t-tests; thus, for this 
analysis, significance was set at p < 0.016. 
To analyze the effects of chronic exposure to fish oil, the post-incubation 
contractility of the tissue samples throughout the dose response curves was calculated 
as a percent of the maximum pre-incubation force for each smooth muscle strip.  A two-
way mixed analysis of variance (ANOVA) was then performed to examine the dose 
response to the contractile agonists following incubation; the contractile agonist dose 
was the within-subjects factor while the treatment was the between-subjects factor.  
Mauchley’s test was conducted to determine if sphericity was violated; if it was, a 
Greenhouse-Geisser adjustment was used.  Where a significant interaction was 
observed, a multivariate analysis of variance (MANOVA) was performed to examine the 
simple effect of treatment at each level of the contractile agonist dose.  Separate 
analyses were performed to compare fish oil to control with vehicle, fish oil to soybean 
oil, and control with vehicle to soybean oil.  Significance was set at p < 0.05.   
  The maximum force generated for each smooth muscle strip was established as 
the highest post-incubation force that was previously calculated as a percent of that 
smooth muscle strip’s maximum pre-incubation force.  One-way independent measures 
ANOVAs were then used to determine differences in the maximum force among the fish 
oil, soybean oil, and control with vehicle incubation treatments at each of the time points 
studied (24 hours, 15 hours, 4 hours, and 2 hours).  Where a significant difference was 
detected, a Fisher’s least significant difference (LSD) post-hoc test was used to 
determine where the differences lay.  Significance was set at p < 0.05.  
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SigmaPlot 12 (Systat Software Inc., San Jose, CA) was used to determine the 
effective dose (ED) 50 for each smooth muscle strip.  To determine differences in the ED 
50 among the fish oil, soybean oil, and control with vehicle incubation treatments, one-
way independent ANOVAs were performed for each of the time points studied (24 hours, 
15 hours, 4 hours, and 2 hours).  If a significant difference was detected, Fisher’s LSD 
post-hoc was employed.  Significance was set at p < 0.05.   
The effect of acute exposure to fish oil was studied by determining the degree of 
relaxation for each tissue in response to fish oil, soybean oil, vehicle, or control (sham) 
treatments.  This was calculated by determining the peak force generated by the tissue 
in response to a single dose of the contractile agonist.  The minimum force produced by 
the tissue following treatment was also determined.  The percent relaxation was then 
calculated as 100 – [(minimum force post-treatment / peak force pre-treatment) * 100].  
One-way independent ANOVAs were performed for each dose and type of contractile 
agonist to determine differences among the treatments.  When significant differences 
were detected, Fisher’s LSD was used to isolate the differences between treatments.  
Significance was set at p < 0.05.  
Results 
 Lipid Analysis.  The 1 to 6 day time course revealed that the percent contribution 
of EPA and DHA to the total fatty acid composition continually increased with incubation 
in the fish oil medium.  The difference between incubation in fish oil medium and control 
medium for both the percent composition of EPA and the percent composition of DHA 
was significant (p < 0.05) at 1 and 6 days (figures 4-1, 4-2).  There was not a significant 
difference (p > 0.05) between incubation in fish oil medium and control medium for the 
percent composition of arachidonic acid at any of the time points measured (figure 4-3). 
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Figure 4-1.  Eicosapentaenoic acid (EPA) composition of canine tracheal smooth 
muscle tissue incubated in either control or fish oil media for 1 to 6 days.  The 
percent of the total fatty acid composition containing EPA continually increased with 
incubation in the fish oil medium for 1 to 6 days.  The EPA composition following 
incubation in the fish oil medium was significantly greater (p < 0.05) than that of tissues 
incubated in the control medium at 1 day and 6 days.  Data points reflect the mean 
values of the incubated tissue strips (n = 2 for control; n = 2 for fish oil at 1, 2, and 4 
days; n = 3 for fish oil at 6 days). Error bars represent standard error of the mean.  *, 
significantly different from control 
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Figure 4-2.  Docosahexaenoic acid (DHA) composition of canine tracheal smooth 
muscle tissue incubated in either control or fish oil media for 1 to 6 days.  The 
percent of the total fatty acid composition containing DHA continually increased with 
incubation in the fish oil medium for 1 to 6 days.  The DHA composition following 
incubation in the fish oil medium was significantly greater (p < 0.05) than that of tissues 
incubated in the control medium at 1 day and 6 days.  Data points reflect the mean 
values of the incubated tissue strips (n = 2 for control; n = 2 for fish oil at 1, 2, and 4 
days; n = 3 for fish oil at 6 days).  Error bars represent standard error of the mean.  *, 
significantly different from control 
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Figure 4-3.  Arachidonic acid composition of canine tracheal smooth muscle 
tissue incubated in either control or fish oil media for 1 to 6 days.  The percent of 
the total fatty acid composition containing arachidonic acid following incubation in the 
fish oil medium was not significantly different from that of tissues incubated in the control 
medium at 1 day and 6 days.  Data points reflect the mean values of the incubated 
tissue strips (n = 2 for control; n = 2 for fish oil at 1, 2, and 4 days; n = 3 for fish oil at 6 
days). Error bars represent standard error of the mean. 
 
 Lipid analysis was also performed on tissues that had been incubated in fish oil, 
soybean oil, control with vehicle, and control media for 4 hours in the tissue baths or for 
15 hours in an incubator.  These tissues had been studied for their contractility pre- and 
post-incubation.  There was not a significant difference (p > 0.016) in the percent 
contribution of EPA or arachidonic acid to the total fatty acid composition between 
incubation in fish oil and incubation in any of the other three treatments for tissues 
incubated for 4 hours; however, there was a significant increase (p < 0.016) in the 
percent contribution of DHA to the total fatty acid composition between incubation in fish 
oil and incubation in either control or control with vehicle media (table 4-1).  There was 
not a significant difference (p > 0.016) in the percent contribution of EPA, DHA, or 
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arachidonic acid to the total fatty acid composition between incubation in fish oil and 
incubation in any of the other three treatments for tissues incubated for 15 hours (table 
4-2).  
 
  Control (%) Vehicle (%) 
Soybean Oil 
(%) Fish Oil (%) 
Arachidonic Acid 2.38 ± 0.69 10.04 ± 4.58 3.90 ± 1.09 1.32 ± 0.06 
EPA 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
DHA 0.00 ± 0.00 0.00 ± 0.00 0.39 ± 0.09 0.14 ± 0.02* 
Table 4-1.  Percent composition of arachidonic acid, eicosapentaentoic acid 
(EPA), and docosahexaenoic acid (DHA) in tissues incubated in control, vehicle, 
soybean oil, or fish oil media for 4 hours.  There were not any significant differences 
(p > 0.016) in arachidonic acid or EPA composition between fish oil and the other three 
treatments following the 4-hour incubation in control (n = 3), vehicle (n = 3),  soybean oil 
(n = 3),  or fish oil media (n = 3). There was a significant difference (p < 0.016) in DHA 
composition between fish oil and the control or vehicle treatments.  The data are 
presented as mean percent ± standard error of the mean.  *, significantly different from 
control and vehicle 
 
  Control (%) Vehicle (%) 
Soybean Oil 
(%) Fish Oil (%) 
Arachidonic Acid 2.48 ± 0.19 2.25 ± 0.21 3.45 ± 0.81 2.06 ± 0.32 
EPA 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
DHA 0.38 ±0.06 0.3 ± 0.06 0.41 ± 0.12 0.19 ± 0.02 
Table 4-2.  Percent composition of arachidonic acid, eicosapentaentoic acid 
(EPA), and docosahexaenoic acid (DHA) in tissues incubated in control, vehicle, 
soybean oil, or fish oil media for 15 hours.  There were not any significant differences 
(p > 0.016) in arachidonic acid, EPA, or DHA composition between fish oil and the other 
three treatments following the 15-hour incubation in control (n = 3), vehicle (n = 3),  
soybean oil (n = 3),  or fish oil media (n = 3).  The data are presented as mean percent ± 
standard error of the mean. 
 
 Chronic Exposure to Fish Oil.  Following a 24-hour incubation, there was not a 
significant interaction (p > 0.05) between treatment and the ACh dose or a significant 
difference (p > 0.05) in the post-incubation contractility of the tissues incubated in fish oil 
medium compared to the tissues incubated in control with vehicle medium when treated 
with half-logarithmic doses of ACh from 10-9 to 10-4 M (figure 4-4).  Moreover, there was 
not a significant difference (p > 0.05) in the maximum force produced by the tissues 
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incubated in the fish oil medium as compared to that of the tissues incubated in the 
control with vehicle medium (figure 4-4).  There was also no significant difference (p > 
0.05) in the effective dose (ED) 50 between the tissues incubated in the fish oil medium 
and the tissues incubated in the control with vehicle medium (figure 4-5).   
 
Figure 4-4.  The force produced by canine tracheal smooth muscle strips in 
response to half-logarithmic doses of acetylcholine following 24 hours of 
incubation in control with vehicle or fish oil media.  There was not a significant 
difference (p > 0.05) between the control with vehicle (n = 7) and fish oil (n = 7) 
treatments in terms of the post-incubation contractility or maximum force generated.  
Force was calculated as a percent of the pre-incubation maximum force produced by 
each smooth muscle strip.  Error bars represent standard error of the mean.    
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Figure 4-5.  The effective dose (ED) 50 was not significantly altered by treatment.  
The force produced in response to half-logarithmic doses of acetylcholine following 
incubation was normalized with respect to the maximum post-incubation force produced 
by each canine tracheal smooth muscle strip to illustrate the ED 50 of each treatment.  
There were no significant differences (p > 0.05) in the ED 50 between the 24-hour 
incubation in control with vehicle medium (n = 7) and incubation in fish oil medium (n = 
7).  Error bars represent standard error of the mean.  
 
For tissue strips incubated overnight (15 hours) in fish oil medium and control 
with vehicle medium, the two-way mixed ANOVA demonstrated a significant interaction 
(p < 0.05) between the treatment and ACh dose.  Consequently, the contractility of the 
tissue incubated in fish oil medium was determined with a MANOVA to be significantly 
greater (p < 0.05) than that of the tissue incubated in control with vehicle medium at the 
six highest doses of ACh: 3.16 x 10-7 M, 10-6 M, 3.16 x 10-6 M, 10-5 M, 3.16 x 10-5 M, and 
10-4 M (figure 4-6).   
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Figure 4-6.  The force produced by canine tracheal smooth muscle strips in 
response to half-logarithmic doses of acetylcholine following 15 hours of 
incubation in control with vehicle or fish oil media.  There was a significant 
difference (p < 0.05) between the control with vehicle (n = 7) and fish oil (n = 7) 
treatments at the six highest doses of acetylcholine.  Force was calculated as a percent 
of the pre-incubation maximum force produced by each smooth muscle strip.  Error bars 
represent standard error of the mean. *, significantly different from control with vehicle    
 
 
There was not a significant interaction (p > 0.05) between treatment and ACh 
dose for tissues incubated overnight in the fish oil medium compared to the soybean oil 
medium.  Moreover, the post-incubation contractility of the tissue samples incubated in 
the fish oil medium was not significantly different (p < 0.05) from the samples incubated 
in the soybean oil medium (figure 4-7).  Additionally, there was neither a significant 
interaction (p < 0.05) between the treatment and ACh dose nor a significant difference (p 
< 0.05) in contractility between the tissues incubated in the control with vehicle medium 
compared to those incubated in the soybean oil medium (figure 4-8).   
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Figure 4-7.  The force produced by canine tracheal smooth muscle strips in 
response to half-logarithmic doses of acetylcholine following 15 hours of 
incubation in fish oil or soybean oil media.  There was not a significant difference (p 
> 0.05) between the fish oil (n = 9) and soybean oil (n = 10) treatments.  Force was 
calculated as a percent of the pre-incubation maximum force produced by each smooth 
muscle strip.  Error bars represent standard error of the mean.    
 
 
 
 
 
 
 
 
-20
0
20
40
60
80
100
9 8.5 8 7.5 7 6.5 6 5.5 5 4.5 4
Force 
(% of Pre-
Incubation 
Maximum)
Acetlycholine Concentraction (-log M)
Fish Oil
Soybean Oil
 140 
 
Figure 4-8.  The force produced by canine tracheal smooth muscle strips in 
response to half-logarithmic doses of acetylcholine following 15 hours of 
incubation in control with vehicle or soybean oil media.  There was not a significant 
difference (p > 0.05) between the control with vehicle (n = 5) and soybean oil (n = 6) 
treatments.  Force was calculated as a percent of the pre-incubation maximum force 
produced by each smooth muscle strip.  Error bars represent standard error of the 
mean.    
 
 
A one-way independent measures ANOVA revealed significant differences (p < 
0.05) among the maximum force generated by tissues following incubation in fish oil, 
soybean oil, or control with vehicle media (figure 4-9).  Fisher’s LSD post-hoc indicated 
that the maximum contraction of the fish oil-treated tissues and soybean oil-treated 
tissues were each significantly greater (p < 0.05) than that of the control with vehicle-
treated tissues while there was no significant difference (p > 0.05) between the 
maximum contraction of the fish oil-treated and soybean oil-treated tissues.  The ED 50 
was compared among the tissues incubated in fish oil medium, soybean oil medium, or 
control with vehicle medium with a one-way repeated measures ANOVA; there were no 
significant differences (p > 0.05) among the incubation treatments (figure 4-10).   
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Figure 4-9.  The maximum force generated by the canine tracheal smooth muscle 
strips was significantly altered by treatment.  The force produced in response to half-
logarithmic doses of acetylcholine following incubation was normalized with respect to 
the maximum pre-incubation force produced by each canine tracheal smooth muscle 
strip.  The tissue incubated in either fish oil (n = 11) or soybean oil (n = 10) media 
demonstrated significantly greater (p < 0.05) maximum force generation than the tissue 
incubated in control with vehicle (n = 7).  There was no significant difference (p > 0.05) 
between the fish oil and soybean oil treatments. Error bars represent standard error of 
the mean.  
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Figure 4-10.  The effective dose (ED) 50 was not significantly altered by treatment.  
The force produced in response to half-logarithmic doses of acetylcholine following 
incubation was normalized with respect to the maximum post-incubation force produced 
by each canine tracheal smooth muscle strip to illustrate the ED 50 of each treatment.  
There were no significant differences (p > 0.05) in the ED 50 among the 15-hour 
incubation in control with vehicle medium (n = 7), incubation in fish oil medium (n = 11), 
and incubation in soybean oil medium (n = 10).  Error bars represent standard error of 
the mean.  
 
Tissues incubated for 4 hours in their baths in either fish oil or control with vehicle 
treatment did not demonstrate a significant interaction (p > 0.05) between treatment and 
ACh dose.  There was not a significant difference (p > 0.05) in the post-incubation 
contractility between the fish oil treatment and control with vehicle treatment (figure 4-
11).   
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Figure 4-11.  The force produced by canine tracheal smooth muscle strips in 
response to half-logarithmic doses of acetylcholine following 4 hours of 
incubation in control with vehicle or fish oil media.  There was not a significant 
difference (p > 0.05) between the control with vehicle (n = 5) and fish oil (n = 5) 
treatments.  Force was calculated as a percent of the pre-incubation maximum force 
produced by each smooth muscle strip.  Error bars represent standard error of the 
mean.    
 
Similarly, there was not a significant interaction (p > 0.05) between treatment and 
ACh dose for tissue strips incubated in either fish oil or soybean oil media.  Also, there 
was not a significant difference (p > 0.05) between the fish oil and soybean oil 
treatments in the post-incubation contractility (figure 4-12).  Lastly, there was not a 
significant interaction (p > 0.05) between the treatment and ACh dose or a significant 
difference (p > 0.05) in the post-incubation contractility between the treatments for 
tissues incubated in control with vehicle medium and those incubated in soybean oil 
medium (figure 4-13).   
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Figure 4-12.  The force produced by canine tracheal smooth muscle strips in 
response to half-logarithmic doses of acetylcholine following 4 hours of 
incubation in fish oil or soybean oil media.  There was not a significant difference (p 
> 0.05) between the fish oil (n = 5) and soybean oil (n = 6) treatments.  Force was 
calculated as a percent of the pre-incubation maximum force produced by each smooth 
muscle strip.  Error bars represent standard error of the mean.    
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Figure 4-13.  The force produced by canine tracheal smooth muscle strips in 
response to half-logarithmic doses of acetylcholine following 4 hours of 
incubation in control with vehicle or soybean oil media.  There was not a significant 
difference (p > 0.05) between the control with vehicle (n = 5) and soybean oil (n = 6) 
treatments.  Force was calculated as a percent of the pre-incubation maximum force 
produced by each smooth muscle strip.  Error bars represent standard error of the 
mean.    
 
There were no significant differences in either the post-incubation maximum 
force generated by the tissues (p < 0.05) or the ED 50 for the tissues (p > 0.05) among 
the fish oil, soybean oil, and control with vehicle incubation treatments (figures 4-14, 4-
15).  
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Figure 4-14.  The maximum force generated by the canine tracheal smooth muscle 
strips was not significantly altered by treatment.  The force produced in response to 
half-logarithmic doses of acetylcholine following incubation was normalized with respect 
to the maximum pre-incubation force produced by each canine tracheal smooth muscle 
strip.  There were no significant differences (p > 0.05) in the maximum force generated 
among the control with vehicle (n = 5), fish oil (n = 5), and soybean oil (n = 6) treatments. 
Error bars represent standard error of the mean.  
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Figure 4-15.  The effective dose (ED) 50 was not significantly altered by treatment.  
The force produced in response to half-logarithmic doses of acetylcholine following 
incubation was normalized with respect to the maximum post-incubation force produced 
by each canine tracheal smooth muscle strip to illustrate the ED 50 of each treatment.  
There were no significant differences (p > 0.05) in the ED 50 among the 4-hour 
incubation in control with vehicle medium (n = 5), incubation in fish oil medium (n = 5), 
and incubation in soybean oil medium (n = 6).  Error bars represent standard error of the 
mean.  
 
 
A 2-hour incubation in the tissue baths was also completed.  There was not a 
significant interaction (p > 0.05) between the treatment and ACh dose or a significant 
difference (p > 0.05) between the treatments for tissues incubated in fish oil or in control 
with vehicle (figure 4-16).   
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Figure 4-16.  The force produced by canine tracheal smooth muscle strips in 
response to half-logarithmic doses of acetylcholine following 2 hours of 
incubation in control with vehicle or fish oil media.  There was not a significant 
difference (p > 0.05) between the control with vehicle (n = 2) and fish oil (n = 3) 
treatments.  Force was calculated as a percent of the pre-incubation maximum force 
produced by each smooth muscle strip.  Error bars represent standard error of the 
mean.    
 
 
Similarly, there was not a significant interaction (p > 0.05) between the treatment 
and ACh dose or a significant difference (p > 0.05) in the post-incubation contractility 
between the treatments for tissues incubated in fish oil compared to soybean oil (figure 
4-17) or for tissues incubated in control with vehicle compared to soybean oil (figure 4-
18).   
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Figure 4-17.  The force produced by canine tracheal smooth muscle strips in 
response to half-logarithmic doses of acetylcholine following 4 hours of 
incubation in fish oil or soybean oil media.  There was not a significant difference (p 
> 0.05) between the fish oil (n = 3) and soybean oil (n = 3) treatments.  Force was 
calculated as a percent of the pre-incubation maximum force produced by each smooth 
muscle strip.  Error bars represent standard error of the mean.    
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Figure 4-18.  The force produced by canine tracheal smooth muscle strips in 
response to half-logarithmic doses of acetylcholine following 2 hours of 
incubation in control with vehicle or soybean oil media.  There was not a significant 
difference (p > 0.05) between the control with vehicle (n = 2) and soybean oil (n = 3) 
treatments.  Force was calculated as a percent of the pre-incubation maximum force 
produced by each smooth muscle strip.  Error bars represent standard error of the 
mean.    
 
 
Finally, there were no significant differences in either the post-incubation 
maximum force generated by the tissues (p < 0.05) or the ED 50 for the tissues (p > 
0.05) among the fish oil, soybean oil, and control with vehicle incubation treatments 
(figures 4-19, 4-20).     
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Figure 4-19.  The maximum force generated by the canine tracheal smooth muscle 
strips was not significantly altered by treatment.  The force produced in response to 
half-logarithmic doses of acetylcholine following incubation was normalized with respect 
to the maximum pre-incubation force produced by each canine tracheal smooth muscle 
strip.  There were no significant differences (p > 0.05) in the maximum force generated 
among the control with vehicle (n = 2), fish oil (n = 3), and soybean oil (n = 3) treatments. 
Error bars represent standard error of the mean.  
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Figure 4-20.  The effective dose (ED) 50 was not significantly altered by treatment.  
The force produced in response to half-logarithmic doses of acetylcholine following 
incubation was normalized with respect to the maximum post-incubation force produced 
by each canine tracheal smooth muscle strip to illustrate the ED 50 of each treatment.  
There were no significant differences (p > 0.05) in the ED 50 among the 2-hour 
incubation in control with vehicle medium (n = 2), incubation in fish oil medium (n = 3), 
and incubation in soybean oil medium (n = 3).  Error bars represent standard error of the 
mean. 
 
Acute Exposure to Fish Oil.  Once a plateau in the force generated by each 
smooth muscle strip treated with a single dose of ACh was established, treatments were 
added to the tissue baths.  A significant relaxation in the force elicited by 10-6 M ACh was 
observed among the fish oil, soybean oil, vehicle, and control (sham) treatments (figure 
4-21).  Fisher’s LSD post-hoc determined that the percent relaxation with the fish oil 
treatment was significantly greater (p < 0.05) than both the vehicle and control 
treatments; there was no significant difference between the fish oil and soybean oil 
treatments.  When the smooth muscle strips were contracted with 10-7 M ACh, there was 
not a significant difference (p > 0.05) in the percent relaxation occurring with fish oil, 
soybean oil, and vehicle treatments (figure 4-22). 
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Figure 4-21.  Canine tracheal smooth muscle strips relaxed in response to the 
acute exposure of fish oil.  Following contraction of the tissue with 10-6 M 
acetylcholine, fish oil (n = 3), soybean oil (n = 3), vehicle (n = 3), or control (sham) (n = 
2) treatments were administered to the tissue baths. The percent relaxation associated 
with the fish oil treatment was significantly greater (p < 0.05) than that of the vehicle and 
control treatments.  There were no significant differences (p > 0.05) between the fish oil 
and soybean oil treatments.  Error bars represent standard error of the mean.  *, 
significantly different from vehicle and control 
 
 
 
 
 
 
 
 
0
1
2
3
4
5
6
7
8
9
Fish Oil Soybean Vehicle Control
% Relaxation 
after Treatment
 * 
 154 
 
Figure 4-22.  Acute exposure to fish oil did not significantly relax the canine 
tracheal smooth muscle response to 10-7 M acetylcholine.  Following contraction of 
the tissue with 10-7 acetylcholine, fish oil (n = 4), soybean oil (n = 4), or control with 
vehicle (n = 4) treatments were administered to the tissue baths. There were no 
significant differences (p > 0.05) in the percent relaxation among the fish oil, soybean oil, 
and vehicle treatments.  Error bars represent standard error of the mean. 
 
Contractions with Other Agonists.  PGF2 failed to contract smooth muscle strips 
at any half-logarithmic dose between 10-9 to 10-4 M.  The same doses of ACh were 
tested in tandem as a positive control.  Additional studies using PGF2 as the contractile 
agonist were not conducted. 
A dose response curve was obtained with half-logarithmic doses of 5-HT 
between 10-9 to 10-4 M.  To demonstrate the repeatability of this response, the dose 
response curve was repeated 4 hours later.  Again, the same doses of ACh were tested 
in tandem as a positive control.  The tissues demonstrated good retention of their 
responses to both contractile agonists with the repeated dose response curve (figures 4-
23, 4-24).  Thus, additional studies using 5-HT as the contractile agonist were 
undertaken. 
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Figure 4-23.  The force produced by canine tracheal smooth muscle strips in 
response to half-logarithmic doses of acetylcholine prior to and following a 4-hour 
incubation in physiologic saline solution.  The reproducibility of smooth muscle 
strips’ (n = 4) response to acetylcholine after 4 hours of incubation in tissue baths filled 
with physiologic saline solution was tested.  Force was calculated as a percent of the 
pre-incubation maximum force produced by each smooth muscle strip.  Error bars 
represent standard error of the mean.    
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Figure 4-24.  The force produced by canine tracheal smooth muscle strips in 
response to half-logarithmic doses of 5-hydroxytryptamine prior to and following 
a 4-hour incubation in physiologic saline solution.  The reproducibility of smooth 
muscle strips’ (n = 4) response to 5-hydroxytryptamine after 4 hours of incubation in 
tissue baths filled with physiologic saline solution was tested.  Force was calculated as a 
percent of the pre-incubation maximum force produced by each smooth muscle strip.  
Error bars represent standard error of the mean.    
 
Several experiments examining the effect of the chronic exposure of fish oil were 
repeated using half-logarithmic doses of 5-HT as the contractile agonist in place of ACh.  
Following 24 hours of incubation in fish oil or control with vehicle media, there was no 
significant interaction between treatment and 5-HT dose.  Moreover, there was not a 
significant difference in the post-incubation contractility between the fish oil and control 
with vehicle treatments (figure 4-25).  Neither the maximum force produced by the 
tissues nor the ED 50 of the tissues (figure 4-26) were significantly different (p > 0.05) 
between the fish oil and control with vehicle treatments.   
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Figure 4-25.  The force produced by canine tracheal smooth muscle strips in 
response to half-logarithmic doses of 5-hydroxytryptamine following 24 hours of 
incubation in control with vehicle or fish oil media.  There was not a significant 
difference (p > 0.05) between the control with vehicle (n = 6) and fish oil (n = 5) 
treatments in terms of the post-incubation contractility or maximum force generated.  
Force was calculated as a percent of the pre-incubation maximum force produced by 
each smooth muscle strip.  Error bars represent standard error of the mean.    
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Figure 4-26.  The effective dose (ED) 50 was not significantly altered by treatment.  
The force produced in response to half-logarithmic doses of 5-hydroxytryptamine 
following incubation was normalized with respect to the maximum post-incubation force 
produced by each canine tracheal smooth muscle strip to illustrate the ED 50 of each 
treatment.  There was no significant difference (p > 0.05) in the ED 50 between the 24-
hour incubation in control with vehicle medium (n = 6) and incubation in fish oil medium 
(n = 5).  Error bars represent standard error of the mean. 
 
 
The 4-hour incubation in the tissue baths was also conducted with 5-HT as the 
contractile agonist.  There was no significant interaction (p > 0.05) between treatment 
and 5-HT dose at this time point for tissues incubated in fish oil or control with vehicle 
media.  There was also no significant difference (p > 0.05) in the post-incubation 
contractility between the fish oil and control with vehicle treatments (figure 4-27).   
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Figure 4-27.  The force produced by canine tracheal smooth muscle strips in 
response to half-logarithmic doses of 5-hydroxytryptamine following 4 hours of 
incubation in control with vehicle or fish oil media.  There was not a significant 
difference (p > 0.05) between the control with vehicle (n = 2) and fish oil (n = 2) 
treatments.  Force was calculated as a percent of the pre-incubation maximum force 
produced by each smooth muscle strip.  Error bars represent standard error of the 
mean.    
 
Similarly, there was not a significant interaction (p > 0.05) between the treatment 
and 5-HT dose or a significant difference (p > 0.05) in the post-incubation contractility of 
tissues incubated in fish oil or soybean oil media (figure 4-28).  Tissues incubated in 
control with vehicle medium or soybean oil medium did not express a significant 
interaction (p > 0.05) between the treatment and 5-HT dose; there was also no 
significant difference (p > 0.05) in the post-incubation contractility of these treatments 
(figure 4-29).   
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Figure 4-28.  The force produced by canine tracheal smooth muscle strips in 
response to half-logarithmic doses of 5-hydroxytryptamine following 4 hours of 
incubation in fish oil or soybean oil media.  There was not a significant difference (p 
> 0.05) between the fish oil (n = 2) and soybean oil (n = 3) treatments.  Force was 
calculated as a percent of the pre-incubation maximum force produced by each smooth 
muscle strip.  Error bars represent standard error of the mean.    
 
 
-20
0
20
40
60
80
100
120
9 8.5 8 7.5 7 6.5 6 5.5 5
Force 
(% of Pre-
Incubation 
Maximum)
5-Hydroxytryptamine Concentration (- log M)
Fish Oil
Soybean Oil
 161 
 
Figure 4-29.  The force produced by canine tracheal smooth muscle strips in 
response to half-logarithmic doses of 5-hydroxytryptamine following 4 hours of 
incubation in control with vehicle or soybean oil media.  There was not a significant 
difference (p > 0.05) between the control with vehicle (n = 2) and soybean oil (n = 3) 
treatments.  Force was calculated as a percent of the pre-incubation maximum force 
produced by each smooth muscle strip.  Error bars represent standard error of the 
mean.    
 
 
The maximum force generated by the tissues was not significantly different 
among the fish oil, soybean oil, and control with vehicle treatments (figure 4-30).  
Furthermore, there was not a significant difference in the ED 50 for the tissues treated 
with fish oil, soybean oil, or control with vehicle treatments (figure 4-31). 
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Figure 4-30.  The maximum force generated by the canine tracheal smooth muscle 
strips was not significantly altered by treatment.  The force produced in response to 
half-logarithmic doses of 5-hydroxytryptamine following a 4-hour incubation was 
normalized with respect to the maximum pre-incubation force produced by each canine 
tracheal smooth muscle strip.  There were no significant differences (p > 0.05) in the 
maximum force generated among the control with vehicle (n = 2), fish oil (n = 2), and 
soybean oil (n = 3) treatments. Error bars represent standard error of the mean.  
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Figure 4-31.  The effective dose (ED) 50 was not significantly altered by treatment.  
The force produced in response to half-logarithmic doses of 5-hydroxytryptamine 
following a 4-hour incubation was normalized with respect to the maximum post-
incubation force produced by each canine tracheal smooth muscle strip to illustrate the 
ED 50 of each treatment.  There were no significant differences (p > 0.05) in the ED 50 
among the 4-hour incubation in control with vehicle medium (n = 2), incubation in fish oil 
medium (n = 2), and incubation in soybean oil (n = 3).  Error bars represent standard 
error of the mean. 
 
 
The acute exposure of fish oil was also assessed using 5-HT as the contractile 
agonist.  After a plateau in the force generated by each smooth muscle strip treated with 
a single dose of 5-HT was established, treatments were added to the tissue baths.  A 
significant relaxation (p < 0.05) in the force generated by 10-6 5-HT was demonstrated 
between fish oil and soybean oil, vehicle, or control (sham) (figure 4-32); there were no 
significant differences (p > 0.05) among the percent relaxation associated with soybean 
oil, vehicle, or control treatment administration.   
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Figure 4-32.  Canine tracheal smooth muscle strips relaxed in response to the 
acute exposure of fish oil.  Following contraction of the tissue with 10-6 M 5-
hydroxytryptamine, fish oil (n = 9), soybean oil (n = 6), vehicle (n = 6), or control (sham) 
(n = 5) treatments were administered to the tissue baths. The percent relaxation 
associated with the fish oil treatment was significantly greater (p < 0.05) than that of the 
three other treatments.  There were no significant differences (p > 0.05) among the 
soybean oil, vehicle, and control (sham) treatments.  Error bars represent standard error 
of the mean.  *, significantly different 
 
Using 10-7 5-HT to contract the smooth muscle strips, this acute experiment 
protocol was repeated.  There were no significant differences among the percent 
relaxations provoked by the addition of fish oil, soybean oil, and control with vehicle 
treatments (figure 4-33). 
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Figure 4-33.  Acute exposure to fish oil did not significantly relax the canine 
tracheal smooth muscle response to 10-7 M 5-hydroxytryptamine.  Following 
contraction of the tissue with 10-7 5-hydroxytryptamine, fish oil (n = 7), soybean oil (n = 
4), or control with vehicle (n = 7) treatments were administered to the tissue baths. There 
were no significant differences (p > 0.05) in the percent relaxation among the fish oil, 
soybean oil, and vehicle treatments.  Error bars represent standard error of the mean.   
 
Discussion 
 A series of experiments were undertaken to test the hypothesis that the 
treatment of canine tracheal smooth muscle tissue with fish oil would reduce arachidonic 
acid content and increase EPA and DHA content in smooth muscle cell membranes and 
would be associated with a decrease in the airway smooth muscle responsiveness to a 
contractile agonist.  Although significant changes in both omega-3 polyunsaturated fatty 
acid content and smooth muscle contractility were demonstrated, these alterations did 
not occur in concert and therefore are likely unrelated. 
 Lipid analysis revealed significant incorporation of EPA and DHA in smooth 
muscle strips incubated for at least 24 hours in fish oil medium as compared to tissue 
incubated in control medium.  Previous studies that have assessed fatty acid 
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composition following fish oil supplementation have reported the concentration of 
arachidonic acid, EPA, and DHA in murine lung tissue (102), human neutrophils (47, 61), 
and human plasma phospholipids (47) but not canine airway smooth muscle (table 4-3).  
While these studies supplemented the diet with fish oil for weeks, the trend of changes in 
the lipid profile between treated and control samples are similar to the current study.  
Notably, examination of the comparative concentrations of the fatty acids indicates that 
the degree of incorporation seems to vary by the tissue type as well as by the duration of 
exposure to omega-3 fatty acids. 
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Arachidonic 
Acid (%) EPA (%) DHA (%) 
Current Study 
  
Control 16.38 ± 3.69 0.00 ± 0.00 0.21 ± 0.02 
Fish Oil 8.90 ± 2.96 5.97 ± 1.12 2.37 ± 0.12 
Kew et al., 2004 
(Plasma Phospholipids) 
  
Placebo Supplementation 12.0 ± 2.6 1.3 ± 0.7 7.3 ± 1.6 
EPA Supplementation 10.2 ± 1.0 7.2 ± 1.9 7.6 ± 1.1 
DHA Supplementation 10.2 ± 2.2 4.5 ± 1.3 13.5 ± 3.1 
Kew et al., 2004 
(Neutrophils) 
  
Placebo Supplementation 14.1 ± 1.8 0.6 ± 0.3 2.5 ± 0.9 
EPA Supplementation 12.7 ± 2.1 3.0 ± 1.1 2.7 ± 0.9 
DHA Supplementation 12.2 ± 1.5 1.8 ± 0.5 5.3 ± 1.1 
Mickleborough et al., 2006 
(Neutrophils) 
  
Normal Diet 22.3 ± 0.97 0.18 ± 0.03 2.16 ± 0.33 
Placebo Supplementation 22.6 ± 0.92 0.15 ± 0.04 2.2 ± 0.41 
Fish Oil Supplementation 13.1 ± 1.02 4.01 ± 0.45 3.32 ± 0.45 
Table 4-3.  Comparison of the arachidonic acid, eicosapentaenoic acid (EPA), and 
docosahexaenoic acid (DHA) fatty acid composition reported in the current study 
and the literature.  Two in vivo studies determined the percent contribution of 
arachidonic acid, EPA, and DHA to the total fatty acid composition in the subjects’ 
neutrophils and/or plasma phospholipids following supplementation with placebo, EPA-
rich, DHA-rich, or fish oil capsules.  Healthy subjects were supplemented for 4 weeks in 
the Kew et al. (47, 61) study while asthmatic subjects with exercise-induced 
bronchoconstriction were supplemented for 3 weeks in the Mickleborough et al. (61) 
study.  Both studies used olive oil as the placebo treatment.  For the current study, 
canine tracheal smooth muscle strips were incubated in either control or fish oil media 
for 1 day.  Data are reported as the mean percent contribution to total fatty acid 
composition ± standard error of the mean for the current study and the Kew et al. study.  
Data are reported as the mean percent contribution to total fatty acid composition ± 
standard deviation for the Mickleborough et al. study. 
 
 Following 15 hours of incubation in fish oil media, there was not a significant 
change in arachidonic acid, EPA, or DHA as compared to smooth muscle strips 
incubated in soybean oil, control with vehicle, or control media.  Additionally, following 4 
hours of incubation in fish oil media, there was a statistically significant increase in DHA, 
but not EPA or arachidonic acid, as compared to tissue incubated in control with vehicle 
or control media; there was not a significant difference in arachidonic acid, EPA, or DHA 
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composition between tissues incubated in fish oil and soybean oil.  Because the percent 
contribution of DHA to the total fatty acid composition after 4 hours of incubation in fish 
oil (0.14 ± 0.02%) was similar to that for the tissues incubated in control media for 1 day 
(0.21 ± 0.02%), this statistically significant difference is likely not physiologically 
significant.  Moreover, although there was not a significant difference between the 
soybean oil and fish oil treated tissues after 4 hours of incubation, the percent 
contribution of DHA to the total fatty acid composition was greater with soybean oil (0.39 
± 0.09%) than with fish oil (0.14 ± 0.02%), which should not be due to differences in fatty 
acid incorporation as soybean oil does not contain either EPA or DHA. 
In contrast to the tissue samples that were incubated for a longer time course, 
the tissues incubated for 4 and 15 hours were contracted in the dose response 
experiments prior to and following their incubation.  Thus, although it may be that these 
shorter time points did not permit adequate time for lipid incorporation, it is also possible 
that the lipids that were incorporated were subsequently metabolized to produce ATP for 
the contraction experiments.  This is a feasible explanation as it has been shown that 
vascular smooth muscle can utilize a variety of endogenous and exogenous substrates 
for energy production, and at least at rest, endogenous substrates are preferentially 
oxidized by vascular smooth muscle (21).  Furthermore, Odessey et al. (73) determined 
that for resting vascular smooth muscle, endogenous lipids account for approximately 
77% of oxygen consumption when exogenous glucose is present and nearly 100% of 
oxygen consumption when exogenous glucose is absent.  Thus, despite the presence of 
glucose in the PSS in the tissue baths of the current study, the smooth muscle strips 
may have oxidized endogenous lipids during the contraction experiments.   
 Since lipid metabolism was recognized as a potential confounding factor for our 
experiments, we reduced the washout periods as much as possible and maintained the 
treatments in the tissue baths.  Allen et al. (7)  reported that exogenous acetate provided 
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the major source for ATP production via the citric acid cycle both at rest and during 
contraction for vascular smooth muscle; importantly, they demonstrated that the 
muscle’s endogenous substrates were not oxidized when exogenous acetate was 
present.  However, longer chain fatty acids, such as EPA (C20) and DHA (C22), are not 
as readily oxidized as short chain fatty acids when added exogenously to resting 
vascular smooth muscle (21).  Moreover, it was noted by Odessey, et al. (73) that when 
incubating vascular smooth muscle with longer chain fatty acids, it is the endogenous 
lipids that are oxidized.  Nevertheless, these findings may not hold true for contracting 
airway smooth muscle.  Thus, in the future, lipid analysis should be performed in tandem 
on tissue that has only been incubated in the particular treatment and on tissue that was 
similarly incubated but also used in contraction experiments.  This would help elucidate 
whether the lipids were incorporated at the shorter time points and then metabolized or 
simply not incorporated at all. 
 The effect of chronic exposure of fish oil on canine tracheal smooth muscle was 
tested after a range of incubation periods.  Following a 24-hour incubation in fish oil 
medium, there was no significant change in the smooth muscle’s contractile response to 
half-logarithmic doses of either ACh or 5-HT as compared to tissue incubated in control 
with vehicle medium.  Although significant omega-3 fatty acid incorporation was 
demonstrated at this time point, there was not an associated reduction in contractility as 
expected.  Since lipid analysis was only performed on tissue that had been incubated for 
24 hours and not contracted, it is possible that the dose response experiment tissues 
metabolized their newly incorporated lipids during the contractions.  Additionally, 
differences in contractility between tissues incubated in fish oil or control with vehicle 
media may have been masked by the deterioration of the post-incubation response to 
the contractile agonists for both sets of tissues; specifically, observable contractions 
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were not elicited until the fourth or fifth dose of the agonist post-incubation as opposed to 
typically the second or third dose of the agonist pre-incubation. 
 Interestingly, increased smooth muscle contractility was observed at the highest 
six doses of ACh following 15 hours of incubation in fish oil medium as compared to 
incubation in control with vehicle medium.  The maximum force generated by the fish oil-
treated tissues was also significantly greater than that of the control with vehicle-treated 
tissues.  These results were contrary to the hypothesis.  Therefore, this set of 
experiments showed that, if anything, fish oil improved or maintained the tracheal 
smooth muscle’s condition compared to the control with vehicle treatment.  Furthermore, 
as there was not a significant difference in the contractility between tissues incubated in 
soybean oil and those incubated in control with vehicle, it is likely that the differences 
with fish oil treatment are due to the presence of the omega-3 fatty acids it contains and 
not just that fact that the tissue was incubated with oil.  
 The shorter incubation periods of 2 and 4 hours did not demonstrate any 
changes in contractility, maximum force generation, or the ED 50 among the treatments.  
These tissues received their treatments while remaining in their tissue baths.  Thus, the 
incubation media (PSS plus treatment) was different from that for the 15 and 24 hour 
incubations in an incubator (DMEM plus treatment).  Again, for the tissues incubated for 
4 hours, it is unknown whether the fish oil lipids were incorporated and then metabolized 
or never incorporated.  Lipid analysis was not performed on the tissues incubated for 2 
hours.  The post-incubation contractions were very similar to the pre-incubation 
contractions for this time point.   
 The limited literature on chronic exposure to fish oil also shows variable results 
for airway smooth muscle contractility.  Morin et al. (69) showed that following a 48-hour 
incubation with tumor necrosis factor-α (TNF-α) to induce bronchial hyperactivity either 
in the presence or absence of the EPA metabolite 17(18)-epoxyeicosatetraenoic acid  
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(17(18)-EpETE), there was a significant difference in the tension produced by the human 
bronchial smooth muscle tissues in response to methacholine or histamine; the tissues 
incubated in the presence of 17(18)-EpETE developed less tension.  Although not 
reported as a significant difference, the figures in the Morin et al. (69) study show that 
incubation with TNF-α and the EPA metabolite was associated with increased tension to 
higher doses of methacholine and histamine compared to the control tissues incubated 
with neither TNF-α nor the EPA metabolite; this was a trend similar to the significant 
effects seen with our tissues incubated for 15 hours.  Another study examined the effect 
of omega-3 and omega-6 fatty acid enriched diets on airway smooth muscle contractility.  
Here, Abeywardena et al. (4) fed guinea pigs different diets containing a range of 
omega-3 and omega-6 fatty acids.  They did not observe any significant differences in 
bronchial and tracheal smooth muscle contractility in response to a range of agonists 
(histamine, carbechol, leukotriene C4, and prostaglandin-2α) among the high, moderate, 
and low omega-6:omega-3 fatty acid ratio diets.  Fatty acid incorporation in the lung 
tissue was measured; however, there was not a significant change in the percent 
composition of EPA and DHA.  This contrasts the significant changes in EPA and DHA 
composition shown in murine lung tissue following dietary supplementation with fish oil in 
mice (102).   
 Significant relaxation was observed when fish oil was introduced into the baths of 
smooth muscle strips contracted with either 10-6 M ACh or 10-6 M 5-HT.  Even though 
the percent relaxation was 7.58 ± 0.09% for tissues contracted with 10-6 M ACh and 9.07 
± 2.19% for tissues contracted with 10-6 M 5-HT, these minor changes may be 
physiologically significant if they are occurring in the small airways throughout the lungs 
as this would magnify the overall effect of the changes.  When the acute exposure 
experiment was conducted with a lower dose (10-7 M) of ACh or 5-HT, significant 
relaxation was not observed following the administration of fish oil to the baths.  In the 
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case of 5-HT, this may have been because most of the smooth muscle strips were not 
able to maintain a stable contraction throughout the duration of the experiment making it 
difficult to detect changes.     
 The literature also reports both significant relaxation and no significant changes 
following acute treatment of airway smooth muscle with omega-3 fatty acids.  Hichami et 
al. (39) demonstrated significant relaxation of the basal tone of guinea pig bronchial 
smooth muscle with DHA although no such relaxation occurred when the smooth muscle 
was first contracted with carbamylcholine.  In contrast, Morin et al. (69) reported a 
concentration-dependent relaxing effect of acute treatment with the EPA metabolite 
17(18)-EpETE on both resting and contracted human bronchial smooth muscle. 
 In addition to more fully coordinating lipid analysis with the contraction 
experiments, future studies in this area should focus on creating a model that better 
mimics asthma.  For example, interleukin-13 could be used to induce 
hyperresponsiveness of the canine tracheal smooth muscle just as Morin et al. (69) used 
TNF-α to induce hyperresponsiveness in human bronchial smooth muscle.  Airway 
hyperresponsiveness is a classic feature of asthma.  Furthermore, as it is known that the 
presence of epithelium affects airway reactivity (48), tissue with and without epithelium 
could be tested to determine if fish oil treatment affects them differently.  It has been 
shown that the vascular smooth muscle of some vessels is relaxed by fish oil treatment 
in an endothelium-dependent manner (101).  If the presence of epithelium is shown to 
be important to the responsiveness of tissue treated with fish oil, this would afford a 
possible reason for the somewhat variable response of subjects with asthma to fish oil 
as the airway epithelium is impaired to varying degrees in asthma (48).  Moreover, as 
the clinical application of fish oil is through chronic supplementation, studies using 
airway smooth muscle tissue obtained from animal models fed fish oil instead of 
incubating the tissue in fish oil would more closely resemble the practical situation. 
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 Overall, these experiments suggest that fish oil exposure can be associated with 
changes in airway smooth muscle contractility.  However, these changes do not seem to 
be related to EPA and DHA incorporation.  On the other hand, these lipid analysis 
results may have been confounded by endogenous substrate usage as proposed above.  
Moreover, in the case of 15 hours of chronic exposure, fish oil incubation was 
surprisingly associated with increased force generation.  Nevertheless, minor, but 
significant, relaxation of ACh- and 5-HT-stimulated contractions were observed with 
acute exposure to fish oil.  Thus, these results encourage additional research on the 
impact of fish oil on airway smooth muscle as in vivo fish oil supplementation studies 
purport significant reductions in exercise-induced bronchoconstriction in human subjects. 
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CHAPTER 5 
DISCUSSION 
Summary of Findings 
 According to the most recent report from the Center for Disease Control (CDC), 
the prevalence of asthma in the United States is increasing after remaining stable for 
several years (6).  Consequently, the economic burden of asthma from healthcare costs 
for prescription medications and emergency room visits along with indirect costs related 
to missed days of school and work for children and adults, respectively, is an important 
issue.  Thus, the optimal management of asthma is imperative.  
 Given that the prevalence of asthma seems to be linked to societal changes in 
diet, nutritional strategies may offer a viable alternative to traditional pharmaceutical 
regimens (77).  Specifically, a relatively high intake of omega-6 polyunsaturated fatty 
acids (PUFAs) in comparison to omega-3 PUFA intake may be contributing to chronic 
inflammatory diseases such as asthma (40, 57).  Accordingly, omega-3 PUFA 
supplementation has reportedly reduced exercise-induced bronchoconstriction (EIB) in 
asthmatics treated with fish oil (61, 93).  Therefore, the inclusion of dietary modification 
or supplementation in an asthma management plan may reduce reliance on medications 
that may have side effects or reduced efficacy over time (60).   
Our primary objective was to determine the effects of novel nutritional strategies 
on hyperpnea-induced bronchoconstriction (HIB) in asthmatic individuals.  HIB can 
identify EIB by using a rapid breathing challenge instead of an exercise protocol (9).  
Although our laboratory has previously demonstrated that fish oil alleviates EIB and HIB 
(61, 62, 93), several important questions remain unanswered.  In particular, fish oil’s use 
in combination with other nutritional supplements, the optimal fish oil formula, and fish 
oil’s effect on airway smooth muscle responsiveness have not been fully explored.  In 
attempt to address these issues, the following specific aims were undertaken: 
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1. Determine the effect of fish oil and antioxidant supplementation and their 
combination on hyperpnea-induced bronchoconstriction (HIB) and airway 
inflammation in asthmatic individuals.  When taken in isolation, fish oil 
supplementation significantly attenuated HIB while vitamin C supplementation 
seemed to positively affect airway inflammation as measured by the fraction of 
exhaled nitric oxide (FENO).  The combination treatment also significantly reduced 
HIB and may have affected FENO; however, the effects of the combination treatment 
were not greater than that of either treatment alone as hypothesized.  
2. Determine the effects of docosahexaenoic acid (DHA), a component of fish oil, 
on hyperpnea-induced bronchoconstriction (HIB) and airway inflammation in 
asthmatic individuals.  Although previous in vitro studies suggested that DHA can 
alleviate inflammation on its own and may be the more potent component of fish oil 
(52, 98), there were no significant changes in pulmonary function, airway 
inflammation, DHA metabolite concentrations, or levels of 8-isoprostane, a marker of 
oxidative stress, with DHA supplementation in the current in vivo study.   
3. Determine whether fish oil is associated with a reduction in the contractility of 
canine tracheal smooth muscle.  A series of experiments tested the impact of 
chronic fish oil incubation and acute fish oil administration on canine tracheal smooth 
muscle contractility.  Following 15 hours of incubation, tissue treated with fish oil 
generated a greater maximum force in response to acetylcholine than tissue treated 
with vehicle.  However, significant relaxation of smooth muscle strips contracted with 
10-6 M acetylcholine or 10-6 M 5-hydroxytryptamine was observed following the acute 
administration of fish oil as compared to smooth muscle strips acutely receiving 
vehicle or control treatments.   
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Figure 5-1.  Proposed mechanism of how omega-3 fatty acids reduce airway 
inflammation and constriction in hyperpnea-induced bronchoconstriction. The 
results from these experiments confirmed that fish oil reduces hyperpnea-induced 
bronchoconstriction and suggest that fish oil may influence smooth muscle contractility.  
However, the action of vitamin C, and thus an additive effect with the combination 
treatment, may have been masked by the inclusion of subjects who did not respond to 
vitamin C supplementation.  
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Clinical Implications 
 The research presented here has important clinical implications.  First and 
foremost, it is clear from the in vivo studies that the fish oil formula in supplements is an 
essential consideration.  We have confirmed that fish oil containing 3.2 g EPA and 2.0 g 
DHA is effective in attenuating hyperpnea-induced bronchoconstriction while fish oil 
containing 4.0 g DHA is not.  Therefore, to continue to move the field of research on the 
clinical benefits of omega-3 fatty acid supplementation forward, it is imperative that the 
optimal fish oil formula be determined and subsequently standardized.  This is a vital 
step in helping patients reap the full advantages of fish oil, whether they are trying to 
treat pulmonary, cardiovascular, or chronic inflammatory conditions, because differences 
in the supplements’ contents may affect digestion or absorption and thus alter their 
effects (70).  Commercial fish oil can contain omega-3 fatty acids in different synthetic 
compounds such as ethyl esters that may be absorbed differently than their natural 
triglyceride form found in fish (5).   Ethyl ester derivatives of fish oil have been shown to 
have reduced bioavailability compared to natural fish oil (28).  Importantly, the 
supplements provided by Nordic Naturals (Watsonville, CA) and Martek Biosciences 
Corporation (Columbia, MD) for these studies did not contain ethyl esters; instead, they 
contained re-esterified triglycerides, which have been shown to yield greater omega-3 
fatty acid incorporation than ethyl ester forms of fish oil (72).  In fact, one study 
demonstrated that the bioavailability of re-esterified triglycerides was greater than that of 
natural fish oil (28).     
 The lack of any significant effect of DHA supplementation on pulmonary function, 
airway inflammation, or the levels of the metabolites tested indicates that DHA did not 
attenuate HIB or airway inflammation in asthmatic subjects.  Therefore, it appears that 
DHA is not a potent supplement on its own, and it suggests that either EPA is the more 
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effective component of fish oil or that the combination of EPA and DHA is necessary to 
improve HIB.  
Furthermore, the in vivo study on the combination of nutritional supplements 
signifies that similar to prescription asthma medications, nutritional strategies may not be 
equally effective for all patients.  Despite the encouraging results for vitamin C 
supplementation reducing exercise–induced bronchoconstriction reported by 
Tecklenberg et al. (94), the current study did not demonstrate a significant improvement 
in HIB following vitamin C supplementation.  However, four individuals within the group 
of seven subjects receiving only vitamin C for the first supplementation period did 
demonstrate improvements in their post-challenge pulmonary function at the laboratory 
test.  This suggests that vitamin C is an effective supplement in a subset of the asthma 
population, which supports an earlier finding of Cohen et al. (22) that only nine of twenty 
asthmatic subjects exhibited improved post-exercise pulmonary function following a 
single 2000 mg dose of vitamin C compared to placebo.  Moreover, if vitamin C 
supplementation is only effective in a specific subset of asthmatics, it would help explain 
the variable results described in a meta-analysis of the literature pertaining to 
randomized, placebo-controlled studies on treating asthma with vitamin C (46); the 
studies examined also demonstrated incongruent protocols that may have added to their 
differences. 
 Unfortunately, the in vivo study on the combination of nutritional supplements did 
not demonstrate an additive effect for fish oil and vitamin C supplementation as 
hypothesized.  Because of the noted overall lack of significant improvements with 
vitamin C in this study, the potential benefits of this combination treatment in a more 
homogenous, vitamin C-responsive asthmatic population should not be ruled out.  
Furthermore, the possibility that other combinations of nutritional supplements may be 
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effective should continue to be considered as the underlying principles advocating this 
strategy remain.  
 Because the basis of fish oil’s in vivo effects are still being elucidated, the in vitro 
study on canine airway smooth muscle has important clinical implications as well.  The 
experiments using an acute administration of fish oil demonstrated that fish oil has a 
significant relaxing effect on tracheal smooth muscle strips that were contracted with 10-6 
M acetylcholine or 10-6 M 5-hydroxytryptamine.  These statistically significant changes in 
the smooth muscle contraction of the large airways may be clinically significant if similar 
changes occur at the level of the small airways because a minor percent relaxation as 
exhibited here experimentally would be magnified.  Additionally, the chronic exposure to 
fish oil experiments and lipid analysis suggest that the mechanism by which fish oil 
supplementation affects airway smooth muscle responsiveness does not require the 
incorporation of omega-3 fatty acids; however, it is possible that these results were 
confounded by the oxidation of endogenous lipids during airway smooth muscle 
contraction experiments.  Although lipid incorporation of EPA and DHA was shown to be 
significant following 24 hours of incubation in fish oil medium, there was no associated 
change in the airway smooth muscle contractility at this time point.  Furthermore, there 
was a significant difference in the responsiveness to acetylcholine between tissues 
incubated for 15 hours in fish oil and those incubated in control with vehicle media 
despite no concurrent significant changes in the EPA and DHA composition according to 
the subsequent lipid analysis.  Surprisingly, these fish oil-treated tissues displayed a 
greater contractility during the course of the dose response experiment as compared to 
the control with vehicle-treated tissues.  Even though this was contrary to the hypothesis 
for this aim, these results may simply indicate that the fish oil treatment maintained the 
physiologic condition of the tissue samples better than the control with vehicle treatment.  
Because there was a significant difference between 15 hours of incubation in fish oil and 
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control with vehicle media but not between 15 hours of incubation in soybean oil and 
control with vehicle media, it suggests that the omega-3 fatty acids EPA and DHA, which 
are absent from soybean oil, have an important role in airway smooth muscle 
responsiveness.  
Future Directions and Proposed Studies 
 Additional research to further examine asthma management through nutritional 
means is necessary.  As dietary supplements are widely used among asthmatics (54), it 
is important to formally test their efficacy to educate physicians and patients on their 
proper use.  This should lead to improved safety in terms of understanding potential side 
effects.  Moreover, it is critical to distinguish effective strategies from unsubstantiated 
claims; otherwise, patients may have the false impression that their asthma is being 
properly managed.  Similarly, although nutritional modifications have the potential to 
reduce spending on prescription drugs for asthma, it would be just as imprudent for 
patients to spend money on supplements that are not supported by sound research. 
 Future studies on nutritional supplements for treating asthma should strive to 
encompass both basic science and clinical trials.  Basic science will be vital to explain 
the effectiveness of current nutritional strategies as well as propose new approaches.  
However, large-scale clinical trials will be of the utmost importance.  Even though basic 
science research can suggest possible treatments, it is the results from the practical 
application of these suggestions that ultimately matter.  For example, an understanding 
of the negative effects reactive oxygen species (ROS) can have on the airways along 
with associated findings that ROS production may be increased and antioxidant 
defenses diminished in asthma supports the use of antioxidant supplementation in 
asthmatics.  Yet, the findings from clinical trials employing this strategy are inconclusive 
(46).  Nevertheless, these negative results can help structure future research at the 
bench and bedside. 
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 With this in mind, future studies should address some of the negative findings of 
the current studies.  Research assessing vitamin C supplementation, whether alone or in 
combination with other nutrients or medications, should plan to screen subjects for 
vitamin C responsiveness.  Regarding DHA supplementation, an increase in dosage, a 
change in the method of administration, or an extended time course may yield more 
positive results.  Lastly, alterations in the protocol for the canine airway smooth muscle 
study involving fish oil exposure should be undertaken.  To determine whether the 
omega-3 fatty acids were incorporated during incubation in fish oil and subsequently 
metabolized during contraction experiments, lipid analysis should be performed on 
tissue that has only been incubated in the particular treatment as well as on tissue that 
was similarly incubated but also used in contraction experiments.  Moreover, treating the 
tissue with interleukin-13 would induce hyperresponsiveness to better imitate the airway 
smooth muscle conditions in asthma.  In addition, the role of airway epithelium in the 
smooth muscle’s response to fish oil should be addressed given the importance of the 
epithelium in airway reactivity (15, 48) and the endothelium-dependent findings for 
vascular smooth muscle treated with fish oil (101). 
 Additionally, some important issues stemming from these studies remain 
unresolved.  Determining the optimal formula for fish oil supplementation is essential at 
this juncture.  In order to better compare and build upon the data from different studies 
on omega-3 fatty acid supplementation, a standard fish oil formula will be needed.  With 
the negative results obtained for the DHA supplementation and HIB study, it may be 
prudent to begin with a similar study involving EPA supplementation.  Should EPA be 
effective in reducing HIB in subjects with asthma, it could be concluded that it is the 
more potent component of fish oil and the standardization of the optimal formula could 
proceed from there.  Moreover, experiments involving the metabolites of the omega-3 
fatty acids may be a prudent course of action.  Morin et al. (69) showed that an EPA 
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metabolite relaxed human bronchial smooth muscle tissue in vitro while Levy et al. (52) 
showed that a DHA metabolite reduced methacholine-induced bronchoconstriction in 
mice in vivo.  Other combinations of two or more nutritional supplements should also be 
investigated.  Biltagi et al. (17) demonstrated that a combination of fish oil, ascorbic acid, 
and zinc, which is a cofactor in prostaglandin synthesis, was more effective than any one 
supplement alone in treating children with moderately persistent asthma.  Finally, 
whether the benefits of nutrition are better achieved through supplementation or dietary 
modification is of interest.  Several articles have reviewed the existing literature on 
epidemiologic studies examining nutrient intake and respiratory health (25, 34, 56, 79); 
the results generally indicate that a healthy diet is related to better pulmonary function 
and symptoms.  Furthermore, it has been pointed out that it was the low rate of 
cardiovascular disease among populations who regularly consume fish that spurred the 
fish oil supplementation trend (71).  Although subsequent research has demonstrated 
the benefits of supplementation, it may be that dietary modification is more efficacious.      
Concluding Remarks 
 The central goal of these studies was to investigate the effects of omega-3 
polyunsaturated fatty acid-based nutritional strategies on hyperpnea-induced 
bronchoconstriction (HIB) in asthmatic individuals and on isolated canine airway smooth 
muscle’s responsiveness to contractile agonists.  Results from in vivo studies 
demonstrated that fish oil containing 3.2 g EPA and 2.0 g DHA improved post-eucapnic 
voluntary hyperventilation (EVH) pulmonary function although there was no further 
significant improvement from adding vitamin C to the regimen; however, subjects who 
were unresponsive to vitamin C supplementation may have obscured the potential 
additive effect of the combination treatment.  Supplementation with fish oil containing 4.0 
g DHA did not improve the post-EVH pulmonary function of asthmatics with HIB 
indicating that DHA is not the most effective element in fish oil.  In vitro experiments 
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demonstrated that lipid incorporation of omega-3 fatty acids may not be necessary for 
fish oil to affect airway smooth muscle responsiveness.  With acute exposure to fish oil, 
the airway smooth muscle tissue exhibited significant relaxation of agonist-induced 
contractions.  Overall, these studies have confirmed that fish oil represents a viable 
treatment modality for asthmatic individuals with HIB and suggest that fish oil may 
influence airway smooth muscle contractility. 
 184 
APPENDIX A 
INSTITUTIONAL REVIEW BOARD DOCUMENTS FOR CHAPTER 2 
 
  
 185 
 
 
 186 
 
  
 187 
 
 
 
 
 188 
 
 
 
 189 
 
 
 
 
 190 
 
 
 
 
 
 
 
 
 
 
 191 
IRB Study #0910000751 
 
INDIANA UNIVERSITY BLOOMINGTON 
 
INFORMED CONSENT STATEMENT 
 
Comparative Effects of Fish Oil and Ascorbic Acid Supplementation on Exercise-
Induced Bronchoconstriction and Airway Inflammation in Asthma  
 
You are invited to participate in a research study of the effect of dietary supplementation on 
asthma and exercise-induced bronchoconstriction (EIB).  You were selected as a possible subject 
because you identified yourself as having asthma.  We ask that you read this form and ask any 
questions you may have before agreeing to be in the study.  
 
The study is being conducted by Sally Head, an MD/PhD candidate in the Department of Cellular 
and Integrative Physiology at the Indiana University School of Medicine.  It is not funded by any 
agency and is being conducted under the supervision of Dr. Timothy Mickleborough in the 
Department of Kinesiology at Indiana University Bloomington. 
 
STUDY PURPOSE 
 
The purpose of this study is to determine the roles of two different dietary supplements in 
alleviating signs and symptoms of exercise-induced bronchconstriction (EIB).  Fish oil and 
ascorbic acid (vitamin C) have each been shown to have positive effects on lung function and 
inflammation related to EIB.  Our goal is to compare these nutritional interventions as well as to 
determine if the combination of supplements is better than either alone.   
 
NUMBER OF PEOPLE TAKING PART IN THE STUDY: 
 
If you agree to participate, you will be one of thirty subjects with EIB who will be participating in 
this research. 
 
PROCEDURES FOR THE STUDY: 
 
If you agree to be in the study, you will do the following things: 
 
You will be asked to volunteer a total of about 7 ½ hours of your time over 10-12 weeks, 
plus an additional 5 minutes per day throughout the study.  You will need to come to the 
laboratory a total of 4 times.  The first visit is simply a familiarization session lasting about 30 
min to introduce you to the study and allow you to ask questions.  If you decide to participate in 
the study, you will be given materials regarding the study and asked to complete some at-home 
logs and peak flow tests at home (about 5 min/day) prior to the supplementation part of the study.  
You will be given a log book to record your daily medication use and a diary to record your daily 
symptoms during the course of the study.  Each week throughout the study, the primary 
investigator will email you to check-in with you about your asthma symptoms, peak flows, and 
completing your at-home logs.   
The other 3 visits will require about 1 hour each and you will be asked to do some lung 
function tests and a simulated exercise test involving only heavy breathing.  You will be asked to 
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abstain from exercise for at least 24 hours before coming to the laboratory, not to drink 
caffeinated beverages 8 hours before the test, and not to take any inhaler medication in the 6 
hours preceding the laboratory test.  However, if you need to use your inhaler within the 6 hours 
prior to your scheduled test session, you should do so, and we will reschedule your session.   If 
you are on other medications for your asthma you will be asked to refrain from using them for 2-4 
weeks before the study with the permission of your doctor. You will be asked to limit your fish 
consumption to 1 fish meal per week throughout the course of the study.  You will also be asked 
to avoid vitamin C-rich foods during the course of the study.  You will be encouraged to drink 6-
8 glasses of water per day during the course of the study.  You will also receive 8 unannounced 
phone calls throughout the 10-12 week study to complete 24-hour dietary recall interviews, which 
will last about 30 minutes each.   
 
Familiarization Session & Study Entry Procedures:  
  For the familiarization session, you will meet with the primary investigator in the 
exercise physiology labs in HPER (room 076) for approximately 30 minutes.  The details of the 
study will be explained to you and you will have the opportunity to ask any questions that you 
may have.  You will be asked to complete a questionnaire which asks about medications you are 
taking and whether you have allergies to the supplements to be given in the study.  This 
questionnaire will take about 5 minutes to complete.  If you are currently taking medications for 
your asthma, you will be asked to stop taking them before you start the study.  Depending upon 
the type of medication you are taking, you will have to stop taking it 2-4 weeks before you start 
the study with permission from your doctor.  You will be given a form that needs to be completed 
by your doctor and brought back to your first lab testing session.  On this form, your physician 
will set limitations on your rescue inhaler use and peak flow measures such that if you exceed 
these values you will be removed from the study for your safety.  If you are not currently taking 
any asthma maintenance medications, you will not need to have a doctor fill out the permission 
form.  Dr. Greg Montgomery, a pulmonologist, will set the limitations on your rescue inhaler use 
and peak flow measures such that if you exceed these values you will be removed from the study 
for your safety.  If you are taking a corticosteroid inhaler such as Advair®, Flovent ®, 
Azmacort®, Pulmicort®, or Beclovent®, you will need to stop taking it for 4 weeks before the 
study and during the study.  If you are taking a leukotriene receptor antagonist or 5-lipoxygenase 
inhibitor such as Singulair®, Accolate®, Zyflo®, or Ultair®, you will be asked to stop taking it 
for 2 weeks before the study and during the study.  If you are taking theophylline, Theo-Dur®, 
Uni-Dur®, Bronkodyl® , Elixophyllin® , Slo-bid®, Slo-Phyllin® , Theo-24® , Theolair®, or  
Uniphyl®, you will be asked to stop taking it 1 week before the study and during the study.   You 
may use your rescue inhaler anytime during the course of the study.  You will be asked not to use 
it 6 hours before any testing session in the lab, but may use it if you need to.  If you do use your 
inhaler within 6 hours of a lab session, you will need to reschedule your test. If you do not drop in 
pulmonary function by at least 10%, you will not be eligible for the study. 
 You will be talked through the lab testing procedures for the simulated exercise test, lung 
function tests, exhaled nitric oxide tests, and exhaled breath condensate procedures, which will all 
occur on the three lab testing days. 
  You will also receive information on the tasks to be completed at home, including peak 
flow readings, recording rescue inhaler usage, recording daily symptoms, and dietary recall 
interviews.  You will receive a peak flow meter to take with you.  Instructions for its use will be 
provided to you and reviewed.  You will receive a log book to record your peak flow (the fastest 
speed a person can blow air out of their lungs), FEV1 (the amount of air blown out in the 
first second of a forced exhalation), and rescue inhaler use every day for the duration of 
the study.  You will also receive a daily symptom diary containing 4 questions about 
daytime symptoms and 1 question about nighttime symptoms that is to be completed 
every day throughout the study.  The 24-hour dietary recall interview procedure will be 
explained to you.  Between the familiarization session and first lab testing day, you will 
receive 2 unannounced phone calls from a professional trained to interview you about 
everything you have had to eat and drink over the previous 24-hour period.  These dietary 
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recall interviews will last about 30 minutes each.  
  You will not receive any supplements at this time.  If you qualify and choose to 
participate in the study, you will receive either active or placebo (inactive) ascorbic acid 
(vitamin C) and fish oil pills for two separate 3-week periods.  During the supplementation  
periods, you will take 2ascorbic acid pills (active or placebo) and 10 fish oil pills (active or 
placebo) per day.  
 
Lab Testing Sessions (approximately 1.5 hours each) 
      First Testing (following 2-4-week run-in period) 
  You will come to the lab in HPER 076.  You should not have exercised for 24 hours 
before arriving and should not have had any caffeine for 8 hours before arriving.  You will be 
asked to return your peak flow/rescue inhaler logs and daily symptom diaries from the run-in 
period (time between the familiarization session and first lab testing session) at this time.  You 
will have your height and weight measured.  You will perform an exhaled nitric oxide test that 
will measure the amount of nitric oxide in your exhaled breath, which indicates the presence of 
inflammation in the lungs.  This procedure requires that you inhale to a full lung and then exhale 
immediately while wearing a nose clip.  This will be followed by a pulmonary function test where 
you will have to wear a nose clip while you inhale and exhale maximally through a mouthpiece 
connected to a computerized instrument that measures lung volumes.  If your FEV1 (the amount 
of air blown out in the first second of a forced exhalation) is less than 60% of your predicted 
value, you will be excluded from the study.  Next, you will do the exhaled breath condensate 
procedure where you will have the breath that you breathe out collected.  You sill sit in a chair, 
wear a nose clip, and breathe through a mouthpiece for 10 minutes such that you are breathing in 
normal room air and the breath you breathe out will be collected in a tube on the other side of the 
mouthpiece.  Following these pre-tests, a simulated exercise test called eucapnic voluntary 
hyperventilation (EVH) will be performed.  For the EVH test, you will sit in a chair and breathe 
gases from a large bag through a mouthpiece while wearing a nose clip.  The bag is supplied with 
gas from a tank with air that has the same amount of oxygen as regular room air, but the air will 
be drier and will contain 5% carbon dioxide to help you breathe at the levels you need to breathe 
and to keep you from fainting.  You will be asked to breathe at a fast and deep rate like you 
would during exercise, but you will just be sitting in a chair.  You will breathe this air at the high 
rate for 6 minutes.  You may stop the test at any time if you become too uncomfortable.  You may 
use your inhaler if necessary, but this may mean that we would need to re-test you if you still 
wish to participate in the study.  This method is routinely used in laboratories for the diagnosis of 
exercise-induced asthma.   
 Immediately after the EVH test, you will do the exhaled breath condensate procedure for 
5 minutes.  A break will be taken for the 5 minute post-EVH pulmonary function test.  You will 
then return to do the final 5 minutes of the exhaled breath condensate procedure.  Additional 
pulmonary function tests will be performed at 10, 15, and 20 minutes post-EVH.  If your FEV1 
(the amount of air blown out in the first second of a forced exhalation) drops by more than 
10% of your pre-EVH value, you will qualify to continue in the study.  You will perform a post-
EVH exhaled nitric oxide test.   
If you qualify and choose to continue in the study, you will be given a set fish oil pills 
(active or placebo) and ascorbic acid pills (active or placebo), a new peak flow/rescue inhaler log 
book, and a new daily symptom diary.  You will be reminded of the instructions received during 
your familiarization session for taking the pills and filling out the peak flow/rescue inhaler log 
and daily symptom diary.  You will also be reminded that you will receive two phone calls for 
24-hour dietary recall interviews, lasting approximately 30 minutes each, during the 3-week 
supplementation period.      
 
      Second Testing (following 3-week supplementation period) 
  The procedures for the second lab testing session will be the same as at the first lab 
testing session.  You will be asked to return your peak flow/rescue inhaler logs and daily 
symptom diaries from the first supplementation period as well as any leftover pills at this time.  
 194 
You will have your weight measuredand perform pre- and post-EVH exhaled nitric oxide tests, 
EBC procedures, and pulmonary function tests as before.  You will be given the pills for the 
second supplementation period but instructed to wait 2 weeks before taking this set of pills.  The 
primary investigator will contact you by phone and/or email (whichever you prefer) to remind 
you when to begin taking the pills.  This set of pills will include fish oil pills (active or placebo) 
and ascorbic acid pills (active or placebo).  You will be given a new peak flow/rescue inhaler log 
book and a new daily symptom diary.  You will be reminded to fill out the peak flow/rescue 
inhaler log and daily symptom diary throughout the washout (2 weeks) and second 
supplementation period (3 weeks).  You will be informed that you will receive two phone calls 
for 24-hour dietary recall interviews during the 2-week washout period and two phone calls for 
24-hour dietary recall interviews during the 3-week supplementation period.  Each call will last 
approximately 30 minutes.  
 
      Third Testing (following a 2-week washout and a 3-week supplementation period) 
  The procedures for the third lab testing session will be the same as at the first and second 
lab testing sessions.  You will be asked to return your peak flow meter, peak flow/rescue inhaler 
logs, daily symptom diaries, and any leftover pills at this time.  You will have your weight 
measured and perform pre- and post-EVH exhaled nitric oxide tests, EBC procedures, and 
pulmonary function tests as before.   
 
RISKS OF TAKING PART IN THE STUDY: 
 
While on the study, the risks are: 
 
1. The exercise simulation test, EVH, may induce bronchospasm (rapid narrowing of the 
airways).   
2. Headache, transient light-headedness, or fainting may occur during the pulmonary 
function tests, nitric oxide procedure, or the exhaled breath procedure.  
3. Contamination or infection from mouthpieces is unlikely.  
4. There are no known risks of taking fish oil or ascorbic acid for subjects who are not 
allergic.   
 
To minimize the risks listed above, the following measures will be employed: 
 
1. Subjects who have severe and moderate asthma will be excluded from the study to 
avoid the greatest risk of bronchospasm.  These subjects will be identified at the first lab 
testing session (when they have been off their medication for 2-4 weeks depending on the 
type of medication) by a resting FEV1 (the amount of air blown out in the first 
second of a forced exhalation) less than 60% of their predicted value based on age, 
sex, height, and weight. 
2. All subjects will be required to bring their bronchodilators (rescue inhalers) with them 
to all testing sessions. 
3. If severe wheezing begins during EVH, the EVH test will be immediately stopped and 
the subject will be given their bronchodilator and oxygen if necessary. 
4.  The subject will be seated and carefully monitored during EVH, pulmonary function 
tests, the nitric oxide procedure, and the exhaled breath procedure. 
5. To avoid the risk of infection, disposable mouthpieces are used for most testing 
procedures, and when rubber mouthpieces are used, they are cleansed in a detergent 
solution and disinfected following each use.6. Subjects who are allergic to fish oil or 
ascorbic acid will be excluded from the study. 
7. Subjects will be instructed to report any adverse effects to the principal investigator. 
8. Subjects will be instructed to discontinue the study procedures and return to their 
medications if they reach the rescue inhaler usage and peak flow measurement limitations 
set by their own physicians or Dr. Montogomery.      
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BENEFITS OF TAKING PART IN THE STUDY: 
 
The benefits to participation that are reasonable to expect are a better understanding of how fish 
oil and ascorbic acid supplementation affect the signs and symptoms of exercise-induced 
bronchoconstriction.  Subjects will have access to all their own data regarding their own personal 
lung function and markers of inflammation, which they can share with their personal physician.   
 
ALTERNATIVES TO TAKING PART IN THE STUDY: 
 
An alternative to participating in the study is to choose not to participate. 
 
 
CONFIDENTIALITY 
 
Efforts will be made to keep your personal information confidential.  We cannot guarantee 
absolute confidentiality.  Your personal information may be disclosed if required by law.  Your 
identity will be held in confidence in reports in which the study may be published and in 
databases in which results may be stored.    
 
Organizations that may inspect and/or copy your research records for quality assurance and data 
analysis include groups such as the study investigator and his/her research associates, the IUB 
Institutional Review Board or its designees, the study sponsor, Dr. Timothy Mickleborough, and 
(as allowed by law) state or federal agencies, specifically the Office for Human Research 
Protections (OHRP) who may need to access your medical and/or research records. 
 
COSTS 
 
Taking part in this study will lead to no added costs to you.   
 
PAYMENT 
 
You will be paid $150 for taking part in this study.  You will not receive any compensation for 
the 30 minute familiarization session where you will learn about the study, receive study 
materials, and fill out the informed consent, health questionnaire, and asthma medication 
questionnaire.  You will receive $10 at the first actual testing session, $25 after the 2nd  testing 
session, and $115 after the last testing session.  You will be compensated for the completion of 
each session.  If you withdraw from the study, you will be compensated for the completed tests. 
 
COMPENSATION FOR INJURY 
 
In the event of physical injury resulting from your participation in this research, necessary 
medical treatment will be provided to you and billed as part of your medical expenses.  Costs not 
covered by your health care insurer will be your responsibility.  Also, it is your responsibility to 
determine the extent of your health care coverage.  There is no program in place for other 
monetary compensation for such injuries.  However, you are not giving up any legal rights or 
benefits to which you are otherwise entitled. 
 
CONTACTS FOR QUESTIONS OR PROBLEMS 
 
For questions about the study or a research-related injury, contact the researcher Sally Head at 
812-855-4632.   
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For questions about your rights as a research participant or to discuss problems, complaints or 
concerns about a research study, or to obtain information, or offer input, contact the IUB Human 
Subjects office, 530 E Kirkwood Ave, Carmichael Center, 203, Bloomington IN 47408, 812-856-
4242 or by email at iub_hsc@indiana.edu 
 
VOLUNTARY NATURE OF STUDY 
 
Taking part in this study is voluntary.  You may choose not to take part or may leave the study at 
any time.  Leaving the study will not result in any penalty or loss of benefits to which you are 
entitled.  Your decision whether or not to participate in this study will not affect your current or 
future relations with the investigator(s). 
 
SUBJECT’S CONSENT 
 
In consideration of all of the above, I give my consent to participate in this research study.   
 
I will be given a copy of this informed consent document to keep for my records.  I agree to take 
part in this study. 
 
Subject’s Printed Name:  
 
Subject’s Signature:_________________________________________Date:  
 (must be dated by the subject) 
 
Printed Name of Person Obtaining Consent:  
 
Signature of Person Obtaining Consent:________________________Date:  
 
Form date: December 2, 2010 
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Email for Response to Potential Subjects 
 
Thank you for your interest in our study.  I have a few initial questions that you can either 
respond to by email or by calling me at 812-855-4632.   
 
First, do you take any maintenance medications for asthma?  For this study you are required to 
stop taking certain medications with your doctor’s permission.  If you take a corticosteroid, such 
as advair or flovent for example, you need to be off of it for 4 weeks before starting the study.  If 
you take a leukotriene receptor antagonist, such as singulair or accolade for example, you need to 
be off it for 2 weeks before starting the study.  If you take theophylline, you need to be off it for 1 
week before starting the study.  You can still take your rescue inhaler.   
 
Second, do you have any other medical conditions such as heart disease, hypertension, or high 
cholesterol, or are you pregnant?  Everyone with any of these conditions will not be able to take 
part in our study. 
 
Third, do you currently take any nutritional supplements, including fish oil and vitamin C?  This 
study requires that you stop taking fish oil and vitamin C.  You would need to stop taking these 
supplements for 2 weeks before beginning the study until the study is over, for a total of 10-12 
weeks.  
 
Depending on your responses to these questions, you may meet the criteria to be a part of our 
study.  Here is a little more information about it.  We are doing a study to look at nutritional 
supplements for treating asthma, specifically fish oil and vitamin C.  You would take two sets of 
pills for two 3 week periods and be tested at the beginning of the study and after each of the 3 
weeks of pills. Some of the pills are placebo and you might be assigned to a group with a placebo. 
You will also do a simulated exercise test where you will breathe fast and deep like you would 
during exercise, but you will be seated in a chair.  You will also have some lung function tests 
done before and after each simulated exercise test.  You will also be asked to breathe into a tube 
for collection of your exhaled breath.  You will be asked to provide urine and blood samples.  
You also need to do peak flow measurements at home during the study. 
 
If you are still interested in participating, please let me know your response to the above 
questions.  If you have any questions, please contact me at skhead@indiana.edu or 812-855-4632. 
 
If you do meet the criteria for participation and are interested in participating, I will contact you 
about setting up an initial appointment for a half-hour familiarization session. 
 
Thank you, 
Sally Head 
MD/PhD Student 
Indiana University School of Medicine 
skhead@indiana.edu 
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Medication & Allergy Questionnaire 
 
 
1. What medications do you take on a daily basis for your asthma? 
 
 
 
 
2. What medications do you take just before exercise for your asthma? 
 
 
 
 
3.  How many times a week on average do you use your rescue inhaler? 
 
 
 
4. Do you take any of medications like the following (circle any that apply): 
Advair®, Flovent ®, Azmacort®, Pulmicort®, Beclovent® Singulair®, Accolate®, 
Zyflo®, Ultair®,  Theo-Dur®, Uni-Dur®, Bronkodyl® , Elixophyllin® , Slo-bid®, 
Slo-Phyllin® , Theo-24® , Theolair®, or  Uniphyl®   
 
 
 
5. Are you allergic to ascorbic acid (vitamin C)? 
 
 
 
6. Are you allergic to fish oil? 
 
 
 
7. Do you have any other allergies, including seasonal allergies? 
 
 
 
8. Have you ever been diagnosed as being atopic (hyperallergic)? 
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Subject #_______Week #_______ 
Peak Flow & Rescue Inhaler Log 
 
Record your best of 3 tries for peak flow and FEV1 both for morning and evening.  Also, 
record the number of puffs you took of your rescue inhaler. 
 
Date Peak Flow 
Morning 
Peak Flow 
Evening 
FEV1 
morning 
FEV1 
evening 
# of puffs from rescue inhaler 
(including pre-exercise) 
 
     
 
     
 
     
 
     
 
     
 
     
 
     
 
 
Subject #________Week #_______ 
Exercise Log 
 
Date Type of 
Exercise 
Duration Symptoms/ 
Comments 
# of puffs of 
rescue inhaler 
immediately 
before exercise 
# of puffs of 
rescue inhaler 
during or after 
exercise 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
      
 
 200 
Daily Symptom Diary 
Date:_______________ 
Daytime symptom diary scale questions 
1) How often did you experience asthma symptoms today? 
 0 1 2 3 4 5 6 
      None of               All of  
      the time               the time 
2) How much did your asthma symptoms bother you today? 
0 1 2 3 4 5 6 
      Not at all               Severely  
      bothered               bothered 
3) How much activity could you do today? 
 0 1 2 3 4 5 6 
      More than               Less than  
   usual activity            usual activity 
4) How often did your asthma affect your activities today? 
 0 1 2 3 4 5 6 
      None of               All of  
      the time               the time 
 
Nocturnal diary scale question 
1) Did you wake up with asthma symptoms (This can be awakening in the middle of the night or 
on awakening in the morning)? 
           No   Once  More than once  Awake “all night” 
 
 
 
 
 
Copyright ©1997, Merck and Co. Inc., Whitehouse Station, NJ, USA.   
Santanello NC, Barber BL, Reiss TF, Friedman BS, Juniper EF, and Zhang J. Measurement 
characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J 10: 646-
651, 1997. 
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Nutrition Coordinating Center (NCC) Standard Introduction Script for Dietary Recalls 
If you are conducting the 24-hour recall in person: 
A. “Hello, my name is __________.  Thank you for agreeing to participate in this study.  During 
this part of your visit, I will be collecting the 24-hour dietary recall, where you tell me everything 
you had to eat and drink during the past 24 hours.  Everything you tell me is confidential and this 
will take about 30 minutes, OK?” 
B. “What we’ll do first is make a list of the foods and beverages you had from 12 a.m. yesterday 
until 12 midnight last night.  This includes all meals snacks, beverages, including tap water (and 
alcoholic beverages), as well as sampling of foods.” 
C. If you are collecting supplements during the recall: 
“I’ll also ask you about any vitamin, mineral, or other supplements that you may have taken.” 
D. “I’ll ask you questions to help you remember what you ate yesterday, so the information about 
your diet can be used for (per study protocol, insert this important research project or study.)” 
E. “I’ll need you to tell me an approximate time you had each item.  For example, “At 8 a.m. I 
had this, at 10 a.m. I had that.”  We’ll make a general list at first and then we’ll go back and fill it 
in with more detail.  Finally, we’ll go through the list once more to make sure we haven’t missed 
anything.  We can use these (refer to amount estimation tools) to estimate the amount of what you 
ate yesterday.” 
“Do you have any questions before we begin?” 
F.  If the response is no, reply “OK”. 
“Take a moment to think about yesterday, what you did, where you went and so forth.  Thinking 
about the day can help you remember what you did yesterday and when you ate.” 
“Now let’s begin.” 
Refer to the Quick List window: “After midnight, what was the first time you had something to 
eat or drink?”  
If you are conducting the 24-hour recall by phone: 
A. “Hello!  My name is use your first name only and I am calling for (per study protocol, insert 
name of study or institution) to collect 24-hour dietary recalls.  Is this a good time to talk?” 
Hesitate and wait for a response. 
If the response is “no”, ask if you can call back later that day.  If they tell you that yesterday was 
an atypical day (e.g. they were ill), tell them that you will call back on another day.  If they sat, 
“Call tomorrow,” explain that you can’t make any appointments beyond today, as our calls need 
to be unannounced.  Thank them for their time and tell them we’ll try another day. 
If the response is “yes”, say: 
“Thank you for agreeing to participate in this study.  Before we begin, I’d like to explain that for 
the dietary recall, you’ll tell me everything you had to eat and drink during the past 24-hours.  
Everything you tell me is confidential and this will take about 30 minutes, OK?” 
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Continue with the introduction script starting with section B. 
 
The questions the interviewer will ask are in bold. 
After the introduction a quick list of foods eaten the previous day is compiled.  The list is 
assembled by asking the following questions: 
After midnight, what was the first time you had something to eat or drink? 
What did you have at that time? 
Did you have anything else at that time? 
These three questions are asked repeatedly, the first question then changes to “When was the next 
time you had something to eat or drink?” 
Once the quick list is compiled it is reviewed with the interviewer asking: 
At (time) you had (read all foods).  Can you think of anything else you had at that time? 
Did you have a beverage with that meal? (If a beverage is not listed.) 
Did you have any snacks between means or did you sample food as you prepared for the 
meal? 
Now we will fill in your list with more detail. 
At 6:30 am you had breakfast at home.  Is this correct? 
You said you had coffee, did you add anything to the coffee? (for example milk added) 
What type of coffee was it?  The computer goes to a food hierarchy to select from the type of 
coffee; made from ground, made from instant, unknown preparation, from vending machine, dry 
instant-unprepared. 
How much coffee did you drink? 
What brand or type of milk was it? The computer goes to a food hierarchy to select from the 
type of milk; whole, 2% fat or reduced fat, 1 ½%, 1% fat or lowfat, ½% fat, skim, nonfat, or fat 
free, unknown % fat, reconstituted from dry, unprepared dry powder, buttermilk. 
You also had a bagel for breakfast, what type of bagel was it? Again the computer goes 
through a food hierarchy to determine what kind of bagel was eaten. 
This process of asking questions is repeated for all foods the interviewee can recall. 
At the end of the interview, the interviewer will ask: 
Now we will review the record.  Tell me if I have missed anything. 
The interviewer will read through the list of foods and amounts. 
And concluded with: 
Please tell me if the amount of intake was: Usual, considerably more than usual, or 
considerably less than usual. 
Thank you for your time and help in our study. 
 
 
 203 
Study # 0910000751 
Do You Have Asthma? 
Indiana University Research Study 
 
Who: People who have asthma  
 
What:  This study is testing the effects of fish oil (omega-3 
fatty acid) supplementation and vitamin C (ascorbic acid) 
supplementation on asthma.  It will take place over 10-12 
weeks with 4 total lab visits.  The study requires: 
- one 30min familiarization visit to the lab 
- three  1 hour lab testing visits  
- eight 30min dietary recall phone interviews  
- daily at home peak flow measurements (2-5 min/day) 
for 10-12 weeks 
 
You may receive supplements. Participation will involve a 
simulated exercise test, lung function tests, and exhaled 
breath test. 
 
When:  Whenever your schedule permits 
 
Benefits:  You will receive all data and information on how 
fish oil and vitamin C supplementation can affect your 
asthma.  
 
Compensation: $150 
 
Who to contact if interested:  Sally Head 
      073 HPER 
      855-4632 
      skhead@indiana.edu 
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APPENDIX B 
INSTITUTIONAL REVIEW BOARD DOCUMENTS FOR CHAPTER 3 
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IRB Study #1005001346 
 
INDIANA UNIVERSITY BLOOMINGTON 
 
INFORMED CONSENT STATEMENT 
 
Docosahexaenoic Acid (DHA) as a Nutritional Treatment for Exercise-Induced 
Bronchoconstriction and Airway Inflammation in Asthma 
 
You are invited to participate in a research study of the effect of dietary supplementation on 
asthma and exercise-induced bronchoconstriction (EIB).  You were selected as a possible subject 
because you identified yourself as having asthma.  We ask that you read this form and ask any 
questions you may have before agreeing to be in the study.  
 
The study is being conducted by Sally Head, an MD/PhD candidate in the Department of Cellular 
and Integrative Physiology at the Indiana University School of Medicine.  It is funded by a grant 
received from the Department of Kinesiology’s AAU/Bell-Updyke-Willett Research Fund and is 
being conducted under the supervision of Dr. Timothy Mickleborough in the Department of 
Kinesiology at Indiana University Bloomington. 
 
STUDY PURPOSE 
 
The purpose of this study is to determine the role of a specific component of fish oil, 
docosahexanoic acid (DHA), in alleviating signs and symptoms of exercise-induced 
bronchoconstriction (EIB).  Fish oil has been shown to have positive effects on lung function and 
inflammation related to EIB; however, it is not known which component of fish oil is more 
potent.  Our goal is to determine if the supplementation with DHA is better than placebo.   
 
NUMBER OF PEOPLE TAKING PART IN THE STUDY: 
 
If you agree to participate, you will be one of thirty-two subjects with EIB who will be 
participating in this research. 
 
PROCEDURES FOR THE STUDY: 
 
If you agree to be in the study, you will do the following things: 
 
  You will be asked to volunteer a total of about 5 ½ hours of your time over 10-12 weeks, 
plus an additional 5 minutes per day throughout the study.  You will need to come to the 
laboratory a total of 4 times.  The first visit is simply a familiarization session lasting about 30 
min to introduce you to the study and allow you to ask questions.  If you decide to participate in 
the study, you will be given materials regarding the study and asked to complete some at-home 
logs and peak flow tests at home (about 5 min/day) prior to the supplementation part of the study.  
You will be given a log book to record your daily medication use and a diary to record your daily 
symptoms during the course of the study.  Each week throughout the study, the primary 
investigator will email you to check-in with you about your asthma symptoms, peak flows, and 
completing your at-home logs.  If you are currently taking asthma maintenance medication, you 
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will be asked to obtain your physician’s approval to stop for the duration of the study.  You will 
be given a form to give to your physician to sign.  This must be returned at the first lab testing 
session.  
  The other 3 visits will require about 1.5 hours each and you will be asked to do some 
lung function tests and a simulated exercise test involving only heavy breathing.  You will also be 
asked to fill out a food frequency questionnaire about your eating habits during the preceding 
phase of the study.  You will be asked to abstain from exercise for at least 24 hours before 
coming to the laboratory, not to drink caffeinated beverages 8 hours before the test, and not to 
take any inhaler medication in the 6 hours preceding the laboratory test.  However, if you need to 
use your inhaler within the 6 hours prior to your scheduled test session, you should do so, and we 
will reschedule your session.   If you are on other medications for your asthma you will be asked 
to refrain from using them for 2-4 weeks before the study with the permission of your doctor. 
You will be asked to limit your fish consumption to 1 fish meal per week throughout the course 
of the study.   
Familiarization Session & Study Entry Procedures:  
  For the familiarization session, you will meet with the primary investigator in the 
exercise physiology labs in HPER (room 076) for approximately 30 minutes.  The details of the 
study will be explained to you and you will have the opportunity to ask any questions that you 
may have.  You will be asked to complete a questionnaire which asks about medications you are 
taking and whether you have allergies to the supplements to be given in the study.  This 
questionnaire will take about 5 minutes to complete.  If you are currently taking medications for 
your asthma, you will be asked to stop taking them before you start the study.  Depending upon 
the type of medication you are taking, you will have to stop taking it 2-4 weeks before you start 
the study with permission from your doctor.  If you need to stop taking asthma medication, you 
will be given a form that needs to be completed by your doctor and brought back to your first lab 
testing session.  On this form, your physician will set limitations on your rescue inhaler use and 
peak flow measures such that if you exceed these values you will be removed from the study for 
your safety.  If you are not currently taking any asthma maintenance medications, you will not 
need to have a doctor fill out the permission form.  In this case, Dr. Greg Montgomery, a 
pulmonologist, will be sent information on your rescue inhaler use and peak flow measures.  He 
will use this information  to set the limitations on your rescue inhaler use and peak flow measures 
such that if you exceed these values you will be removed from the study for your safety.  If you 
are taking a corticosteroid inhaler such as Advair®, Flovent ®, Azmacort®, Pulmicort®, or 
Beclovent®, you will need to stop taking it for 4 weeks before the study and during the study.  If 
you are taking a leukotriene receptor antagonist or 5-lipoxygenase inhibitor such as Singulair®, 
Accolate®, Zyflo®, or Ultair®, you will be asked to stop taking it for 2 weeks before the study 
and during the study.  If you are taking theophylline, Theo-Dur®, Uni-Dur®, Bronkodyl® , 
Elixophyllin® , Slo-bid®, Slo-Phyllin® , Theo-24® , Theolair®, or  Uniphyl®, you will be asked 
to stop taking it 1 week before the study and during the study.   You may use your rescue inhaler 
anytime during the course of the study.  You will be asked not to use it 6 hours before any testing 
session in the lab, but may use it if you need to.  If you do use your inhaler within 6 hours of a lab 
session, you will need to reschedule your test. If you do not drop in pulmonary function by at 
least 10%, you will not be eligible for the study. 
 You will be talked through the lab testing procedures for the simulated exercise test, lung 
function tests, exhaled nitric oxide tests, exhaled breath condensate procedures, and food 
frequency questionnaire which will all occur on the three lab testing days. 
  You will also receive information on the tasks to be completed at home, including peak 
flow readings, recording rescue inhaler usage, recording daily symptoms, and dietary recall 
interviews.  You will receive a peak flow meter to take with you.  Instructions for its use will be 
provided to you and reviewed.  You will receive a log book to record your peak flow (the fastest 
speed a person can blow air out of their lungs), FEV1 (the amount of air blown out in the first 
second of a forced exhalation), and rescue inhaler use every day for the duration of the study.  
You will also receive a daily symptom diary containing 4 questions about daytime symptoms and 
1 question about nighttime symptoms that is to be completed every day throughout the study.  
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 You will not receive any supplements at this time.  If you qualify and choose to 
participate in the study, you will receive either active or placebo (inactive) DHA pills for two 
separate 3-week periods.  During the supplementation periods, you will take 8 active DHA pills 
or 8 placebo DHA pills per day. 
 
Lab Testing Sessions (approximately 1 hour each) 
      First Testing (following 2-4-week run-in period) 
  You will come to the lab in HPER 076.  You should not have exercised for 24 hours 
before arriving and should not have had any caffeine for 8 hours before arriving.  You will be 
asked to return your peak flow/rescue inhaler logs and daily symptom diaries from the run-in 
period (time between the familiarization session and first lab testing session) at this time.  You 
will have your height and weight measured.    You will perform an exhaled nitric oxide test that 
will measure the amount of nitric oxide in your exhaled breath, which indicates the presence of 
inflammation in the lungs.  This procedure requires that you inhale to a full lung and then exhale 
immediately while wearing a nose clip.  This will be followed by a pulmonary function test where 
you will have to wear a nose clip while you inhale and exhale maximally through a mouthpiece 
connected to a computerized instrument that measures lung volumes.  Next, you will do the 
exhaled breath condensate procedure where you will have the breath that you breathe out 
collected.  You sill sit in a chair, wear a nose clip, and breathe through a mouthpiece for 10 
minutes such that you are breathing in normal room air and the breath you breathe out will be 
collected in a tube on the other side of the mouthpiece.  Following these pre-tests, a simulated 
exercise test called eucapnic voluntary hyperventilation (EVH) will be performed.  For the EVH 
test, you will sit in a chair and breathe gases from a large bag through a mouthpiece while 
wearing a nose clip.  The bag is supplied with gas from a tank with air that has the same amount 
of oxygen as regular room air, but the air will be drier and will contain 5% carbon dioxide to help 
you breathe at the levels you need to breathe and to keep you from fainting.  You will be asked to 
breathe at a fast and deep rate like you would during exercise, but you will just be sitting in a 
chair.  You will breathe this air at the high rate for 6 minutes.  You may stop the test at any time 
if you become too uncomfortable.  You may use your inhaler if necessary, but this may mean that 
we would need to re-test you if you still wish to participate in the study.  This method is routinely 
used in laboratories for the diagnosis of exercise-induced asthma.   
 Immediately after the EVH test, you will do the exhaled breath condensate procedure for 
5 minutes.  A break will be taken for the 5 minute post-EVH pulmonary function test.  You will 
then return to do the final 5 minutes of the exhaled breath condensate procedure.  Additional 
pulmonary function tests will be performed at 10, 15, and 20 minutes post-EVH.  If your FEV1 
(the amount of air blown out in the first second of a forced exhalation) drops by more than 10% 
of your pre-EVH value, you will qualify to continue in the study.  However, if your FEV1 
decreases by more than 50% of your pre-EVH value, you will be excluded from the study.  You 
will perform a post-EVH exhaled nitric oxide test.  You will be asked to fill out a food frequency 
questionnaire about the food and beverages you consumed during the run-in phase.     
  If you qualify and choose to continue in the study, you will be given a set of active or 
placebo DHA pills, a new peak flow/rescue inhaler log book, and a new daily symptom diary.  
You will be reminded of the instructions received during your familiarization session for taking 
the pills and filling out the peak flow/rescue inhaler log and daily symptom diary.   
 
      Second Testing (following 3-week supplementation period) 
  The procedures for the second lab testing session will be the same as at the first lab 
testing session.  You will be asked to return your peak flow/rescue inhaler logs and daily 
symptom diaries from the first supplementation period as well as any leftover pills at this time.  
You will have your weight measured and perform pre- and post-EVH exhaled nitric oxide tests, 
EBC procedures, and pulmonary function tests as before.  You will be asked to fill out a food 
frequency questionnaire about the food and beverages you consumed during the first 
supplementation phase.    You will be given the pills for the second supplementation period but 
instructed to wait 2 weeks before taking this set of pills.  You will also be given a food frequency 
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questionnaire to take home and fill out about the food and beverages you consumed during the 
washout phase.  The primary investigator will contact you by phone and/or email (whichever you 
prefer) to remind you when to begin taking the pills and to fill out the food frequency 
questionnaire (this will take approximately 30 minutes).  This set of pills will include either active 
or placebo DHA.  You will be given a new peak flow/rescue inhaler log book and a new daily 
symptom diary.  You will be reminded to fill out the peak flow/rescue inhaler log and daily 
symptom diary throughout the washout (2 weeks) and second supplementation period (3 weeks).    
 
      Third Testing (following a 2-week washout and a 3-week supplementation period) 
  The procedures for the third lab testing session will be the same as at the first and second 
lab testing sessions.  You will be asked to return your peak flow meter, peak flow/rescue inhaler 
logs, daily symptom diaries, and any leftover pills at this time.  You will have your weight 
measured and perform pre- and post-EVH exhaled nitric oxide tests, EBC procedures, and 
pulmonary function tests as before.  You will be asked to fill out a food frequency questionnaire 
about the food and beverages you consumed during the second supplementation phase.     
 
RISKS OF TAKING PART IN THE STUDY: 
 
While on the study, the risks are: 
 
1. The exercise simulation test, EVH, may induce bronchospasm (rapid narrowing of the 
airways).   
2. Headache, transient light-headedness, or fainting may occur during the pulmonary 
function tests, nitric oxide procedure, or the exhaled breath procedure.  
3. Contamination or infection from mouthpieces is unlikely.  
4. There are no known risks of taking fish oil for subjects who are not allergic.   
 
To minimize the risks listed above, the following measures will be employed: 
 
1. Subjects who have severe asthma will be excluded from the study to avoid the greatest 
risk of bronchospasm.  These subjects will be identified at the first lab testing session (if 
they had been taking medication, they will have been off it for 2-4 weeks depending on 
the type of medication).  Subjects whose FEV1 (the amount of air blown out in the first 
second of a forced exhalation) drops by more than 50% of their pre-EVH value will be 
excluded from the study because this is indicative of severe asthma. 
2. All subjects will be required to bring their bronchodilators (rescue inhalers) with them 
to all testing sessions. 
3. If severe wheezing begins during EVH, the EVH test will be immediately stopped and 
the subject will be given their bronchodilator and oxygen if necessary. 
4.  The subject will be seated and carefully monitored during EVH, pulmonary function 
tests, the nitric oxide procedure, and the exhaled breath procedure. 
5. To avoid the risk of infection, disposable mouthpieces are used for most testing 
procedures, and when rubber mouthpieces are used, they are cleansed in a detergent 
solution and disinfected following each use. 
6. Subjects who are allergic to fish oil will be excluded from the study. 
7. Subjects will be instructed to report any adverse effects to the principal investigator. 
8. Subjects will be instructed to discontinue the study procedures and return to their 
medications if they reach the rescue inhaler usage and peak flow measurement limitations 
set by their own physicians or Dr. Montogomery.   
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BENEFITS OF TAKING PART IN THE STUDY: 
 
The benefits to participation that are reasonable to expect are a better understanding of how DHA 
supplementation affects the signs and symptoms of exercise-induced bronchoconstriction.  
Subjects will have access to all their own data regarding their own personal lung function and 
markers of inflammation, which they can share with their personal physician.   
 
ALTERNATIVES TO TAKING PART IN THE STUDY: 
 
An alternative to participating in the study is to choose not to participate. 
 
CONFIDENTIALITY 
 
Efforts will be made to keep your personal information confidential.  We cannot guarantee 
absolute confidentiality.  Your personal information may be disclosed if required by law.  Your 
identity will be held in confidence in reports in which the study may be published and in 
databases in which results may be stored.    
 
Organizations that may inspect and/or copy your research records for quality assurance and data 
analysis include groups such as the study investigator and his/her research associates, the IUB 
Institutional Review Board or its designees, the study sponsor, Dr. Timothy Mickleborough, and 
(as allowed by law) state or federal agencies, specifically the Office for Human Research 
Protections (OHRP) who may need to access your medical and/or research records. 
 
COSTS 
 
Taking part in this study will lead to no added costs to you. 
 
PAYMENT 
 
You will be paid $150 for taking part in this study.  You will not receive any compensation for 
the 30 minute familiarization session where you will learn about the study, receive study 
materials, and fill out the informed consent, health questionnaire, and asthma medication 
questionnaire.  You will receive $10 after the first actual testing session, $25 after the 2nd testing 
session, and $115 after the last testing session.  You will be compensated for the completion of 
each session.  If you withdraw from the study, you will be compensated for the completed tests. 
 
COMPENSATION FOR INJURY  
 
In the event of physical injury resulting from your participation in this research, necessary 
medical treatment will be provided to you and billed as part of your medical expenses.  Costs not 
covered by your health care insurer will be your responsibility.  Also, it is your responsibility to 
determine the extent of your health care coverage.  There is no program in place for other 
monetary compensation for such injuries.  However, you are not giving up any legal rights or 
benefits to which you are otherwise entitled. 
 
CONTACTS FOR QUESTIONS OR PROBLEMS 
 
For questions about the study or a research-related injury, contact the researcher Sally Head at 
812-855-4632.   
 
For questions about your rights as a research participant or to discuss problems, complaints or 
concerns about a research study, or to obtain information, or offer input, contact the IUB Human 
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Subjects office, 530 E Kirkwood Ave, Carmichael Center, 203, Bloomington IN 47408, 812-855-
3067 or by email at iub_hsc@indiana.edu 
 
VOLUNTARY NATURE OF STUDY 
 
Taking part in this study is voluntary.  You may choose not to take part or may leave the study at 
any time.  Leaving the study will not result in any penalty or loss of benefits to which you are 
entitled.  Your decision whether or not to participate in this study will not affect your current or 
future relations with the investigator(s). 
 
 
SUBJECT’S CONSENT 
 
In consideration of all of the above, I give my consent to participate in this research study.   
 
I will be given a copy of this informed consent document to keep for my records.  I agree to take 
part in this study. 
 
 
Subject’s Printed Name:  
 
Subject’s Signature:_____________________________________Date:  
             
(must be dated by the subject) 
 
Printed Name of Person Obtaining Consent:  
 
Signature of Person Obtaining Consent:____________________Date:  
 
Form date: December 2, 2010 
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Email for Response to Potential Subjects 
 
Thank you for your interest in our study.  I have a few initial questions that you can either 
respond to by email or by calling me at 812-855-4632.   
 
First, are you between 18-40 years old?  This is the age range we are testing for this study. 
 
Second, do you take any maintenance medications for asthma?  For this study you are required to 
stop taking certain medications with your doctor’s permission.  If you take a corticosteroid, such 
as advair or flovent for example, you need to be off of it for 4 weeks before starting the study.  If 
you take a leukotriene receptor antagonist, such as singulair or accolade for example, you need to 
be off it for 2 weeks before starting the study.  If you take theophylline, you need to be off it for 1 
week before starting the study.  You can still take your rescue inhaler.   
 
Third, do you have any other medical conditions such as heart disease, hypertension, or high 
cholesterol, or are you pregnant?  Everyone with any of these conditions will not be able to take 
part in our study. 
 
Fourth, do you currently take any nutritional supplements, including fish oil?  This study requires 
that you stop taking fish oil.  You would need to stop taking these supplements for 2 weeks 
before beginning the study until the study is over, for a total of 10-12 weeks.  
 
Depending on your responses to these questions, you may meet the criteria to be a part of our 
study.  Here is a little more information about it.  We are doing a study to look at nutritional 
supplements for treating asthma, specifically a component of fish oil called docosahexaenoic acid 
or DHA for short.  You would take 8 pills per day for two 3 week periods and be tested at the 
beginning of the study and after each of the 3 weeks of pills. Some of the pills are placebo and 
you might be assigned to a group with a placebo. You will also do a simulated exercise test where 
you will breathe fast and deep like you would during exercise, but you will be seated in a chair.  
You will also have some lung function tests done before and after each simulated exercise test.  
You will also be asked to breathe into a tube for collection of your exhaled breath.  You will be 
asked to complete a food frequency questionnaire at each test to assess the nutrients in your diet.  
You also need to do peak flow measurements at home during the study. 
 
If you are still interested in participating, please let me know your response to the above 
questions.  If you have any questions, please contact me at skhead@indiana.edu or 812-855-4632. 
 
If you do meet the criteria for participation and are interested in participating, I will contact you 
about setting up an initial appointment for a half-hour familiarization session. 
 
Thank you, 
Sally Head  
MD/PhD Student 
Indiana University School of Medicine 
skhead@indiana.edu 
 
 
 
 
 213 
Medication & Allergy Questionnaire 
 
 
1. What medications do you take on a daily basis for your asthma? 
 
 
 
 
2. What medications do you take just before exercise for your asthma? 
 
 
 
 
3. How many times a week on average do you use your rescue inhaler? 
 
 
 
4. Do you take any of medications like the following (circle any that apply): Advair®, 
Flovent ®, Azmacort®, Pulmicort®, Beclovent® Singulair®, Accolate®, Zyflo®, Ultair®,  
Theo-Dur®, Uni-Dur®, Bronkodyl® , Elixophyllin® , Slo-bid®, Slo-Phyllin® , Theo-24® , 
Theolair®, or  Uniphyl®   
 
 
 
5. Are you allergic to fish oil? 
 
 
 
6. Are you allergic to corn or soy products? 
 
 
 
7. Do you have any other allergies, including seasonal allergies? 
 
 
 
8. Have you ever been diagnosed as being atopic (hyperallergic)? 
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Subject #_______Week #_______ 
Peak Flow & Rescue Inhaler Log 
 
Record your best of 3 tries for peak flow and FEV1 both for morning and evening.  Also, 
record the number of puffs you took of your rescue inhaler. 
 
Date Peak Flow 
Morning 
Peak Flow 
Evening 
FEV1 
morning 
FEV1 
evening 
# of puffs from rescue inhaler 
(including pre-exercise) 
 
     
 
     
 
     
 
     
 
     
 
     
 
     
 
 
Subject #________Week #_______ 
Exercise Log 
 
Date Type of 
Exercise 
Duration Symptoms/ 
Comments 
# of puffs of 
rescue inhaler 
immediately 
before exercise 
# of puffs of 
rescue inhaler 
during or after 
exercise 
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Daily Symptom Diary 
Date:_______________ 
Daytime symptom diary scale questions 
1) How often did you experience asthma symptoms today? 
 0 1 2 3 4 5 6 
      None of               All of  
      the time               the time 
2) How much did your asthma symptoms bother you today? 
0 1 2 3 4 5 6 
      Not at all               Severely  
      bothered               bothered 
3) How much activity could you do today? 
 0 1 2 3 4 5 6 
      More than               Less than  
   usual activity            usual activity 
4) How often did your asthma affect your activities today? 
 0 1 2 3 4 5 6 
      None of               All of  
      the time               the time 
 
Nocturnal diary scale question 
1) Did you wake up with asthma symptoms (This can be awakening in the middle of the night or 
on awakening in the morning)? 
           No   Once  More than once  Awake “all night” 
 
 
 
 
Copyright ©1997, Merck and Co. Inc., Whitehouse Station, NJ, USA.   
Santanello NC, Barber BL, Reiss TF, Friedman BS, Juniper EF, and Zhang J. Measurement 
characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J 10: 646-
651, 1997. 
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Study #1005001346 
EXERCISE-INDUCED ASTHMA 
 
Indiana University Research Study 
 
Who: People with asthma or exercise-induced asthma between 18-40 
years old 
 
What:  This study is testing the effects of a specific component of fish 
oil called docosahaexanoic acid (DHA, an omega-3 fatty acid) on 
asthma.  It will take place over 10-12 weeks with 4 total lab visits.  
The study requires: 
 
- one 30 min familiarization visit to the lab 
- three 1.5 hour lab testing visits  
- daily at home peak flow measurements (2-5 min/day) for 10-
12 weeks 
 
You may receive supplements. Participation will involve a simulated 
exercise test, lung function tests, exhaled breath test, and a 
questionnaire about what you eat.  You will need your physician’s 
approval to stop taking asthma maintenance medication (rescue 
inhaler use is permitted during the study).  
 
When:  Whenever your schedule permits 
 
Benefits:  You will receive all data and information on how DHA 
supplementation can affect your asthma.  
 
Compensation: $150 
 
Who to contact if interested:   Sally Head 
      073 HPER 
      855-4632 
      skhead@indiana.edu 
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APPENDIX C 
RAW DATA FOR CHAPTER 2 
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Maximum Drop in FEV1 (L) 
Subject Pre-Supplementation Fish Oil Fish Oil + Vitamin C 
1 -1.13 -0.57 -0.61 
4 -0.86 -0.54 -0.84 
8 -0.76 -0.56 -0.60 
9 -0.36 -0.30 -0.12 
13 -0.68 -0.21 -0.07 
18 -0.55 -0.15 -0.31 
19 -0.28 -0.40 -0.93 
Mean -0.66 -0.39 -0.50 
Standard Deviation 0.29 0.17 0.34 
Standard Error 0.11 0.07 0.13 
 
Subject Pre-Supplementation Vitamin C Fish Oil + Vitamin C 
2 -1.78 -2.28 -0.47 
3 -0.89 -0.98 -0.56 
7 -1.16 -1.34 -0.54 
10 -0.32 -0.23 -0.24 
14 -0.41 -0.14 -0.13 
17 -0.88 0.08 0.04 
20 -0.73 -0.43 -0.45 
Mean -0.88 -0.76 -0.34 
Standard Deviation 0.49 0.83 0.23 
Standard Error 0.19 0.32 0.09 
 
Subject Pre-Supplementation Fish Oil + Vitamin C 
1 -1.13 -0.61 
4 -0.86 -0.84 
8 -0.76 -0.60 
9 -0.36 -0.12 
13 -0.68 -0.07 
18 -0.55 -0.31 
19 -0.28 -0.93 
2 -1.78 -0.47 
3 -0.89 -0.56 
7 -1.16 -0.54 
10 -0.32 -0.24 
14 -0.41 -0.13 
17 -0.88 0.04 
20 -0.73 -0.45 
Mean -0.77 -0.42 
Standard Deviation 0.41 0.29 
Standard Error 0.11 0.08 
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Maximum Drop in FEV1 (%) 
Subject Pre-Supplementation Fish Oil Fish Oil + Vitamin C 
1 -20.14 -11.45 -11.07 
4 -23.89 -15.47 -24.35 
8 -17.39 -13.15 -13.61 
9 -11.84 -10.83 -3.86 
13 -18.99 -5.56 -1.92 
18 -11.51 -3.20 -6.35 
19 -10.77 -15.94 -37.35 
Mean -16.36 -10.80 -14.07 
Standard Deviation 5.07 4.82 12.70 
Standard Error 1.92 1.82 4.80 
 
Subject Pre-Supplementation Vitamin C Fish Oil + Vitamin C 
2 -46.35 -52.90 -10.02 
3 -24.12 -26.06 -15.64 
7 -23.72 -25.48 -10.65 
10 -10.16 -7.21 -8.51 
14 -12.02 -3.99 -3.76 
17 -26.99 2.17 1.08 
20 -20.98 -12.76 -12.97 
Mean -23.48 -18.03 -8.64 
Standard Deviation 11.91 18.65 5.66 
Standard Error 4.50 7.05 2.14 
 
Subject Pre-Supplementation Fish Oil + Vitamin C 
1 -20.14 -11.07 
4 -23.89 -24.35 
8 -17.39 -13.61 
9 -11.84 -3.86 
13 -18.99 -1.92 
18 -11.51 -6.35 
19 -10.77 -37.35 
2 -46.35 -10.02 
3 -24.12 -15.64 
7 -23.72 -10.65 
10 -10.16 -8.51 
14 -12.02 -3.76 
17 -26.99 1.08 
20 -20.98 -12.97 
Mean -19.92 -11.36 
Standard Deviation 9.54 9.86 
Standard Error 2.55 2.63 
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Maximum Drop in FVC (L) 
Subject Pre-Supplementation Fish Oil Fish Oil + Vitamin C 
1 -0.77 -0.41 -0.44 
4 -0.30 -0.14 -0.33 
8 -0.64 -0.29 -0.27 
9 -0.15 -0.09 -0.18 
13 -0.76 -0.35 0.00 
18 -0.54 -0.13 -0.28 
19 -0.08 -0.17 -0.27 
Mean -0.46 -0.23 -0.25 
Standard Deviation 0.29 0.12 0.14 
Standard Error 0.11 0.05 0.05 
 
Subject Pre-Supplementation Vitamin C Fish Oil + Vitamin C 
2 -1.62 -1.99 -0.28 
3 -0.54 -0.43 -0.32 
7 -1.01 -0.98 -0.46 
10 -0.27 -0.10 -0.09 
14 -0.34 -0.02 -0.01 
17 -0.15 -0.29 0.16 
20 -0.47 -0.13 -0.24 
Mean -0.63 -0.56 -0.18 
Standard Deviation 0.52 0.71 0.21 
Standard Error 0.20 0.27 0.08 
 
Subject Pre-Supplementation Fish Oil + Vitamin C 
1 -0.77 -0.44 
4 -0.30 -0.33 
8 -0.64 -0.27 
9 -0.15 -0.18 
13 -0.76 0.00 
18 -0.54 -0.28 
19 -0.08 -0.27 
2 -1.62 -0.28 
3 -0.54 -0.32 
7 -1.01 -0.46 
10 -0.27 -0.09 
14 -0.34 -0.01 
17 -0.15 0.16 
20 -0.47 -0.24 
Mean -0.55 -0.22 
Standard Deviation 0.41 0.17 
Standard Error 0.11 0.05 
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Maximum Drop in FVC (%) 
Subject Pre-Supplementation Fish Oil Fish Oil + Vitamin C 
1 -11.16 -6.65 -6.38 
4 -5.75 -2.80 -6.65 
8 -10.79 -4.87 -4.52 
9 -3.79 -2.36 -4.63 
13 -18.72 -8.22 0.00 
18 -8.53 -2.05 -4.42 
19 -1.76 -4.97 -7.96 
Mean -8.64 -4.56 -4.94 
Standard Deviation 5.65 2.32 2.55 
Standard Error 2.14 0.88 0.96 
 
Subject Pre-Supplementation Vitamin C Fish Oil + Vitamin C 
2 -27.69 -34.37 -4.83 
3 -10.31 -8.14 -6.07 
7 -14.49 -13.94 -6.50 
10 -7.18 -2.61 -2.43 
14 -8.08 -0.47 -0.24 
17 -3.77 -6.49 3.86 
20 -12.95 -3.83 -6.84 
Mean -12.07 -9.98 -3.29 
Standard Deviation 7.77 11.61 3.96 
Standard Error 2.94 4.39 1.50 
 
Subject Pre-Supplementation Fish Oil + Vitamin C 
1 -11.16 -6.38 
4 -5.75 -6.65 
8 -10.79 -4.52 
9 -3.79 -4.63 
13 -18.72 0.00 
18 -8.53 -4.42 
19 -1.76 -7.96 
2 -27.69 -4.83 
3 -10.31 -6.07 
7 -14.49 -6.50 
10 -7.18 -2.43 
14 -8.08 -0.24 
17 -3.77 3.86 
20 -12.95 -6.84 
Mean -10.35 -4.11 
Standard Deviation 6.77 3.31 
Standard Error 1.81 0.89 
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Maximum Drop in FEF25-75% (L/s) 
Subject Pre-Supplementation Fish Oil Fish Oil + Vitamin C 
1 -2.07 -0.97 -1.04 
4 -0.89 -0.86 -0.62 
8 -0.83 -0.75 -0.96 
9 -0.77 -0.47 -0.27 
13 -1.19 -0.27 -0.38 
18 -0.64 -0.17 -0.49 
19 -0.60 -0.44 -1.33 
Mean -1.00 -0.56 -0.73 
Standard Deviation 0.51 0.30 0.39 
Standard Error 0.19 0.11 0.15 
 
Subject Pre-Supplementation Vitamin C Fish Oil + Vitamin C 
2 -1.70 -2.61 -1.27 
3 -0.98 -1.33 -0.73 
7 -1.32 -1.67 -0.58 
10 -0.66 -0.70 -0.45 
14 -0.75 -0.70 -0.41 
17 -1.56 0.47 -0.17 
20 -2.08 -2.07 -1.34 
Mean -1.29 -1.23 -0.71 
Standard Deviation 0.52 1.02 0.44 
Standard Error 0.20 0.39 0.17 
 
Subject Pre-Supplementation Fish Oil + Vitamin C 
1 -2.07 -1.04 
4 -0.89 -0.62 
8 -0.83 -0.96 
9 -0.77 -0.27 
13 -1.19 -0.38 
18 -0.64 -0.49 
19 -0.60 -1.33 
2 -1.70 -1.27 
3 -0.98 -0.73 
7 -1.32 -0.58 
10 -0.66 -0.45 
14 -0.75 -0.41 
17 -1.56 -0.17 
20 -2.08 -1.34 
Mean -1.15 -0.72 
Standard Deviation 0.52 0.40 
Standard Error 0.14 0.11 
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Maximum Drop in FEF25-75% (%) 
Subject Pre-Supplementation Fish Oil Fish Oil + Vitamin C 
1 -38.33 -20.73 -20.76 
4 -35.74 -33.33 -25.41 
8 -24.13 -23.58 -27.75 
9 -29.39 -22.27 -12.56 
13 -26.50 -6.03 -8.52 
18 -15.88 -4.64 -11.53 
19 -26.55 -23.53 -64.88 
Mean -28.08 -19.16 -24.49 
Standard Deviation 7.47 10.29 19.24 
Standard Error 2.82 3.89 7.27 
 
Subject Pre-Supplementation Vitamin C Fish Oil + Vitamin C 
2 -63.91 -74.79 -26.40 
3 -37.84 -48.19 -30.42 
7 -36.46 -39.29 -15.14 
10 -18.80 -20.59 -13.39 
14 -21.80 -18.67 -11.85 
17 -53.42 13.35 -4.04 
20 -42.71 -40.91 -27.92 
Mean -39.28 -32.73 -18.45 
Standard Deviation 16.09 27.65 9.86 
Standard Error 6.08 10.45 3.73 
 
Subject Pre-Supplementation Fish Oil + Vitamin C 
1 -38.33 -20.76 
4 -35.74 -25.41 
8 -24.13 -27.75 
9 -29.39 -12.56 
13 -26.50 -8.52 
18 -15.88 -11.53 
19 -26.55 -64.88 
2 -63.91 -26.40 
3 -37.84 -30.42 
7 -36.46 -15.14 
10 -18.80 -13.39 
14 -21.80 -11.85 
17 -53.42 -4.04 
20 -42.71 -27.92 
Mean -33.68 -21.47 
Standard Deviation 13.38 15.02 
Standard Error 3.58 4.01 
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Pre-EVH FENO (ppb) 
Subject Pre-Supplementation Fish Oil Fish Oil + Vitamin C 
1 18.8 22.1 21.2 
4 63.0 68.8 35.3 
8 31.6 67.9 39.1 
9 27.7 33.8 32.1 
13 17.1 13.1 13.9 
18 42.6 42.6 44.3 
19 110.1 114.0 166.3 
Mean 44.4 51.8 50.3 
Standard Deviation 32.9 34.7 52.2 
Standard Error 12.4 13.1 19.7 
 
Subject Pre-Supplementation Vitamin C Fish Oil + Vitamin C 
2 67.0 61.6 59.0 
3 82.6 78.8 99.3 
7 47.7 50.2 34.5 
10 42.5 34.6 41.2 
14 21.0 22.7 23.2 
17 353.3 311.3 169.0 
20 13.6 19.7 36.2 
Mean 89.7 82.7 66.1 
Standard Deviation 118.7 103.0 51.8 
Standard Error 44.9 38.9 19.6 
 
Subject Pre-Supplementation Fish Oil + Vitamin C 
1 18.8 21.2 
4 63.0 35.3 
8 31.6 39.1 
9 27.7 32.1 
13 17.1 13.9 
18 42.6 44.3 
19 110.1 166.3 
2 67.0 59.0 
3 82.6 99.3 
7 47.7 34.5 
10 42.5 41.2 
14 21.0 23.2 
17 353.3 169.0 
20 13.6 36.2 
Mean 67.0 58.2 
Standard Deviation 86.9 50.6 
Standard Error 23.2 13.5 
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Post-EVH FENO (ppb) 
Subject Pre-Supplementation Fish Oil Fish Oil + Vitamin C 
1 13.9 18.4 16.8 
4 66.5 61.5 33.6 
8 27.2 44.1 30.2 
9 36.4 39.4 34.9 
13 10.9 9.2 10.0 
18 42.0 44.1 41.3 
19 87.8 89.6 124.7 
Mean 40.7 43.8 41.6 
Standard Deviation 28.0 26.7 38.2 
Standard Error 10.6 10.1 14.4 
 
Subject Pre-Supplementation Vitamin C Fish Oil + Vitamin C 
2 45.2 43.8 58.7 
3 75.2 62.1 73.9 
7 34.3 33.9 28.2 
10 37.3 28.1 33.9 
14 17.1 16.0 13.8 
17 221.8 305.7 152.0 
20 30.1 18.4 22.9 
Mean 65.8 72.6 54.8 
Standard Deviation 71.1 104.0 47.7 
Standard Error 26.9 39.3 18.0 
 
Subject Pre-Supplementation Fish Oil + Vitamin C 
1 13.9 16.8 
4 66.5 33.6 
8 27.2 30.2 
9 36.4 34.9 
13 10.9 10.0 
18 42.0 41.3 
19 87.8 124.7 
2 45.2 58.7 
3 75.2 73.9 
7 34.3 28.2 
10 37.3 33.9 
14 17.1 13.8 
17 221.8 152.0 
20 30.1 22.9 
Mean 53.3 48.2 
Standard Deviation 53.5 42.1 
Standard Error 14.3 11.2 
 
 237 
Pre-EVH Exhaled Breathe Condensate pH 
Subject Pre-Supplementation Fish Oil Fish Oil + Vitamin C 
1 7.10 7.52 7.24 
4 6.39 6.98 6.63 
8 6.88 7.24 6.41 
9 7.41 7.30 7.01 
13 7.03 6.70 6.68 
18 6.74 7.20 6.82 
19 6.87 7.30 7.15 
Mean 6.92 7.18 6.85 
Standard Deviation 0.32 0.26 0.30 
Standard Error 0.12 0.10 0.11 
 
Subject Pre-Supplementation Vitamin C Fish Oil + Vitamin C 
2 - 7.13 6.96 
3 7.12 7.13 7.07 
7 7.16 6.96 7.21 
10 7.04 6.92 6.79 
14 7.21 6.84 6.89 
17 6.54 7.11 6.53 
20 7.23 6.50 6.91 
Mean 7.05 6.94 6.91 
Standard Deviation 0.26 0.23 0.21 
Standard Error 0.11 0.09 0.08 
 
Subject Pre-Supplementation Fish Oil + Vitamin C 
1 7.10 7.24 
4 6.39 6.63 
8 6.88 6.41 
9 7.41 7.01 
13 7.03 6.68 
18 6.74 6.82 
19 6.87 7.15 
2 - 6.96 
3 7.12 7.07 
7 7.16 7.21 
10 7.04 6.79 
14 7.21 6.89 
17 6.54 6.53 
20 7.23 6.91 
Mean 6.98 6.88 
Standard Deviation 0.29 0.25 
Standard Error 0.08 0.07 
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Post-EVH Exhaled Breathe Condensate pH 
Subject Pre-Supplementation Fish Oil Fish Oil + Vitamin C 
1 6.78 7.50 7.28 
4 6.59 6.93 6.33 
8 7.14 7.08 6.02 
9 6.99 7.04 6.51 
13 6.81 7.40 6.92 
18 6.97 7.24 6.63 
19 6.68 7.32 7.05 
Mean 6.85 7.22 6.68 
Standard Deviation 0.19 0.21 0.44 
Standard Error 0.07 0.08 0.17 
 
Subject Pre-Supplementation Vitamin C Fish Oil + Vitamin C 
2 7.34 7.24 6.98 
3 7.37 7.16 7.25 
7 7.23 7.01 7.54 
10 6.83 6.89 6.95 
14 6.76 6.79 6.89 
17 6.79 7.47 7.31 
20 7.40 6.86 7.45 
Mean 7.10 7.06 7.20 
Standard Deviation 0.29 0.24 0.26 
Standard Error 0.11 0.09 0.10 
 
Subject Pre-Supplementation Fish Oil + Vitamin C 
1 6.78 7.28 
4 6.59 6.33 
8 7.14 6.02 
9 6.99 6.51 
13 6.81 6.92 
18 6.97 6.63 
19 6.68 7.05 
2 7.34 6.98 
3 7.37 7.25 
7 7.23 7.54 
10 6.83 6.95 
14 6.76 6.89 
17 6.79 7.31 
20 7.40 7.45 
Mean 6.98 6.94 
Standard Deviation 0.27 0.44 
Standard Error 0.07 0.12 
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Daily Symptom Score 
Subject 
Pre-
Supplementation Fish Oil Washout Fish Oil + Vitamin C 
1 0.75 0.75 0.75 0.75 
4 1.83 1.63 1.52 1.50 
8 0.74 0.39 0.39 0.39 
9 1.27 0.72 0.30 0.33 
13 1.24 0.85 0.84 0.92 
18 1.56 1.46 1.20 0.84 
19 0.56 0.51 0.54 0.62 
Mean 1.13 0.90 0.79 0.76 
Standard Deviation 0.47 0.47 0.44 0.39 
Standard Error 0.18 0.18 0.17 0.15 
 
Subject 
Pre-
Supplementation Vitamin C Washout 
Fish Oil + Vitamin 
C 
2 2.78 2.24 2.22 2.03 
3 1.23 0.43 0.88 2.67 
7 1.75 1.86 1.86 1.88 
10 1.38 1.27 2.00 1.09 
14 2.24 0.66 0.79 0.86 
17 0.98 - 2.08 1.33 
20 1.04 0.79 0.68 0.75 
Mean 1.63 1.21 1.50 1.52 
Standard Deviation 0.67 0.72 0.68 0.70 
Standard Error 0.25 0.27 0.26 0.27 
 
Subject Pre-Supplementation Fish Oil + Vitamin C 
1 0.75 0.75 
4 1.83 1.50 
8 0.74 0.39 
9 1.27 0.33 
13 1.24 0.92 
18 1.56 0.84 
19 0.56 0.62 
2 2.78 2.03 
3 1.23 2.67 
7 1.75 1.88 
10 1.38 1.09 
14 2.24 0.86 
17 0.98 1.33 
20 1.04 0.75 
Mean 1.38 1.14 
Standard Deviation 0.61 0.67 
Standard Error 0.16 0.18 
 240 
Nightly Symptom Score 
Subject 
Pre-
Supplementation Fish Oil Washout Fish Oil + Vitamin C 
1 0.00 0.00 0.00 0.00 
4 0.00 0.00 0.00 0.00 
8 0.00 0.00 0.00 0.00 
9 0.62 0.28 0.00 0.00 
13 0.06 0.00 0.00 0.00 
18 0.00 0.00 0.00 0.00 
19 0.00 0.00 0.00 0.00 
Mean 0.10 0.04 0.00 0.00 
Standard Deviation 0.23 0.10 0.00 0.00 
Standard Error 0.09 0.04 0.00 0.00 
 
Subject 
Pre-
Supplementation Vitamin C Washout Fish Oil + Vitamin C 
2 0.53 0.29 0.47 0.55 
3 0.38 0.00 0.00 0.27 
7 0.29 0.00 0.00 0.00 
10 0.00 0.00 0.07 0.00 
14 0.00 0.00 0.00 0.00 
17 0.25 - 0.42 0.10 
20 0.00 0.00 0.07 0.05 
Mean 0.21 0.05 0.15 0.14 
Standard Deviation 0.21 0.12 0.21 0.21 
Standard Error 0.08 0.05 0.08 0.08 
 
Subject Pre-Supplementation Fish Oil + Vitamin C 
1 0.00 0.00 
4 0.00 0.00 
8 0.00 0.00 
9 0.62 0.00 
13 0.06 0.00 
18 0.00 0.00 
19 0.00 0.00 
2 0.53 0.55 
3 0.38 0.27 
7 0.29 0.00 
10 0.00 0.00 
14 0.00 0.00 
17 0.25 0.10 
20 0.00 0.05 
Mean 0.15 0.07 
Standard Deviation 0.22 0.16 
Standard Error 0.06 0.04 
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Bronchodilator Use (number of puffs per day) 
Subject 
Pre-
Supplementation Fish Oil Washout Fish Oil + Vitamin C 
1 0.00 0.00 0.00 0.00 
4 2.15 0.00 0.29 0.20 
8 0.00 0.00 0.00 0.00 
9 0.15 0.22 0.00 0.29 
13 0.35 0.05 0.00 0.00 
18 0.00 0.00 0.14 0.00 
19 0.00 0.00 0.15 0.05 
Mean 0.38 0.04 0.08 0.08 
Standard Deviation 0.79 0.08 0.11 0.12 
Standard Error 0.30 0.03 0.04 0.04 
 
Subject 
Pre-
Supplementation Vitamin C Washout Fish Oil + Vitamin C 
2 4.73 3.42 1.93 1.79 
3 0.18 0.14 - 0.37 
7 0.06 0.00 0.33 0.32 
10 0.23 0.00 0.00 0.09 
14 0.71 0.50 0.00 0.00 
17 0.00 0.00 0.00 0.00 
20 0.00 0.00 0.00 0.00 
Mean 0.84 0.58 0.38 0.37 
Standard Deviation 1.73 1.27 0.77 0.65 
Standard Error 0.65 0.48 0.32 0.24 
 
Subject Pre-Supplementation Fish Oil + Vitamin C 
1 0.00 0.00 
4 2.15 0.20 
8 0.00 0.00 
9 0.15 0.29 
13 0.35 0.00 
18 0.00 0.00 
19 0.00 0.05 
2 4.73 1.79 
3 0.18 0.37 
7 0.06 0.32 
10 0.23 0.09 
14 0.71 0.00 
17 0.00 0.00 
20 0.00 0.00 
Mean 0.61 0.22 
Standard Deviation 1.32 0.47 
Standard Error 0.35 0.13 
 242 
Morning FEV1 (L) 
Subject 
Pre-
Supplementation Fish Oil Washout Fish Oil + Vitamin C 
1 5.55 5.58 5.56 5.78 
4 3.03 2.51 2.49 2.96 
8 4.28 4.23 4.20 4.17 
9 2.75 3.03 3.02 2.99 
13 3.04 3.62 3.19 3.55 
18 4.37 4.17 4.43 4.49 
19 2.53 2.50 2.52 2.63 
Mean 3.65 3.66 3.63 3.80 
Standard Deviation 1.11 1.11 1.14 1.10 
Standard Error 0.42 0.42 0.43 0.42 
 
Subject 
Pre-
Supplementation Vitamin C Washout Fish Oil + Vitamin C 
2 3.42 3.09 3.24 3.29 
3 3.47 3.42 - 3.53 
7 5.15 5.68 5.52 5.52 
10 3.03 3.06 2.98 3.12 
14 2.87 3.00 2.89 2.52 
17 2.24 2.49 2.51 2.50 
20 2.30 2.02 2.46 2.40 
Mean 3.21 3.25 3.27 3.27 
Standard Deviation 0.98 1.17 1.14 1.09 
Standard Error 0.37 0.44 0.47 0.41 
 
Subject Pre-Supplementation Fish Oil + Vitamin C 
1 5.55 5.78 
4 3.03 2.96 
8 4.28 4.17 
9 2.75 2.99 
13 3.04 3.55 
18 4.37 4.49 
19 2.53 2.63 
2 3.42 3.29 
3 3.47 3.53 
7 5.15 5.52 
10 3.03 3.12 
14 2.87 2.52 
17 2.24 2.50 
20 2.30 2.40 
Mean 3.43 3.53 
Standard Deviation 1.03 1.09 
Standard Error 0.28 0.29 
 243 
Evening FEV1 (L) 
Subject 
Pre-
Supplementation Fish Oil Washout Fish Oil + Vitamin C 
1 5.57 5.75 5.55 5.71 
4 2.49 2.42 2.61 2.92 
8 4.32 4.20 4.19 4.21 
9 2.79 2.98 3.03 2.99 
13 3.06 3.63 3.26 3.55 
18 4.21 4.16 4.43 4.47 
19 2.58 2.62 2.67 2.66 
Mean 3.57 3.68 3.68 3.79 
Standard Deviation 1.15 1.15 1.09 1.08 
Standard Error 0.44 0.44 0.41 0.41 
 
Subject 
Pre-
Supplementation Vitamin C Washout Fish Oil + Vitamin C 
2 3.19 3.04 3.21 3.34 
3 3.29 3.40 - 3.38 
7 5.56 6.48 6.03 6.11 
10 3.12 3.13 3.05 3.15 
14 2.88 3.19 2.84 2.83 
17 2.72 2.80 2.68 2.67 
20 2.25 2.07 2.49 2.40 
Mean 3.29 3.44 3.39 3.41 
Standard Deviation 1.06 1.41 1.32 1.24 
Standard Error 0.40 0.53 0.54 0.47 
 
Subject Pre-Supplementation Fish Oil + Vitamin C 
1 5.57 5.71 
4 2.49 2.92 
8 4.32 4.21 
9 2.79 2.99 
13 3.06 3.55 
18 4.21 4.47 
19 2.58 2.66 
2 3.19 3.34 
3 3.29 3.38 
7 5.56 6.11 
10 3.12 3.15 
14 2.88 2.83 
17 2.72 2.67 
20 2.25 2.40 
Mean 3.43 3.60 
Standard Deviation 1.08 1.14 
Standard Error 0.29 0.30 
 244 
 
Morning PEF (L/min) 
Subject 
Pre-
Supplementation Fish Oil Washout Fish Oil + Vitamin C 
1 692.20 714.76 703.69 741.25 
4 310.15 265.62 287.86 303.96 
8 592.63 611.15 605.00 612.95 
9 323.23 407.67 415.87 416.00 
13 382.00 425.65 409.94 402.52 
18 579.08 606.95 635.71 650.82 
19 287.46 292.45 263.54 280.10 
Mean 452.39 474.89 474.51 486.80 
Standard Deviation 164.47 172.03 174.40 180.66 
Standard Error 62.16 65.02 65.92 68.28 
 
Subject 
Pre-
Supplementation Vitamin C Washout Fish Oil + Vitamin C 
2 377.53 314.82 273.18 325.80 
3 450.27 446.36 - 410.68 
7 601.47 593.50 572.07 569.32 
10 360.91 352.71 377.14 393.68 
14 414.47 329.20 357.40 390.15 
17 252.77 279.00 260.00 265.24 
20 256.14 192.22 304.86 298.00 
Mean 387.65 358.26 357.44 378.98 
Standard Deviation 120.18 128.91 114.73 99.92 
Standard Error 45.42 48.72 46.84 37.76 
 
Subject Pre-Supplementation Fish Oil + Vitamin C 
1 692.20 741.25 
4 310.15 303.96 
8 592.63 612.95 
9 323.23 416.00 
13 382.00 402.52 
18 579.08 650.82 
19 287.46 280.10 
2 377.53 325.80 
3 450.27 410.68 
7 601.47 569.32 
10 360.91 393.68 
14 414.47 390.15 
17 252.77 265.24 
20 256.14 298.00 
Mean 420.02 432.89 
Standard Deviation 142.40 151.00 
Standard Error 38.06 40.36 
 245 
Evening PEF (L/min) 
Subject 
Pre-
Supplementation Fish Oil Washout Fish Oil + Vitamin C 
1 691.60 732.52 707.00 707.16 
4 253.77 236.43 279.00 323.25 
8 590.63 612.30 606.43 614.05 
9 347.54 418.44 418.87 411.43 
13 380.71 419.00 404.44 412.38 
18 570.77 596.70 635.79 661.45 
19 303.00 302.20 310.46 311.57 
Mean 448.29 473.94 480.28 491.61 
Standard Deviation 167.39 179.39 168.51 165.21 
Standard Error 63.27 67.80 63.69 62.44 
 
Subject 
Pre-
Supplementation Vitamin C Washout 
Fish Oil + Vitamin 
C 
2 350.40 325.83 290.13 316.65 
3 411.40 416.70 - 387.31 
7 645.80 662.00 593.08 599.05 
10 390.23 377.09 384.86 387.26 
14 424.29 411.65 399.70 436.30 
17 335.69 360.30 280.15 293.19 
20 269.64 202.68 314.50 307.65 
Mean 403.92 393.75 377.07 389.63 
Standard Deviation 118.82 138.64 116.70 105.98 
Standard Error 44.91 52.40 47.64 40.06 
 
Subject Pre-Supplementation Fish Oil + Vitamin C 
1 691.60 707.16 
4 253.77 323.25 
8 590.63 614.05 
9 347.54 411.43 
13 380.71 412.38 
18 570.77 661.45 
19 303.00 311.57 
2 350.40 316.65 
3 411.40 387.31 
7 645.80 599.05 
10 390.23 387.26 
14 424.29 436.30 
17 335.69 293.19 
20 269.64 307.65 
Mean 426.10 440.62 
Standard Deviation 141.35 143.46 
Standard Error 37.78 38.34 
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Dietary Data: Pre-Supplementation 
Subject Total Grams 
Energy 
(kcal) Total Fat (g) 
Total 
Carbohydrate (g) Total Protein (g) 
Total Dietary 
Fiber (g) 
1 6472.03 4265.87 107.15 617.43 237.15 57.89 
4 4647.08 1663.85 72.42 159.34 96.53 14.73 
8 3997.98 3424.01 64.25 427.30 101.08 31.78 
9 2440.58 2095.23 91.46 261.63 65.96 19.28 
13 2250.57 3520.34 142.17 450.49 120.24 19.34 
18 4283.80 3224.07 178.77 271.54 136.24 15.56 
19 2374.25 1863.75 80.33 202.15 84.00 7.47 
Mean 3780.90 2865.30 105.22 341.41 120.17 23.72 
Standard 
Deviation 1549.71 989.20 41.52 162.92 56.44 16.75 
Standard Error 585.73 373.88 15.69 61.58 21.33 6.33 
 
Subject Linoleic Acid (g) 
Linolenic 
Acid (g) 
Arachidonic 
Acid (g) 
Eicosapentaenoic 
Acid (EPA) (g) 
Docosahexaenoic 
Acid (DHA) (g) 
1 16.13 3.27 0.08 0.01 0.02 
4 17.08 0.83 0.23 0.07 0.18 
8 11.98 2.20 0.20 0.07 0.09 
9 19.68 1.79 0.14 0.00 0.03 
13 37.05 4.38 0.15 0.02 0.05 
18 31.62 3.16 0.39 0.04 0.13 
19 13.74 2.00 0.18 0.01 0.04 
Mean 21.04 2.52 0.20 0.03 0.07 
Standard 
Deviation 9.53 1.17 0.10 0.03 0.06 
Standard Error 3.60 0.44 0.04 0.01 0.02 
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Dietary Data: Pre-Supplementation 
       
Subject 
Total Vitamin A 
Activity 
(International 
Units) 
Vitamin E 
(Total Alpha-
Tocopherol) 
(mg) 
Vitamin C 
(ascorbic 
acid) (mg) 
Lycopene 
(mcg) 
Zinc 
(mg) 
Selenium 
(mcg) 
Sodium 
(mg) 
Caffeine 
(mg) 
1 14168.74 35.78 197.13 36289.35 41.51 259.49 6191.33 21.84 
4 5243.08 10.97 49.08 2573.85 9.62 137.50 3940.92 0.00 
8 4049.29 9.24 107.90 15441.63 10.87 142.48 5017.03 178.78 
9 4862.07 14.33 81.74 875.37 13.44 115.40 5111.90 1.24 
13 2864.92 10.79 89.63 6372.32 11.16 170.66 5764.29 29.13 
18 1302.02 8.30 35.81 0.00 16.13 171.93 5219.02 4.22 
19 2871.09 5.65 108.83 1149.49 10.80 99.82 4378.08 55.24 
Mean 5051.60 13.58 95.73 8957.43 16.22 156.76 5088.94 41.49 
Standard 
Deviation 4238.61 10.15 52.60 13184.78 11.36 52.45 765.64 63.65 
Standard Error 1602.04 3.84 19.88 4983.38 4.29 19.82 289.39 24.06 
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Dietary Data: Pre-Supplementation 
Subject Total Grams 
Energy 
(kcal) Total Fat (g) 
Total 
Carbohydrate (g) Total Protein (g) 
Total Dietary 
Fiber (g) 
2 1402.53 1151.52 46.82 144.20 40.78 
3 3870.35 2453.97 69.57 258.42 82.50 13.90 
7 7390.70 4696.12 179.30 556.08 231.62 38.20 
10 5218.69 2196.79 62.95 306.38 104.60 27.00 
14 5485.37 2768.74 65.72 431.63 88.79 30.01 
17 4254.78 4642.34 159.93 683.63 134.00 23.10 
20 3204.59 940.37 24.69 127.32 54.63 6.81 
Mean 4403.86 2692.84 87.00 358.24 105.27 23.17 
Standard 
Deviation 1893.32 1503.85 58.70 209.04 63.64 11.32 
Standard Error 715.61 568.40 22.19 79.01 24.05 4.28 
 
Subject Linoleic Acid (g) 
Linolenic 
Acid (g) 
Arachidonic 
Acid (g) 
Eicosapentaenoic 
Acid (EPA) (g) 
Docosahexaenoic 
Acid (DHA) (g) 
2 6.95 0.77 0.07 0.00 0.01 
3 13.39 1.20 0.12 0.00 0.03 
7 16.43 1.95 0.35 0.02 0.10 
10 12.25 1.62 0.10 0.04 0.18 
14 19.56 1.98 0.05 0.01 0.02 
17 32.48 4.13 0.23 0.01 0.05 
20 3.01 0.44 0.16 0.02 0.10 
Mean 14.87 1.73 0.16 0.02 0.07 
Standard 
Deviation 9.55 1.21 0.11 0.01 0.06 
Standard Error 3.61 0.46 0.04 0.00 0.02 
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Dietary Data: Pre-Supplementation 
       
Subject 
Total Vitamin A 
Activity 
(International 
Units) 
Vitamin E 
(Total Alpha-
Tocopherol) 
(mg) 
Vitamin C 
(ascorbic 
acid) (mg) 
Lycopene 
(mcg) 
Zinc 
(mg) 
Selenium 
(mcg) 
Sodium 
(mg) 
Caffeine 
(mg) 
2 1297.90 2.08 8.75 0.00 5.29 49.24 1488.50 87.78 
3 5076.58 5.33 87.80 822.54 9.50 158.09 3681.60 2.08 
7 10118.45 9.00 331.71 8179.87 30.73 258.50 8912.32 29.95 
10 9092.69 9.87 75.42 12507.51 13.95 197.99 3019.12 196.31 
14 4181.72 10.18 109.37 36585.68 14.89 138.54 5696.71 0.00 
17 3659.30 9.62 323.39 11357.92 17.10 180.92 6765.00 68.54 
20 1721.18 2.47 9.05 2565.84 4.95 93.63 1273.73 80.08 
Mean 5021.12 6.94 135.07 10288.48 13.77 153.85 4405.28 66.39 
Standard 
Deviation 3412.59 3.57 136.88 12630.34 8.83 68.87 2837.51 67.58 
Standard Error 1289.84 1.35 51.74 4773.82 3.34 26.03 1072.48 25.54 
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Dietary Data: Fish Oil Treatment 
Subject Total Grams 
Energy 
(kcal) Total Fat (g) 
Total 
Carbohydrate (g) Total Protein (g) 
Total Dietary 
Fiber (g) 
1 6862.94 3874.01 104.56 559.13 210.56 66.02 
4 2823.79 3548.07 123.78 512.22 108.13 23.74 
8 2972.81 2900.06 123.66 323.83 128.22 17.99 
9 2147.84 1798.58 59.60 270.95 48.11 10.79 
13 2804.93 1466.93 32.99 224.82 68.72 11.06 
18 3015.64 2361.45 69.82 307.55 86.62 23.15 
19 1999.86 2132.44 75.58 289.16 81.45 14.37 
Mean 3232.54 2583.08 84.29 355.38 104.55 23.87 
Standard 
Deviation 1650.27 895.51 34.27 127.77 53.44 19.31 
Standard Error 623.74 338.47 12.95 48.29 20.20 7.30 
 
Subject Linoleic Acid (g) 
Linolenic 
Acid (g) 
Arachidonic 
Acid (g) 
Eicosapentaenoic 
Acid (EPA) (g) 
Docosahexaenoic 
Acid (DHA) (g) 
1 14.18 2.62 0.18 0.16 0.16 
4 37.73 4.32 0.09 0.01 0.02 
8 18.16 2.40 0.08 0.01 0.03 
9 11.06 1.91 0.03 0.00 0.01 
13 7.18 0.76 0.10 0.01 0.03 
18 4.08 0.74 0.07 0.00 0.01 
19 16.86 1.92 0.10 0.01 0.03 
Mean 15.61 2.10 0.09 0.03 0.04 
Standard 
Deviation 10.99 1.22 0.05 0.06 0.05 
Standard Error 4.15 0.46 0.02 0.02 0.02 
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Dietary Data: Fish Oil Treatment 
       
Subject 
Total Vitamin A 
Activity 
(International 
Units) 
Vitamin E 
(Total Alpha-
Tocopherol) 
(mg) 
Vitamin C 
(ascorbic 
acid) (mg) 
Lycopene 
(mcg) 
Zinc 
(mg) 
Selenium 
(mcg) 
Sodium 
(mg) 
Caffeine 
(mg) 
1 28813.23 45.72 868.11 1029.20 35.81 183.02 3598.65 12.51 
4 2823.39 19.41 76.22 8977.69 10.43 158.33 4818.07 60.53 
8 2350.15 8.15 26.31 2081.01 12.82 159.59 7699.91 1.02 
9 1693.40 5.92 90.91 7596.13 5.50 74.68 2785.74 57.09 
13 3745.11 3.62 25.56 2798.50 7.84 92.86 3480.10 34.87 
18 3963.80 4.87 123.46 9286.28 14.31 107.58 3198.10 0.55 
19 3179.91 12.07 74.14 9528.95 15.10 105.47 3641.99 31.70 
Mean 6652.71 14.25 183.53 5899.68 14.54 125.93 4174.65 28.32 
Standard 
Deviation 9803.09 14.88 303.86 3761.96 9.99 40.66 1674.42 24.79 
Standard Error 3705.22 5.63 114.85 1421.89 3.78 15.37 632.87 9.37 
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Dietary Data: Vitamin C Treatment 
Subject Total Grams 
Energy 
(kcal) Total Fat (g) 
Total 
Carbohydrate (g) Total Protein (g) 
Total Dietary 
Fiber (g) 
2 1575.23 1513.55 58.28 167.95 79.11 7.23 
3 3618.28 3318.07 139.51 306.48 140.86 26.60 
7 4928.50 3864.61 154.80 450.76 176.40 28.13 
10 3393.17 1349.07 48.14 188.08 58.62 27.73 
14 5226.28 4007.65 167.90 491.98 136.46 32.20 
17 2514.11 3031.59 111.25 400.71 118.31 13.27 
20 2895.67 1005.57 41.79 88.43 57.61 7.97 
Mean 3450.18 2584.30 103.10 299.20 109.62 20.45 
Standard 
Deviation 1295.54 1262.82 53.31 155.18 45.59 10.56 
Standard Error 489.67 477.30 20.15 58.65 17.23 3.99 
 
Subject Linoleic Acid (g) 
Linolenic 
Acid (g) 
Arachidonic 
Acid (g) 
Eicosapentaenoic 
Acid (EPA) (g) 
Docosahexaenoic 
Acid (DHA) (g) 
2 14.72 0.76 0.07 0.00 0.00 
3 25.62 1.69 0.11 0.04 0.19 
7 25.77 2.17 0.33 0.02 0.09 
10 12.91 1.27 0.03 0.00 0.01 
14 52.24 5.12 0.19 0.02 0.07 
17 17.66 1.57 0.37 0.02 0.08 
20 4.21 0.56 0.17 0.01 0.04 
Mean 21.88 1.88 0.18 0.02 0.07 
Standard 
Deviation 15.34 1.53 0.13 0.01 0.06 
Standard Error 5.80 0.58 0.05 0.01 0.02 
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Dietary Data: Vitamin C Treatment 
       
Subject 
Total Vitamin A 
Activity 
(International 
Units) 
Vitamin E 
(Total Alpha-
Tocopherol) 
(mg) 
Vitamin C 
(ascorbic 
acid) (mg) 
Lycopene 
(mcg) 
Zinc 
(mg) 
Selenium 
(mcg) 
Sodium 
(mg) 
Caffeine 
(mg) 
2 971.31 7.09 20.86 1253.18 12.92 105.31 2730.60 76.23 
3 2429.76 15.40 33.42 9720.70 22.50 211.26 4375.97 23.68 
7 13385.26 16.30 140.18 5853.55 25.48 280.55 6694.95 0.00 
10 8939.23 16.23 145.89 4281.07 8.02 86.51 2216.45 192.62 
14 7438.03 16.00 71.37 20513.85 11.56 211.33 9286.85 84.06 
17 3789.28 7.41 49.13 4704.19 13.15 170.09 4935.30 7.50 
20 2228.61 3.08 31.81 4072.33 6.56 71.79 1892.97 23.81 
Mean 5597.35 11.64 70.38 7199.84 14.31 162.41 4590.44 58.27 
Standard 
Deviation 4495.54 5.59 52.17 6394.29 7.10 77.49 2677.73 67.57 
Standard Error 1699.15 2.11 19.72 2416.81 2.68 29.29 1012.09 25.54 
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Dietary Data: Washout 
Subject Total Grams 
Energy 
(kcal) Total Fat (g) 
Total 
Carbohydrate (g) Total Protein (g) 
Total Dietary 
Fiber (g) 
1 6738.55 4322.55 108.56 615.30 181.95 56.24 
4 2495.90 4667.49 239.29 510.90 143.82 43.17 
8 2217.97 2148.50 88.56 247.33 89.78 11.30 
9 2271.60 1678.50 45.07 267.88 55.15 7.25 
13 3760.37 1588.24 52.92 162.47 107.09 11.51 
18 5444.49 2852.05 37.80 419.90 95.41 37.26 
19 1485.14 1477.67 49.77 211.88 49.16 10.25 
Mean 3487.72 2676.43 88.85 347.95 103.19 25.28 
Standard 
Deviation 1938.92 1329.20 71.13 169.64 47.15 19.83 
Standard Error 732.84 502.39 26.89 64.12 17.82 7.49 
 
Subject Linoleic Acid (g) 
Linolenic 
Acid (g) 
Arachidonic 
Acid (g) 
Eicosapentaenoic 
Acid (EPA) (g) 
Docosahexaenoic 
Acid (DHA) (g) 
1 15.47 1.56 0.14 0.17 0.18 
4 72.59 7.84 0.27 0.04 0.11 
8 16.20 1.95 0.10 0.01 0.03 
9 4.43 0.41 0.06 0.01 0.01 
13 4.55 0.72 0.14 0.12 0.39 
18 8.58 1.39 0.06 0.01 0.02 
19 7.89 0.87 0.04 0.00 0.01 
Mean 18.53 2.11 0.11 0.05 0.11 
Standard 
Deviation 24.30 2.58 0.08 0.07 0.14 
Standard Error 9.19 0.98 0.03 0.02 0.05 
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Dietary Data: Washout 
       
Subject 
Total Vitamin A 
Activity 
(International 
Units) 
Vitamin E 
(Total Alpha-
Tocopherol) 
(mg) 
Vitamin C 
(ascorbic 
acid) (mg) 
Lycopene 
(mcg) 
Zinc 
(mg) 
Selenium 
(mcg) 
Sodium 
(mg) 
Caffeine 
(mg) 
1 16232.92 19.57 388.05 10719.81 27.28 230.56 5614.01 58.11 
4 5840.83 34.37 267.05 2541.01 16.19 207.88 6546.54 33.52 
8 940.03 6.20 6.68 1474.90 7.37 135.02 4700.91 0.00 
9 2647.65 1.94 92.44 334.49 9.28 62.76 2334.06 0.00 
13 10202.07 6.41 78.14 14737.65 14.12 114.00 3664.91 28.42 
18 12428.52 4.82 117.27 108.58 11.16 128.61 4278.86 118.40 
19 2719.05 2.56 32.77 0.00 11.91 91.37 2568.76 30.09 
Mean 7287.30 10.84 140.34 4273.78 13.90 138.60 4244.01 38.36 
Standard 
Deviation 5769.57 11.94 137.57 5958.36 6.58 60.49 1537.22 40.68 
Standard Error 2180.69 4.51 52.00 2252.05 2.49 22.86 581.01 15.38 
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Dietary Data: Washout 
Subject Total Grams 
Energy 
(kcal) Total Fat (g) 
Total 
Carbohydrate (g) Total Protein (g) 
Total Dietary 
Fiber (g) 
2 1563.82 1699.08 69.91 184.67 82.07 7.83 
3 1848.02 832.57 41.14 101.42 19.94 11.42 
7 3955.87 3617.07 132.51 441.73 161.09 25.44 
10 3579.67 1906.43 58.31 259.75 81.36 31.64 
14 5183.77 1548.42 21.54 278.82 44.95 22.76 
17 2124.80 2261.71 77.81 324.88 75.32 8.51 
20 2942.11 1050.32 29.87 126.38 66.72 7.90 
Mean 3028.29 1845.08 61.59 245.38 75.92 16.50 
Standard 
Deviation 1302.05 920.46 37.42 118.86 43.78 9.89 
Standard Error 492.13 347.90 14.14 44.93 16.55 3.74 
 
Subject Linoleic Acid (g) 
Linolenic 
Acid (g) 
Arachidonic 
Acid (g) 
Eicosapentaenoic 
Acid (EPA) (g) 
Docosahexaenoic 
Acid (DHA) (g) 
2 14.62 1.95 0.11 0.01 0.03 
3 5.29 1.72 0.01 0.00 0.00 
7 22.12 2.06 0.39 0.02 0.10 
10 10.13 0.64 0.05 0.00 0.01 
14 3.94 0.50 0.04 0.01 0.02 
17 15.01 1.43 0.19 0.01 0.04 
20 5.43 0.58 0.19 0.02 0.11 
Mean 10.93 1.27 0.14 0.01 0.04 
Standard 
Deviation 6.67 0.68 0.13 0.01 0.04 
Standard Error 2.52 0.26 0.05 0.00 0.02 
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Dietary Data: Washout 
       
Subject 
Total Vitamin A 
Activity 
(International 
Units) 
Vitamin E 
(Total Alpha-
Tocopherol) 
(mg) 
Vitamin C 
(ascorbic 
acid) (mg) 
Lycopene 
(mcg) 
Zinc 
(mg) 
Selenium 
(mcg) 
Sodium 
(mg) 
Caffeine 
(mg) 
2 1105.39 4.61 20.83 9400.74 8.39 95.12 2956.64 103.95 
3 11763.36 6.69 92.08 5757.85 3.25 24.91 2221.56 2.60 
7 10258.31 15.57 183.79 14545.46 19.76 250.09 13064.01 93.60 
10 6165.54 7.61 99.02 17660.28 11.77 119.96 3139.36 193.27 
14 1150.17 2.74 121.63 1521.47 5.06 65.26 3096.61 0.00 
17 2000.66 5.25 73.47 7238.54 8.48 102.65 3547.09 2.50 
20 2335.92 4.46 16.18 3675.00 6.36 117.30 1879.76 111.10 
Mean 4968.48 6.71 86.72 8542.76 9.01 110.76 4272.15 72.43 
Standard 
Deviation 4487.52 4.22 58.19 5807.29 5.47 69.87 3918.90 73.66 
Standard Error 1696.12 1.59 21.99 2194.95 2.07 26.41 1481.20 27.84 
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Dietary Data: Combination   
                           Treatment 
Subject Total Grams 
Energy 
(kcal) Total Fat (g) 
Total 
Carbohydrate (g) Total Protein (g) 
Total Dietary 
Fiber (g) 
1 6019.51 3661.00 105.60 508.71 190.56 41.58 
4 3023.41 6089.73 290.42 726.33 162.35 44.43 
8 4145.99 3186.62 142.08 332.69 145.79 15.15 
9 2576.31 1882.51 69.39 225.82 92.43 15.07 
13 3504.45 2382.62 80.32 317.07 99.49 18.87 
18 2755.43 3176.94 92.86 422.56 97.13 21.35 
19 996.49 1088.79 27.27 177.88 42.36 13.17 
Mean 3288.80 3066.89 115.42 387.29 118.59 24.23 
Standard Deviation 1546.79 1596.92 84.72 186.54 50.26 13.13 
Standard Error 584.63 603.58 32.02 70.50 19.00 4.96 
 
Subject 
Linoleic Acid 
(g) 
Linolenic 
Acid (g) 
Arachidonic 
Acid (g) 
Eicosapentaenoic 
Acid (EPA) (g) 
Docosahexaenoic 
Acid (DHA) (g) 
1 15.45 3.01 0.14 0.19 0.62 
4 87.97 10.97 0.19 0.04 0.07 
8 23.70 2.31 0.16 0.02 0.04 
9 12.09 1.74 0.13 0.03 0.05 
13 12.17 1.22 0.06 0.00 0.02 
18 11.76 1.20 0.08 0.00 0.01 
19 3.31 0.26 0.04 0.00 0.01 
Mean 23.78 2.96 0.12 0.04 0.12 
Standard Deviation 28.94 3.64 0.06 0.07 0.22 
Standard Error 10.94 1.38 0.02 0.03 0.08 
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Dietary Data: Combination  
                           Treatment 
       
Subject 
Total Vitamin A 
Activity 
(International 
Units) 
Vitamin E 
(Total Alpha-
Tocopherol) 
(mg) 
Vitamin C 
(ascorbic 
acid) (mg) 
Lycopene 
(mcg) 
Zinc 
(mg) 
Selenium 
(mcg) 
Sodium 
(mg) 
Caffeine 
(mg) 
1 8181.36 25.17 244.77 9663.33 29.44 245.59 4800.75 17.24 
4 13918.26 25.00 189.89 6812.64 18.19 254.35 8541.90 16.36 
8 2389.40 10.79 14.06 8722.83 15.05 193.06 7374.84 1.53 
9 11846.07 6.15 91.40 1600.53 13.53 110.05 3350.62 9.04 
13 4579.65 7.13 68.46 12195.17 12.42 137.57 4241.15 71.27 
18 3191.84 7.29 126.57 17966.38 14.04 148.78 4926.53 126.48 
19 2547.68 1.46 43.67 16802.36 6.03 64.64 1413.61 12.03 
Mean 6664.89 11.86 111.26 10537.61 15.53 164.86 4949.91 36.28 
Standard 
Deviation 4715.17 9.44 82.14 5700.67 7.15 69.97 2393.43 45.93 
Standard Error 1782.17 3.57 31.05 2154.65 2.70 26.44 904.63 17.36 
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Dietary Data: Combination  
                           Treatment 
Subject Total Grams 
Energy 
(kcal) Total Fat (g) 
Total 
Carbohydrate (g) Total Protein (g) 
Total Dietary 
Fiber (g) 
2 1288.60 1339.55 49.93 136.54 83.06 6.14 
3 1957.10 1923.28 63.77 282.38 60.23 34.73 
7 4126.06 3226.20 116.75 367.30 177.13 19.51 
10 4408.36 1985.22 68.94 262.40 82.16 26.80 
14 6453.09 2480.62 119.04 198.94 57.34 20.46 
17 2457.68 2573.80 90.15 353.51 97.30 13.80 
20 3925.75 768.91 36.23 68.09 44.37 8.78 
Mean 3516.66 2042.51 77.83 238.45 85.94 18.60 
Standard Deviation 1754.73 817.42 32.02 110.54 44.11 10.05 
Standard Error 663.22 308.96 12.10 41.78 16.67 3.80 
 
Subject 
Linoleic Acid 
(g) 
Linolenic 
Acid (g) 
Arachidonic 
Acid (g) 
Eicosapentaenoic 
Acid (EPA) (g) 
Docosahexaenoic 
Acid (DHA) (g) 
2 4.03 0.55 0.12 0.00 0.01 
3 14.06 1.92 0.14 0.25 0.81 
7 16.22 1.31 0.47 0.02 0.09 
10 20.06 3.26 0.14 0.01 0.04 
14 33.81 3.91 0.16 0.04 0.09 
17 21.76 2.58 0.10 0.04 0.05 
20 2.74 0.69 0.26 0.27 0.96 
Mean 16.10 2.03 0.20 0.09 0.29 
Standard Deviation 10.72 1.28 0.13 0.12 0.41 
Standard Error 4.05 0.48 0.05 0.04 0.15 
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Dietary Data: Combination 
                           Treatment 
       
Subject 
Total Vitamin A 
Activity 
(International 
Units) 
Vitamin E 
(Total Alpha-
Tocopherol) 
(mg) 
Vitamin C 
(ascorbic 
acid) (mg) 
Lycopene 
(mcg) 
Zinc 
(mg) 
Selenium 
(mcg) 
Sodium 
(mg) 
Caffeine 
(mg) 
2 548.14 2.53 16.19 6636.71 14.45 97.04 2906.57 90.09 
3 7289.11 9.01 78.39 0.00 14.97 99.10 4454.68 0.00 
7 6486.54 8.87 192.08 14582.54 24.14 276.45 5606.55 0.00 
10 13327.20 16.35 117.19 4095.71 10.20 118.60 3513.29 199.02 
14 14400.34 13.22 132.63 32989.45 7.45 71.39 4674.90 21.81 
17 4446.47 6.66 74.41 5527.30 10.30 141.54 4572.68 5.00 
20 2759.07 5.41 10.20 162.73 4.83 76.73 1928.91 244.35 
Mean 7036.70 8.86 88.73 9142.06 12.33 125.84 3951.08 80.04 
Standard 
Deviation 5184.41 4.69 64.76 11599.65 6.32 70.60 1243.40 102.54 
Standard Error 1959.52 1.77 24.48 4384.26 2.39 26.68 469.96 38.76 
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APPENDIX D 
RAW DATA FOR CHAPTER 3 
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Maximum Drop in FEV1 (L) 
Subject 
Pre-
Supplementation Placebo  DHA  
201 -1.00 -1.10 -0.77 
202 -1.24 -1.15 -1.26 
203 -0.60 -0.72 -1.78 
204 -0.42 -0.23 -0.36 
205 -0.54 -0.81 -0.50 
206 -1.10 -0.48 -0.71 
207 -0.86 -0.27 -0.18 
208 -1.38 -1.15 -1.24 
212 -0.67 -0.33 -0.28 
Mean -0.87 -0.69 -0.79 
Standard 
Deviation 0.33 0.38 0.54 
Standard Error 0.11 0.13 0.18 
 
 
Maximum Drop in FEV1 (%) 
Subject 
Pre-
Supplementation Placebo  DHA  
201 -19.65 -20.11 -15.10 
202 -33.60 -32.76 -34.52 
203 -21.43 -25.90 -31.27 
204 -10.34 -6.10 -9.11 
205 -10.69 -16.14 -10.20 
206 -26.51 -11.29 -15.40 
207 -18.82 -5.86 -3.80 
208 -30.07 -27.06 -28.05 
212 -18.51 -9.57 -7.95 
Mean -21.07 -17.20 -17.27 
Standard Deviation 7.94 9.81 11.20 
Standard Error 2.65 3.27 3.73 
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Maximum Drop in FVC (L) 
Subject 
Pre-
Supplementation Placebo  DHA  
201 -0.68 -0.86 -0.22 
202 -0.59 -0.67 -0.49 
203 -0.47 -0.69 -1.10 
204 -0.55 -0.05 -0.20 
205 -0.63 -0.83 -0.67 
206 -0.60 -0.38 -0.20 
207 -0.88 -0.26 -0.19 
208 -1.05 -0.93 -0.96 
212 -0.50 -0.31 -0.37 
Mean -0.66 -0.55 -0.49 
Standard 
Deviation 0.19 0.31 0.35 
Standard Error 0.06 0.10 0.12 
 
 
Maximum Drop in FVC (%) 
Subject 
Pre-
Supplementation Placebo DHA 
201 -9.34 -11.23 -3.19 
202 -10.77 -13.06 -9.40 
203 -11.49 -17.25 -28.06 
204 -11.00 -1.08 -4.17 
205 -10.23 -13.67 -11.19 
206 -6.96 -6.82 -3.66 
207 -19.13 -5.58 -3.97 
208 -19.59 -18.13 -18.15 
212 -11.60 -7.58 -8.71 
Mean -12.23 -10.49 -10.06 
Standard 
Deviation 4.28 5.66 8.31 
Standard Error 1.43 1.89 2.77 
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Maximum Drop in FEF25-75% (L/s) 
Subject 
Pre-
Supplementation Placebo  DHA  
201 -1.19 -1.36 -1.23 
202 -1.28 -1.29 -1.23 
203 -0.68 -0.68 -0.57 
204 -0.41 -0.57 -0.62 
205 -0.65 -0.90 -0.26 
206 -1.47 -0.75 -2.03 
207 -0.35 0.30 0.19 
208 -3.35 -2.21 -2.63 
212 -1.15 -0.70 -0.39 
Mean -1.17 -0.91 -0.97 
Standard Deviation 0.91 0.68 0.90 
Standard Error 0.30 0.23 0.30 
 
 
Maximum Drop in FEF25-75% (%) 
Subject 
Pre-
Supplementation Placebo  DHA  
201 -32.16 -32.85 -29.71 
202 -53.33 -53.31 -51.46 
203 -35.60 -36.96 -36.59 
204 -10.76 -15.83 -16.23 
205 -13.29 -18.67 -5.92 
206 -46.37 -21.37 -40.36 
207 -4.88 3.66 2.99 
208 -58.57 -48.46 -53.67 
212 -29.11 -17.99 -10.66 
Mean -31.57 -26.86 -26.85 
Standard Deviation 19.12 17.79 20.35 
Standard Error 6.37 5.93 6.78 
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Pre-Eucapnic Voluntary Hyperventilation FENO (ppb) 
Subject 
Pre-
Supplementation Placebo  DHA  
201 26.97 32.67 21.47 
202 110.85 82.57 144.23 
203 118.43 71.90 108.07 
204 20.10 24.73 23.63 
205 16.23 12.37 11.33 
206 203.60 76.17 188.33 
207 25.50 21.67 32.70 
208 85.33 54.53 78.80 
212 50.20 12.70 12.03 
Mean 73.02 43.26 68.96 
Standard 
Deviation 62.87 28.25 64.93 
Standard Error 20.96 9.42 21.64 
 
 
Post-Eucapnic Voluntary Hyperventilation FENO (ppb) 
Subject 
Pre-
Supplementation Placebo  DHA  
201 30.63 29.43 14.77 
202 86.30 60.10 109.07 
203 119.00 66.13 98.60 
204 19.03 26.27 23.60 
205 12.57 8.87 9.17 
206 155.37 76.13 161.63 
207 23.13 17.50 33.60 
208 81.40 33.87 79.43 
212 44.10 9.20 8.97 
Mean 63.50 36.39 59.87 
Standard 
Deviation 50.02 25.09 54.61 
Standard Error 16.67 8.36 18.20 
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Pre-Eucapnic Voluntary Hyperventilation Exhaled Breath Condensate pH 
Subject 
Pre-
Supplementation Placebo  DHA  
201 6.66 7.12 6.93 
202 7.11 7.29 6.82 
203 7.02 - 7.23 
204 6.56 7.11 6.95 
205 7.41 7.01 7.08 
206 6.95 7.12 6.79 
207 6.78 7.26 6.59 
208 6.58 7.14 6.83 
212 6.83 6.68 - 
Mean 6.88 7.09 6.90 
Standard 
Deviation 0.28 0.19 0.19 
Standard Error 0.09 0.07 0.07 
 
 
Post-Eucapnic Voluntary Hyperventilation Exhaled Breath Condensate pH 
Subject 
Pre-
Supplementation Placebo  DHA  
201 6.48 6.75 7.30 
202 7.11 7.35 7.25 
203 6.92 - 7.15 
204 6.59 7.47 7.33 
205 7.07 7.10 7.67 
206 6.95 6.79 6.45 
207 6.85 6.63 6.58 
208 6.99 6.60 6.46 
212 6.38 6.74 - 
Mean 6.82 6.93 7.02 
Standard 
Deviation 0.27 0.33 0.46 
Standard Error 0.09 0.12 0.16 
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Daily Symptom Score 
Subject 
Pre-
Supplementation Placebo Washout DHA 
201 1.59 1.60 - - 
202 2.05 0.68 0.65 0.33 
203 1.56 0.71 0.93 1.23 
204 0.73 0.25 0.80 0.73 
205 0.05 0.03 0.00 0.03 
206 1.14 0.83 0.93 1.07 
207 0.76 0.64 0.63 0.48 
208 0.75 0.68 0.75 0.79 
212 1.91 1.46 1.25 1.00 
Mean 1.17 0.76 0.74 0.70 
Standard 
Deviation 0.66 0.50 0.36 0.41 
Standard Error 0.22 0.17 0.12 0.14 
 
 
Nightly Symptom Score 
Subject 
Pre-
Supplementation Placebo  Washout DHA 
201 0.00 0.00 - - 
202 0.07 0.00 0.00 0.04 
203 0.15 0.00 0.00 0.00 
204 0.00 0.00 0.00 0.00 
205 0.00 0.00 0.00 0.00 
206 0.21 0.00 0.00 0.00 
207 0.00 0.00 0.00 0.00 
208 0.08 0.00 0.00 0.00 
212 0.82 0.00 0.08 0.14 
Mean 0.15 0.00 0.01 0.02 
Standard 
Deviation 0.26 0.00 0.03 0.05 
Standard Error 0.09 0.00 0.01 0.02 
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Bronchodilator Use (number of puffs per day)  
Subject 
Pre-
Supplementation Placebo  Washout DHA  
201 1.13 0.60 - - 
202 0.36 0.00 0.00 0.19 
203 0.10 0.00 0.00 0.00 
204 0.00 0.00 0.00 0.00 
205 0.00 0.00 0.00 0.00 
206 0.29 0.15 0.21 0.32 
207 0.00 0.00 0.00 0.00 
208 0.31 0.09 0.00 0.30 
212 0.27 0.05 0.00 0.00 
Mean 0.27 0.10 0.03 0.10 
Standard 
Deviation 0.35 0.20 0.08 0.14 
Standard Error 0.12 0.07 0.03 0.05 
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Morning FEV1 (L) 
Subject 
Pre-
Supplementation Placebo Washout DHA 
201 5.45 5.49 - - 
202 3.09 2.60 2.75 2.73 
203 1.96 1.47 1.54 2.02 
204 3.46 3.30 2.80 2.83 
205 4.07 4.12 3.96 4.12 
206 4.24 4.10 4.10 4.18 
207 3.03 3.46 4.03 3.09 
208 4.44 4.65 4.58 4.68 
212 3.48 3.26 3.42 3.43 
Mean 3.69 3.61 3.40 3.38 
Standard 
Deviation 1.00 1.17 0.99 0.89 
Standard Error 0.33 0.39 0.33 0.30 
 
 
Evening FEV1 (L) 
Subject 
Pre-
Supplementation Placebo Washout DHA 
201 5.80 5.87 - - 
202 2.89 2.61 2.52 2.60 
203 2.44 1.54 1.64 2.44 
204 3.73 3.36 2.62 2.84 
205 4.08 4.18 4.08 4.20 
206 4.29 4.23 4.30 4.26 
207 3.03 3.37 3.82 3.19 
208 4.53 4.69 4.60 4.84 
212 3.28 3.40 3.46 3.55 
Mean 3.79 3.69 3.38 3.49 
Standard 
Deviation 1.03 1.24 1.03 0.87 
Standard Error 0.34 0.41 0.34 0.29 
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Morning PEF (L/min) 
Subject 
Pre-
Supplementation Placebo Washout DHA 
201 636.13 635.15 - - 
202 367.00 370.05 376.43 373.57 
203 267.22 318.63 295.47 312.64 
204 415.31 402.36 374.79 368.68 
205 505.74 525.10 515.27 531.56 
206 572.43 585.30 577.77 567.73 
207 467.29 504.00 540.46 488.33 
208 634.23 648.91 621.71 674.75 
212 343.82 358.60 403.62 434.10 
Mean 467.68 483.12 463.19 468.92 
Standard 
Deviation 130.83 125.05 115.86 120.24 
Standard Error 43.61 41.68 38.62 40.08 
 
 
Evening PEF (L/min) 
Subject 
Pre-
Supplementation Placebo Washout DHA 
201 697.56 698.50 - - 
202 332.07 366.00 340.17 349.75 
203 363.95 317.84 270.68 306.66 
204 423.08 407.86 369.64 357.71 
205 516.84 534.30 535.09 560.78 
206 585.64 605.65 603.67 600.80 
207 479.47 503.16 522.46 502.90 
208 642.46 652.18 638.86 686.20 
212 307.45 380.95 418.38 428.19 
Mean 483.17 496.27 462.37 474.12 
Standard 
Deviation 138.98 136.28 132.14 135.51 
Standard Error 46.33 45.43 44.05 45.17 
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8-Isoprostane Concentration (pg/µL) 
  
Pre-
Supplementation Placebo DHA 
Subject Pre Post Pre Post Pre Post 
201 1.43 0.00 6.68 4.19 9.79 10.39 
202 0.00 0.00 3.74 1.07 1.88 0.00 
204 0.00 2.44 1.63 0.00 6.37 2.02 
205 10.56 - 2.24 1.62 1.28 1.78 
206 3.98 8.60 13.90 0.04 1.36 0.00 
207 5.61 0.00 1.00 3.61 5.02 4.67 
208 0.00 - 13.94 13.74 5.67 27.30 
Mean 3.08 2.21 6.16 3.47 4.48 6.59 
Standard Deviation 3.96 3.73 5.61 4.82 3.17 9.81 
Standard Error 1.50 1.67 2.12 1.82 1.20 3.71 
 
Protectin D1 Concentration (pg/µL) 
    
  
Pre-
Supplementation Placebo DHA 
Subject 
Pre-
EVH 
Post- 
EVH 
Pre-
EVH 
Post-
EVH 
Pre-
EVH 
Post-
EVH 
201 < 0 < 0 < 0 < 0 < 0 < 0 
202 < 0 < 0 < 0 < 0 < 0 < 0 
204 < 0 < 0 < 0 < 0 < 0 < 0 
205 < 0 - < 0 < 0 < 0 < 0 
206 < 0 < 0 < 0 < 0 < 0 < 0 
207 < 0 < 0 < 0 < 0 < 0 < 0 
208 < 0 - < 0 < 0 < 0 < 0 
 
17S-Hydroxy-Docosahexaenoic Acid Concentration (pg/µL) 
  
  
Pre-
Supplementation Placebo DHA 
Subject 
Pre-
EVH 
Post- 
EVH 
Pre-
EVH Post 
Pre-
EVH 
Post-
EVH 
201 < 0 < 0 < 0 < 0 < 0 < 0 
202 < 0 < 0 < 0 < 0 < 0 < 0 
204 < 0 < 0 < 0 < 0 < 0 < 0 
205 < 0 - < 0 < 0 < 0 < 0 
206 < 0 < 0 < 0 < 0 < 0 < 0 
207 < 0 < 0 < 0 < 0 < 0 < 0 
208 < 0 - < 0 < 0 < 0 < 0 
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Dietary Data: Pre-Supplementation 
Subject Total Grams 
Energy 
(kcal) Total Fat (g) 
Total 
Carbohydrate (g) Total Protein (g) 
Total Dietary 
Fiber (g) 
201 7099.63 4711.06 158.70 617.26 230.56 64.89 
202 3783.10 2232.19 50.43 322.15 65.24 22.67 
203 2587.24 2192.12 94.14 232.51 107.81 27.28 
204 2143.08 1408.92 66.34 163.50 51.00 20.27 
205 4463.34 4999.96 210.59 640.23 155.62 30.18 
206 1342.55 1559.86 64.80 158.67 78.05 12.32 
207 3155.40 3766.07 149.85 425.81 174.74 24.72 
208 2905.10 1421.32 45.69 159.04 75.44 17.02 
212 1178.92 1127.69 41.41 131.77 59.39 10.33 
Mean 3184.26 2602.13 98.00 316.77 110.87 25.52 
Standard 
Deviation 1811.68 1497.30 60.59 200.48 62.32 16.16 
Standard Error 603.89 499.10 20.20 66.83 20.77 5.39 
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Dietary Data: Pre-Supplementation 
    
Subject Linoleic Acid (g) 
Linolenic 
Acid (g) 
Arachidonic 
Acid (g) 
Eicosapentaenoic 
Acid (EPA) (g) 
Docosahexaenoic 
Acid (DHA) (g) 
201 28.70 3.60 0.48 0.02 0.09 
202 9.87 1.11 0.05 0.00 0.01 
203 17.13 1.53 0.24 0.04 0.08 
204 17.19 1.18 0.12 0.01 0.03 
205 38.63 4.75 0.18 0.04 0.07 
206 9.98 1.31 0.12 0.00 0.02 
207 21.94 2.22 0.25 0.06 0.09 
208 7.76 0.81 0.15 0.01 0.04 
212 6.75 0.74 0.14 0.01 0.04 
Mean 17.55 1.92 0.19 0.02 0.05 
Standard 
Deviation 10.70 1.38 0.12 0.02 0.03 
Standard Error 3.57 0.46 0.04 0.01 0.01 
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Dietary Data: Pre-Supplementation 
       
Subject 
Total Vitamin A 
Activity 
(International 
Units) 
Vitamin E 
(Total Alpha-
Tocopherol) 
(mg) 
Vitamin C 
(ascorbic 
acid) (mg) 
Lycopene 
(mcg) 
Zinc 
(mg) 
Selenium 
(mcg) 
Sodium 
(mg) 
Caffeine 
(mg) 
201 51570.77 58.07 510.71 13821.27 31.31 313.51 8324.48 2.79 
202 7622.10 18.06 87.39 13387.01 10.97 84.73 3115.62 3.55 
203 13734.50 17.48 101.72 11173.57 14.96 148.20 4321.82 174.64 
204 3716.97 19.96 77.40 2792.82 6.10 79.19 1839.65 11.81 
205 7624.55 28.24 164.30 13667.89 18.67 271.95 7861.19 142.15 
206 5533.29 6.99 56.10 8227.38 10.82 102.11 3223.10 48.80 
207 5143.27 17.16 113.37 15264.53 24.57 212.20 6897.74 16.60 
208 10744.47 9.91 104.72 5519.08 8.72 98.97 2964.98 172.48 
212 2810.80 5.71 30.36 5237.50 8.20 74.47 2109.33 48.17 
Mean 12055.64 20.18 138.45 9899.01 14.92 153.93 4517.55 69.00 
Standard 
Deviation 15209.36 15.85 144.55 4560.34 8.44 90.29 2509.94 73.10 
Standard Error 5069.79 5.28 48.18 1520.11 2.81 30.10 836.65 24.37 
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Dietary Data: Placebo Supplementation 
Subject Total Grams 
Energy 
(kcal) Total Fat (g) 
Total 
Carbohydrate (g) Total Protein (g) 
Total Dietary 
Fiber (g) 
201 6765.48 4543.44 169.98 536.34 231.66 51.06 
202 2056.53 1182.31 34.59 142.43 44.05 14.84 
203 3676.24 2567.37 99.90 301.43 113.61 27.32 
204 2107.03 1163.72 36.01 171.26 42.99 15.59 
205 3701.03 2555.67 98.23 335.46 92.57 19.19 
206 968.50 1075.53 46.01 117.48 53.15 9.32 
207 2731.63 3339.44 142.04 367.08 143.56 23.67 
208 2434.72 1277.03 45.05 137.68 64.39 13.87 
212 1585.11 1581.33 49.00 204.11 81.02 19.31 
Mean 2891.81 2142.87 80.09 257.03 96.33 21.57 
Standard 
Deviation 1704.05 1205.76 50.01 139.31 60.78 12.29 
Standard Error 568.02 401.92 16.67 46.44 20.26 4.10 
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Dietary Data: Placebo Supplementation 
   
Subject Linoleic Acid (g) 
Linolenic 
Acid (g) 
Arachidonic 
Acid (g) 
Eicosapentaenoic 
Acid (EPA) (g) 
Docosahexaenoic 
Acid (DHA) (g) 
201 22.10 3.18 0.56 0.01 0.05 
202 6.53 0.53 0.03 0.01 0.01 
203 14.66 1.79 0.21 0.03 0.12 
204 8.03 0.97 0.16 0.01 0.04 
205 16.09 1.82 0.12 0.01 0.03 
206 10.83 1.23 0.06 0.00 0.01 
207 25.96 2.69 0.17 0.05 0.07 
208 6.94 0.69 0.15 0.01 0.03 
212 7.86 0.88 0.19 0.02 0.05 
Mean 13.22 1.53 0.18 0.02 0.05 
Standard 
Deviation 7.05 0.92 0.15 0.02 0.03 
Standard Error 2.35 0.31 0.05 0.01 0.01 
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Dietary Data: Placebo Supplementation 
      
Subject 
Total Vitamin A 
Activity 
(International 
Units) 
Vitamin E 
(Total Alpha-
Tocopherol) 
(mg) 
Vitamin C 
(ascorbic 
acid) (mg) 
Lycopene 
(mcg) 
Zinc 
(mg) 
Selenium 
(mcg) 
Sodium 
(mg) 
Caffeine 
(mg) 
201 64984.94 24.48 320.97 16013.10 34.34 300.25 7490.73 8.68 
202 10226.71 8.25 92.22 6032.92 6.71 48.96 1791.69 2.03 
203 16022.46 14.60 197.50 12333.07 15.68 144.75 4218.60 160.77 
204 6138.41 14.13 87.30 2190.94 5.41 53.98 1756.03 12.96 
205 2917.27 12.03 103.19 3614.98 10.32 116.13 4104.52 206.36 
206 2251.56 5.90 36.42 5090.72 7.37 63.02 2128.48 53.80 
207 4899.61 17.17 101.80 15118.77 20.28 184.52 6299.31 8.80 
208 4212.94 7.63 76.63 5344.13 8.13 77.87 2410.88 125.00 
212 2478.03 7.39 31.41 5405.74 9.78 129.37 3346.17 6.23 
Mean 12681.33 12.40 116.38 7904.93 13.11 124.32 3727.38 64.96 
Standard 
Deviation 20112.68 5.96 90.45 5155.96 9.26 80.33 2038.05 78.53 
Standard Error 6704.23 1.99 30.15 1718.65 3.09 26.78 679.35 26.18 
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Dietary Data: Washout 
Subject Total Grams 
Energy 
(kcal) Total Fat (g) 
Total 
Carbohydrate (g) Total Protein (g) 
Total Dietary 
Fiber (g) 
201 - - - - - - 
202 2882.23 1299.28 32.65 173.73 44.62 18.40 
203 3197.90 2229.40 93.10 220.79 113.19 18.46 
204 1930.81 1485.60 41.44 230.98 56.38 23.94 
205 2374.76 2080.69 81.74 292.40 52.67 12.75 
206 880.39 811.93 34.72 87.17 36.57 6.42 
207 2143.02 2550.93 116.34 252.65 120.03 14.32 
208 3201.98 1183.96 38.62 119.14 59.43 13.65 
212 1586.49 1600.99 53.73 132.81 74.06 7.59 
Mean 2274.70 1655.35 61.54 188.71 69.62 14.44 
Standard 
Deviation 814.56 586.11 31.51 71.87 31.04 5.82 
Standard Error 287.99 207.22 11.14 25.41 10.97 2.06 
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Dietary Data: Washout 
    
Subject Linoleic Acid (g) 
Linolenic 
Acid (g) 
Arachidonic 
Acid (g) 
Eicosapentaenoic 
Acid (EPA) (g) 
Docosahexaenoic 
Acid (DHA) (g) 
201 - - - - - 
202 6.28 0.58 0.04 0.00 0.01 
203 13.05 1.53 0.35 0.09 0.32 
204 8.14 1.08 0.19 0.02 0.09 
205 20.32 2.50 0.05 0.01 0.01 
206 8.13 1.01 0.03 0.00 0.00 
207 19.19 1.90 0.22 0.06 0.09 
208 5.15 0.57 0.27 0.00 0.02 
212 7.88 0.71 0.14 0.01 0.03 
Mean 11.02 1.23 0.16 0.02 0.07 
Standard 
Deviation 5.87 0.69 0.12 0.03 0.11 
Standard Error 2.07 0.24 0.04 0.01 0.04 
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Dietary Data: Washout 
       
Subject 
Total Vitamin A 
Activity 
(International 
Units) 
Vitamin E 
(Total Alpha-
Tocopherol) 
(mg) 
Vitamin C 
(ascorbic 
acid) (mg) 
Lycopene 
(mcg) 
Zinc 
(mg) 
Selenium 
(mcg) 
Sodium 
(mg) 
Caffeine 
(mg) 
201 - - - - - - - - 
202 6616.50 7.86 79.59 7392.08 6.83 57.03 2108.48 4.92 
203 8901.72 10.54 114.69 9610.77 13.45 140.28 3550.94 158.23 
204 13163.91 22.37 162.01 1905.87 8.05 64.54 1915.61 14.86 
205 2736.51 11.74 83.05 9253.64 6.18 97.17 2951.41 85.07 
206 5999.92 4.37 21.22 4085.15 5.36 40.31 1578.35 57.86 
207 3309.85 12.86 57.68 5351.26 17.17 149.31 4451.82 12.60 
208 14491.77 6.12 63.74 5213.52 8.14 84.00 2294.48 353.55 
212 3063.08 12.80 29.56 6646.79 11.15 102.57 2622.11 8.84 
Mean 7285.41 11.08 76.44 6182.39 9.54 91.90 2684.15 86.99 
Standard 
Deviation 4559.55 5.53 45.67 2596.20 4.08 38.67 944.76 119.86 
Standard Error 1612.04 1.96 16.15 917.90 1.44 13.67 334.02 42.38 
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Dietary Data: DHA Supplementation 
Subject Total Grams 
Energy 
(kcal) Total Fat (g) 
Total 
Carbohydrate (g) Total Protein (g) 
Total Dietary 
Fiber (g) 
201 6195.58 3746.27 118.65 514.40 175.22 58.18 
202 1582.56 1439.59 35.54 198.76 60.58 19.90 
203 2649.15 1939.18 76.97 218.93 92.28 19.74 
204 1889.39 1437.29 44.77 204.27 56.00 21.87 
205 2623.45 1921.24 72.19 286.76 41.07 11.25 
206 1240.35 1272.81 45.89 144.18 54.84 9.26 
207 2369.41 2328.40 106.06 222.21 113.14 13.27 
208 4168.53 1367.68 40.67 155.62 65.28 17.59 
212 1623.51 1593.54 47.04 187.10 75.64 10.64 
Mean 2704.66 1894.00 65.31 236.91 81.56 20.19 
Standard 
Deviation 1568.77 773.84 30.24 111.93 41.28 14.96 
Standard Error 522.92 257.95 10.08 37.31 13.76 4.99 
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Dietary Data: DHA Supplementation 
    
Subject Linoleic Acid (g) 
Linolenic 
Acid (g) 
Arachidonic 
Acid (g) 
Eicosapentaenoic 
Acid (EPA) (g) 
Docosahexaenoic 
Acid (DHA) (g) 
201 17.74 2.16 0.44 0.01 0.05 
202 8.04 0.92 0.10 0.07 0.20 
203 11.99 1.21 0.17 0.04 0.06 
204 8.73 1.09 0.24 0.02 0.10 
205 18.62 2.35 0.04 0.00 0.01 
206 11.03 1.43 0.07 0.00 0.01 
207 14.56 1.65 0.19 0.01 0.04 
208 6.37 0.71 0.14 0.01 0.04 
212 7.04 0.81 0.11 0.01 0.02 
Mean 11.57 1.37 0.17 0.02 0.06 
Standard 
Deviation 4.55 0.58 0.12 0.02 0.06 
Standard Error 1.52 0.19 0.04 0.01 0.02 
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Dietary Data: DHA Supplementation 
       
Subject 
Total Vitamin A 
Activity 
(International 
Units) 
Vitamin E 
(Total Alpha-
Tocopherol) 
(mg) 
Vitamin C 
(ascorbic 
acid) (mg) 
Lycopene 
(mcg) 
Zinc 
(mg) 
Selenium 
(mcg) 
Sodium 
(mg) 
Caffeine 
(mg) 
201 48047.47 21.18 332.92 7294.08 26.41 238.53 5842.59 7.56 
202 6968.95 9.67 47.63 14993.36 7.50 97.53 3065.22 3.70 
203 11077.38 15.02 78.81 11149.61 13.66 133.53 3253.59 141.43 
204 13482.97 12.05 131.22 2017.23 6.25 72.31 2033.72 6.47 
205 1650.69 8.79 71.70 2359.42 5.15 57.51 2169.47 106.07 
206 2109.61 15.50 57.25 3517.52 11.83 72.01 2197.95 60.34 
207 4029.20 9.64 55.33 6378.76 15.53 123.17 3691.23 8.06 
208 6798.72 7.48 95.96 5943.88 7.79 78.92 2593.96 383.18 
212 3416.67 16.76 40.56 6614.26 12.46 98.58 2755.26 9.59 
Mean 10842.41 12.90 101.27 6696.46 11.84 108.01 3067.00 80.71 
Standard 
Deviation 14512.54 4.51 91.23 4190.93 6.53 54.87 1176.74 124.18 
Standard Error 4837.51 1.50 30.41 1396.98 2.18 18.29 392.25 41.39 
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Post-24 Incubation: Control with Vehicle Treatment Force (% of Pre-Incubation Maximum Force) 
 
  
Dose of Acetylcholine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 4.5 4 
1 0.00 0.06 -0.06 0.19 3.37 9.19 26.08 49.26 69.77 85.57 96.96 
2 0.00 0.09 0.09 0.34 2.05 9.39 27.92 53.54 76.94 92.66 101.79 
3 0.00 0.00 0.35 0.35 0.83 5.38 21.05 41.10 60.56 77.41 92.61 
4 0.00 0.00 0.00 0.07 0.92 6.24 23.24 43.07 62.90 79.19 93.70 
5 0.00 0.55 1.00 1.37 3.65 17.88 44.62 68.61 83.67 91.33 93.98 
6 0.00 0.31 1.03 3.21 16.55 43.23 70.42 89.45 98.66 103.72 104.76 
7 0.00 0.00 0.16 0.78 6.60 30.15 57.11 78.01 90.75 97.90 100.08 
Mean 0.00 0.14 0.37 0.90 4.85 17.35 38.64 60.44 77.61 89.68 97.70 
Standard 
Deviation 0.00 0.21 0.46 1.11 5.52 14.32 19.17 18.55 14.27 9.61 4.63 
Standard 
Error of the 
Mean 0.00 0.08 0.18 0.42 2.09 5.41 7.25 7.01 5.39 3.63 1.75 
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Post-24 Incubation: Fish Oil Treatment Force (% of Pre-Incubation Maximum 
Force) 
   
  Dose of Acetylcholine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 4.5 4 
1 0.00 0.06 0.06 0.94 1.00 5.97 22.95 44.91 65.38 81.75 94.41 
2 0.00 0.00 -0.07 0.43 1.35 6.45 22.04 41.46 60.31 74.91 83.56 
3 0.00 0.00 0.00 0.32 1.86 6.40 20.50 42.14 61.91 77.80 90.19 
4 0.00 0.13 0.13 0.25 1.50 8.27 25.06 50.13 74.94 94.36 109.52 
5 0.00 -0.36 -0.43 0.36 3.75 25.38 53.64 76.93 93.80 104.04 108.44 
6 0.00 0.24 0.79 1.74 6.58 28.21 52.06 73.85 89.22 98.18 102.85 
7 0.00 0.18 0.36 1.43 10.98 38.30 63.93 85.36 99.20 106.96 110.89 
Mean 0.00 0.03 0.12 0.78 3.86 17.00 37.17 59.25 77.82 91.14 99.98 
Standard 
Deviation 0.00 0.20 0.38 0.60 3.70 13.36 18.55 18.73 16.15 12.95 10.70 
Standard Error 
of the Mean 0.00 0.07 0.14 0.23 1.40 5.05 7.01 7.08 6.10 4.89 4.04 
 288 
Post-24 Incubation: Maximum Force Generated  
(% of Pre-Incubation Maximum Force) 
Tissue Vehicle 
Fish 
Oil 
1 96.96 94.41 
2 101.79 83.56 
3 92.61 90.19 
4 93.70 109.52 
5 93.98 108.44 
6 104.76 102.85 
7 100.08 110.89 
Mean 97.70 99.98 
Standard 
Deviation 4.63 10.70 
Standard 
Error of the 
Mean 1.75 4.04 
 
 
 
Post-24 Incubation: Effective Dose 50 (- log M Acetylcholine) 
Tissue Vehicle 
Fish 
Oil 
1 5.48 5.41 
2 5.53 5.47 
3 5.31 5.38 
4 5.36 5.37 
5 5.94 5.97 
6 6.33 6.01 
7 6.12 6.17 
Mean 5.73 5.68 
Standard 
Deviation 0.40 0.35 
Standard 
Error of the 
Mean 0.15 0.13 
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Post-24 Incubation: Control with Vehicle Treatment Force (% of Pre-Incubation Maximum Force) 
 
  
Dose of 5-Hydroxytryptamine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 4.5 4 
1 0.00 -0.22 -0.11 0.87 12.28 42.50 66.20 70.43 63.37 55.65 53.04 
2 0.00 -0.16 -0.62 -0.16 7.49 39.16 60.22 54.45 45.40 41.65 42.75 
3 0.00 0.53 3.20 30.09 71.77 93.87 102.26 97.47 87.48 80.83 76.70 
4 0.00 0.00 0.57 10.51 52.98 73.86 80.82 76.56 70.31 62.50 56.11 
5 0.00 -0.45 0.68 24.04 60.32 78.57 86.85 85.71 79.59 74.04 68.71 
6 0.00 -0.24 0.48 10.79 45.82 72.12 80.48 74.42 62.79 50.06 41.58 
Mean 0.00 -0.09 0.70 12.69 41.78 66.68 79.47 76.51 68.16 60.79 56.48 
Standard 
Deviation 0.00 0.34 1.32 12.20 26.20 21.47 14.99 14.51 14.69 14.75 14.01 
Standard 
Error of the 
Mean 0.00 0.14 0.54 4.98 10.69 8.76 6.12 5.92 6.00 6.02 5.72 
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Post-24 Incubation: Fish Oil Treatment Force  
(% of Pre-Incubation Maximum Force) 
   
  Dose of 5-Hydroxytryptamine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 4.5 4 
1 0.00 0.00 0.47 1.49 16.34 47.71 70.21 76.47 72.92 68.35 68.07 
2 0.00 -0.08 0.00 1.41 9.96 37.33 69.65 84.31 83.29 74.82 70.90 
3 0.00 0.44 1.40 26.21 66.17 83.70 90.80 91.50 87.29 81.68 81.33 
4 0.00 0.15 1.92 17.78 50.96 77.55 91.57 95.79 92.11 77.01 76.78 
5 0.00 -0.56 -0.28 12.58 60.59 86.65 98.25 101.40 100.00 84.21 83.93 
Mean 0.00 -0.01 0.70 11.89 40.80 66.59 84.10 89.89 87.12 77.21 76.20 
Standard 
Deviation 0.00 0.37 0.93 10.70 25.92 22.51 13.25 9.76 10.09 6.19 6.72 
Standard 
Error of the 
Mean 0.00 0.16 0.42 4.79 11.59 10.07 5.93 4.36 4.51 2.77 3.00 
 291 
Post-24 Incubation: Maximum Force Generated  
(% of Pre-Incubation Maximum Force) 
Tissue Vehicle 
Fish 
Oil 
1 70.43 76.47 
2 60.22 84.31 
3 102.26 91.50 
4 80.82 95.79 
5 86.85 101.40 
6 80.48 
Mean 80.18 89.89 
Standard 
Deviation 14.33 9.76 
Standard 
Error of the 
Mean 5.85 4.36 
 
 
 
Post-24 Incubation: Effective Dose 50 (- log M 5-Hydroxytryptamine) 
Tissue Vehicle 
Fish 
Oil 
1 6.68 6.68 
2 6.73 6.48 
3 7.34 7.29 
4 7.19 7.11 
5 7.30 7.13 
6 7.19 
Mean 7.07 6.94 
Standard 
Deviation 0.29 0.34 
Standard 
Error of the 
Mean 0.12 0.15 
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Post-15 Incubation: Control Treatment Force  
(% of Pre-Incubation Maximum Force) 
   
  
Dose of Acetylcholine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 4.5 4 
1 0.00 -0.21 -0.21 1.04 5.62 19.69 40.78 58.74 71.15 80.10 85.30 
2 0.00 0.12 0.31 0.75 3.43 13.67 32.21 50.50 62.48 67.54 67.98 
3 0.00 -0.06 0.00 0.28 2.49 11.22 28.47 45.77 58.98 67.05 71.75 
4 0.00 0.00 0.08 0.62 3.39 16.41 38.29 57.63 67.10 67.33 62.56 
Mean 0.00 -0.03 0.05 0.67 3.73 15.25 34.94 53.16 64.93 70.51 71.90 
Standard 
Deviation 0.00 0.14 0.21 0.32 1.33 3.64 5.62 6.13 5.32 6.40 9.70 
Standard 
Error of the 
Mean 0.00 0.07 0.11 0.16 0.67 1.82 2.81 3.07 2.66 3.20 4.85 
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Post-15 Incubation: Control with Vehicle Treatment Force (% of Pre-Incubation Maximum Force) 
 
  Dose of Acetylcholine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 4.5 4 
1 0.00 -0.24 -0.16 -0.24 0.49 5.83 18.96 33.47 45.95 55.67 62.80 
2 0.00 -0.09 0.00 0.28 1.94 13.24 31.11 46.76 58.52 66.67 71.94 
3 0.00 -0.27 -0.09 1.79 16.77 41.52 60.81 73.81 82.51 83.50 83.32 
4 0.00 0.88 2.96 8.72 21.20 38.08 53.84 64.64 70.16 72.16 70.96 
5 0.00 0.07 0.07 0.39 1.31 7.73 23.26 39.32 50.00 55.24 56.68 
6 0.00 0.00 0.05 1.04 2.70 14.78 33.77 51.76 64.68 70.64 71.84 
7 0.00 -0.07 -0.07 0.07 2.40 10.30 24.42 39.03 49.54 55.33 57.16 
Mean 0.00 0.04 0.39 1.72 6.69 18.79 35.17 49.83 60.19 65.60 67.82 
Standard 
Deviation 0.00 0.39 1.13 3.16 8.53 14.71 16.04 14.73 13.17 10.81 9.54 
Standard 
Error of the 
Mean 0.00 0.15 0.43 1.19 3.22 5.56 6.06 5.57 4.98 4.09 3.61 
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Post-15 Incubation: Soybean Oil Treatment Force (% of Pre-Incubation Maximum Force) 
  
  Dose of Acetylcholine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 4.5 4 
1 0.00 -0.45 0.15 5.65 26.28 49.10 68.45 81.85 89.98 93.30 93.22 
2 0.00 0.13 1.86 11.97 31.52 53.46 74.34 89.63 96.94 99.73 99.07 
3 0.00 -0.16 0.47 3.57 19.53 44.19 65.74 82.79 89.92 92.09 91.63 
4 0.00 -0.31 0.63 7.85 31.24 55.26 75.35 87.28 93.56 96.39 97.17 
5 0.00 -0.22 0.00 4.29 25.87 48.12 56.91 68.96 75.54 78.42 78.20 
6 0.00 -0.33 0.25 7.77 34.88 60.91 80.83 94.30 103.47 106.28 103.31 
7 0.00 0.63 3.07 11.66 28.93 50.27 69.08 82.37 90.51 91.86 89.06 
8 0.00 0.13 0.19 0.76 2.40 12.65 31.18 50.92 66.86 77.17 82.16 
9 0.00 0.75 1.71 3.54 7.45 15.96 29.46 44.40 57.58 66.79 72.58 
10 0.00 0.00 0.16 0.85 4.35 15.85 32.40 48.80 61.23 68.14 71.33 
Mean 0.00 0.02 0.85 5.79 21.24 40.58 58.37 73.13 82.56 87.02 87.77 
Standard 
Deviation 0.00 0.41 1.02 3.98 12.16 18.34 19.92 18.57 16.03 13.52 11.20 
Standard 
Error of the 
Mean 0.00 0.13 0.32 1.26 3.85 5.80 6.30 5.87 5.07 4.28 3.54 
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Post-15 Incubation: Fish Oil Treatment Force  
(% of Pre-Incubation Maximum Force) 
   
  Dose of Acetylcholine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 4.5 4 
1 0.00 -0.42 -0.34 0.68 9.68 32.85 53.14 67.66 77.16 83.36 84.72 
2 0.00 0.14 0.29 0.57 2.93 17.51 40.60 59.19 72.19 81.13 85.85 
3 0.00 -0.39 0.29 4.55 27.62 54.07 76.36 92.05 100.87 105.23 107.36 
4 0.00 -0.23 1.04 8.24 28.65 52.67 72.62 85.15 93.85 92.92 91.76 
5 0.00 -0.16 0.24 6.05 26.37 50.16 69.92 84.11 93.31 98.39 100.32 
6 0.00 -0.39 -0.26 1.29 15.44 38.48 60.10 75.80 84.94 90.48 91.63 
7 0.00 -0.22 0.00 4.29 25.87 48.12 56.91 68.96 75.54 78.42 78.20 
8 0.00 -0.33 0.25 7.77 34.88 60.91 80.83 94.30 103.47 106.28 103.31 
9 0.00 0.63 3.07 11.66 28.93 50.27 69.08 82.37 90.51 91.86 89.06 
10 0.00 0.07 0.29 0.43 1.64 11.62 29.58 47.90 62.72 72.20 77.05 
11 0.00 0.11 0.28 0.83 4.02 16.39 34.82 53.85 68.92 78.49 83.44 
Mean 0.00 -0.11 0.47 4.21 18.73 39.37 58.54 73.76 83.95 88.98 90.25 
Standard 
Deviation 0.00 0.32 0.94 3.85 12.26 17.29 17.35 15.52 13.52 11.29 9.93 
Standard 
Error of the 
Mean 0.00 0.10 0.28 1.16 3.70 5.21 5.23 4.68 4.08 3.40 2.99 
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Post-15 Incubation: Maximum Force Generated  
(% of Pre-Incubation Maximum Force) 
Tissue Control Vehicle 
Soybean 
Oil 
Fish 
Oil 
1 85.2982 62.80 93.2982 84.7199 
2 67.9775 71.94 99.734 85.847 
3 71.7523 83.50 92.093 107.364 
4 67.3344 72.16 97.1743 93.8515 
5 56.68 78.4183 100.323 
6 71.84 106.281 91.6345 
7 57.16 91.8626 78.4183 
8 82.1632 106.281 
9 72.5763 91.8626 
10 71.3287 77.0492 
11 83.4433 
Mean 73.0906 68.01 88.493 90.9813 
Standard 
Deviation 8.36848 9.66 11.809 10.361 
Standard 
Error of 
the Mean 4.18424 3.65 3.73432 3.12396 
 
 
Post-15 Incubation: Effective Dose 50 (- log M Acetylcholine) 
Tissue Control Vehicle 
Soybean 
Oil 
Fish 
Oil 
1 5.9399 5.55 6.5532 6.2615 
2 5.9396 5.84 6.6028 5.9202 
3 5.7819 6.46 6.4473 6.5119 
4 6.115 6.57 6.6508 6.6271 
5 5.84 6.6721 6.5047 
6 5.93 6.6586 6.3369 
7 5.85 6.6182 6.6721 
8 5.7392 6.6586 
9 5.7432 6.6182 
10 5.8993 5.7473 
11 5.8145 
Mean 5.9441 6.01 6.35847 6.33391 
Standard 
Deviation 0.13608 0.37 0.39718 0.35181 
Standard 
Error of 
the Mean 0.06804 0.14 0.1256 0.10608 
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Post-4 Incubation: Control Treatment Force (% of Pre-Incubation Maximum Force) 
 
  Dose of Acetylcholine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 
1 0.00 0.00 0.18 11.92 35.32 53.81 70.29 83.87 93.87 
2 0.00 0.40 2.61 18.79 37.69 57.39 74.17 85.93 93.07 
3 0.00 0.00 4.56 24.42 44.20 63.71 80.14 91.23 98.28 
Mean 0.00 0.13 2.45 18.38 39.07 58.30 74.87 87.01 95.07 
Standard 
Deviation 0.00 0.23 2.20 6.26 4.60 5.01 4.96 3.80 2.81 
Standard Error 
of the Mean 0.00 0.13 1.27 3.61 2.65 2.90 2.86 2.19 1.62 
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Post-4 Incubation: Control with Vehicle Treatment Force  
(% of Pre-Incubation Maximum Force) 
  Dose of Acetylcholine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 
1 0.00 0.00 0.00 13.45 32.05 51.63 71.81 87.93 97.73 
2 0.00 -0.18 0.91 9.15 26.35 45.47 65.78 85.45 99.54 
3 0.00 0.47 5.22 16.79 33.02 50.93 68.47 82.37 92.54 
4 0.00 1.04 23.75 38.96 55.52 69.79 81.35 91.15 97.29 
5 0.00 0.43 5.18 27.86 50.86 66.74 79.59 90.28 97.62 
Mean 0.00 0.35 7.01 21.24 39.56 56.91 73.40 87.44 96.94 
Standard 
Deviation 0.00 0.48 9.66 12.09 12.81 10.69 6.83 3.60 2.62 
Standard 
Error of the 
Mean 0.00 0.21 4.32 5.41 5.73 4.78 3.05 1.61 1.17 
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Post-4 Incubation: Soybean Oil Treatment Force (% of Pre-Incubation Maximum Force) 
  Dose of Acetylcholine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 
1 0.00 0.25 5.11 21.30 39.98 60.65 79.83 94.77 102.12 
2 0.00 -0.42 -0.34 10.14 28.13 47.72 66.55 82.77 92.82 
3 0.00 0.27 0.69 14.42 37.09 58.65 78.02 94.23 103.85 
4 0.00 0.21 5.37 27.28 51.77 71.43 86.57 97.64 104.73 
5 0.00 15.38 25.41 34.62 45.33 56.32 66.62 73.35 77.47 
6 0.00 0.25 9.27 26.31 50.93 69.06 81.53 90.73 96.04 
Mean 0.00 2.66 7.59 22.34 42.20 60.64 76.52 88.91 96.17 
Standard 
Deviation 0.00 6.24 9.40 8.98 9.02 8.68 8.21 9.19 10.28 
Standard 
Error of the 
Mean 0.00 2.55 3.84 3.67 3.68 3.54 3.35 3.75 4.20 
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Post-4 Incubation: Fish Oil Treatment Force (% of Pre-Incubation Maximum Force) 
 
  Dose of Acetylcholine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 
1 0.00 0.83 2.28 21.70 39.25 58.67 76.53 90.76 97.20 
2 0.00 0.87 4.87 24.57 45.45 61.26 76.52 87.88 96.21 
3 0.00 0.48 1.75 9.79 26.97 47.57 66.27 83.29 96.58 
4 9.10 17.06 27.01 43.70 60.95 75.83 88.44 97.16 102.94 
5 0.00 2.82 17.00 39.73 59.33 74.45 87.07 95.72 100.00 
Mean 1.82 4.41 10.58 27.90 46.39 63.56 78.96 90.96 98.59 
Standard 
Deviation 4.07 7.13 11.08 13.85 14.22 11.77 9.06 5.69 2.85 
Standard 
Error of the 
Mean 1.82 3.19 4.95 6.19 6.36 5.26 4.05 2.54 1.28 
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Post-4 Incubation: Maximum Force Generated  
(% of Pre-Incubation Maximum Force) 
Tissue Control Vehicle 
Soybean 
Oil 
Fish 
Oil 
1 93.865 97.73 102.1171 97.1963 
2 93.0653 99.54 92.82095 96.2121 
3 98.2803 92.54 103.8462 96.5792 
4 97.29 104.7261 102.938 
5 97.62 77.47253 100 
6 96.0371 
Mean 95.0702 96.94 96.16998 98.5852 
Standard 
Deviation 2.80863 2.62 10.27937 2.85205 
Standard 
Error of 
the Mean 1.62156 1.17 4.196534 1.27548 
 
 
 
Post-4 Incubation: Effective Dose 50 (- log M Acetylcholine) 
Tissue Control Vehicle 
Soybean 
Oil 
Fish 
Oil 
1 6.6907 6.57 6.7526 6.7868 
2 6.8028 6.35 6.5239 6.9487 
3 6.9232 6.63 6.6565 6.4335 
4 7.18 7.015 7.3082 
5 7.08 7.2609 7.1936 
6 7.0928 
Mean 6.80557 6.76 6.883617 6.93416 
Standard 
Deviation 0.11627 0.35 0.283374 0.34634 
Standard 
Error of 
the Mean 0.06713 0.16 0.115687 0.15489 
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Post-4 Incubation: Control Treatment Force (% of Pre-Incubation Maximum Force) 
 
  Dose of Acetylcholine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 
1 0.00 0.27 17.54 32.73 70.59 91.10 106.83 110.88 112.23 
2 0.00 0.56 20.56 51.26 75.07 87.81 94.33 94.88 92.37 
3 0.00 0.08 0.17 28.67 64.72 84.99 96.01 99.41 98.22 
Mean 0.00 0.30 12.75 37.55 70.13 87.97 99.06 101.72 100.94 
Standard 
Deviation 0.00 0.24 11.00 12.04 5.19 3.06 6.79 8.25 10.20 
Standard 
Error of the 
Mean 0.00 0.14 6.35 6.95 3.00 1.77 3.92 4.76 5.89 
 
 
Post-4 Incubation: Control with Vehicle Treatment Force (% of Pre-Incubation Maximum 
Force) 
  Dose of Acetylcholine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 
1 4.24 9.28 18.92 36.43 65.87 85.59 97.70 100.62 99.73 
2 1.20 3.00 21.46 43.69 71.16 88.33 97.42 99.83 100.17 
Mean 2.72 6.14 20.19 40.06 68.51 86.96 97.56 100.22 99.95 
Standard 
Deviation 2.15 4.44 1.79 5.14 3.74 1.94 0.20 0.56 0.31 
Standard 
Error of the 
Mean 1.52 3.14 1.27 3.63 2.64 1.37 0.14 0.40 0.22 
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Post-4 Incubation: Soybean Oil Treatment Force (% of Pre-Incubation Maximum Force) 
  Dose of 5-Hydroxytryptamine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 
1 0.00 4.21 13.36 28.32 56.28 81.55 93.54 98.11 94.77 
2 32.31 40.96 48.65 59.74 79.74 95.72 106.90 110.66 109.87 
3 0.00 0.28 14.09 33.21 58.30 79.48 90.76 94.03 93.10 
Mean 10.77 15.15 25.36 40.42 64.77 85.58 97.07 100.93 99.25 
Standard 
Deviation 18.66 22.44 20.17 16.90 13.00 8.84 8.63 8.66 9.24 
Standard 
Error of the 
Mean 10.77 12.95 11.64 9.76 7.50 5.10 4.98 5.00 5.33 
 
 
Post-4 Incubation: Fish Oil Treatment Force (% of Pre-Incubation Maximum Force) 
 
  Dose of 5-Hydroxytryptamine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 
1 0.00 -0.19 11.03 32.62 62.41 84.66 96.13 100.64 99.42 
2 0.00 9.62 17.91 29.81 57.12 76.06 88.55 93.98 93.17 
Mean 0.00 4.71 14.47 31.22 59.77 80.36 92.34 97.31 96.30 
Standard 
Deviation 0.00 6.94 4.87 1.99 3.74 6.07 5.36 4.71 4.42 
Standard 
Error of the 
Mean 0.00 4.91 3.44 1.41 2.64 4.30 3.79 3.33 3.12 
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Post-4 Incubation: Maximum Force Generated  
(% of Pre-Incubation Maximum Force) 
Tissue Control Vehicle 
Soybean 
Oil 
Fish 
Oil 
1 112.23 100.62 98.11 100.64 
2 94.88 100.17 110.66 93.98 
3 99.41 94.03 
Mean 102.17 100.40 100.93 97.31 
Standard 
Deviation 9.00 0.32 8.66 4.71 
Standard 
Error of 
the Mean 5.20 0.22 5.00 3.33 
 
 
 
Post-4 Incubation: Effective Dose 50 (- log M 5-Hydroxytryptamine) 
Tissue Control Vehicle 
Soybean 
Oil 
Fish 
Oil 
1 7.21 7.24 7.14 7.23 
2 7.59 7.44 7.23 7.19 
3 7.21 7.26 
Mean 7.34 7.34 7.21 7.21 
Standard 
Deviation 0.22 0.14 0.06 0.03 
Standard 
Error of 
the Mean 0.13 0.10 0.04 0.02 
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Post-4 Incubation: Control with Vehicle Treatment Force (% of Pre-Incubation Maximum Force) 
 
  Dose of Acetylcholine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 4.5 4 
1 0.00 -0.33 -0.11 10.34 29.92 48.39 65.29 79.20 88.77 96.11 99.67 
2 0.00 -0.11 0.00 15.50 32.75 50.44 65.17 78.28 87.55 94.76 100.44 
Mean 0.00 -0.22 -0.06 12.92 31.34 49.41 65.23 78.74 88.16 95.43 100.05 
Standard 
Deviation 0.00 0.16 0.08 3.65 2.00 1.45 0.08 0.65 0.86 0.95 0.54 
Standard 
Error of the 
Mean 0.00 0.11 0.06 2.58 1.41 1.02 0.06 0.46 0.61 0.67 0.39 
 
Post-4 Incubation: Soybean Oil Treatment Force (% of Pre-Incubation Maximum Force) 
  
  Dose of Acetylcholine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 4.5 4 
1 0.00 -0.14 0.14 3.33 24.20 49.42 69.86 84.49 93.77 100.14 100.72 
2 0.00 0.11 0.44 15.56 33.30 51.25 67.57 79.22 87.27 93.36 98.91 
3 0.00 -0.15 -0.07 11.68 30.51 46.28 61.98 75.52 85.71 93.97 99.33 
Mean 0.00 -0.06 0.17 10.19 29.34 48.98 66.47 79.74 88.92 95.83 99.66 
Standard 
Deviation 0.00 0.15 0.26 6.25 4.66 2.51 4.05 4.51 4.27 3.75 0.95 
Standard 
Error of the 
Mean 0.00 0.09 0.15 3.61 2.69 1.45 2.34 2.60 2.47 2.17 0.55 
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Post-4 Incubation: Fish Oil Treatment Force (% of Pre-Incubation Maximum Force) 
  
  Dose of Acetylcholine (- log M) 
Tissue 9 8.5 8 7.5 7 6.5 6 5.5 5 4.5 4 
1 0.00 0.58 0.93 14.25 36.15 54.81 70.57 83.08 92.24 96.18 97.22 
2 0.00 0.46 0.69 4.12 23.25 44.90 63.23 77.43 87.51 95.07 99.89 
3 0.00 0.00 0.78 14.90 37.44 55.31 71.89 84.20 93.01 97.80 99.61 
Mean 0.00 0.35 0.80 11.09 32.28 51.67 68.56 81.57 90.92 96.35 98.91 
Standard 
Deviation 0.00 0.31 0.12 6.04 7.84 5.87 4.67 3.63 2.97 1.37 1.47 
Standard Error 
of the Mean 0.00 0.18 0.07 3.49 4.53 3.39 2.69 2.09 1.72 0.79 0.85 
 
 307 
Post-4 Incubation: Maximum Force Generated  
(% of Pre-Incubation Maximum Force) 
Tissue Vehicle 
Soybean 
Oil 
Fish 
Oil 
1 99.67 100.725 97.219 
2 100.44 98.9119 99.8855 
3 99.3304 99.6114 
Mean 100.05 99.6556 98.9053 
Standard 
Deviation 0.54 0.94915 1.46678 
Standard 
Error of 
the Mean 0.39 0.54799 0.84684 
 
 
 
Post-4 Incubation: Effective Dose 50 (- log M Acetylcholine) 
Tissue Vehicle 
Soybean 
Oil 
Fish 
Oil 
1 6.51 6.4684 6.7004 
2 6.61 6.6538 6.3876 
3 6.4931 6.7101 
Mean 6.56 6.53843 6.59937 
Standard 
Deviation 0.07 0.10067 0.18346 
Standard 
Error of 
the Mean 0.05 0.05812 0.10592 
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Percent Relaxation of Contraction with 10-6 M Acetylcholine 
Tissue Control Vehicle 
Soybean 
Oil 
Fish 
Oil 
1 2.57 5.37 4.43 7.51 
2 0.80 5.33 7.38 7.77 
3 2.20 2.61 7.47 
Mean 1.69 4.30 4.81 7.58 
Standard 
Deviation 1.24627 1.82054 2.406545 0.16352 
Standard 
Error of 
the Mean 0.88125 1.05109 1.389419 0.09441 
 
 
Percent Relaxation of Contraction with 10-7 M Acetylcholine 
Tissue Vehicle 
Soybean 
Oil Fish Oil 
1 2.83 7.86 4.49 
2 10.92 3.67 4.52 
3 5.93 7.67 2.87 
4 3.73 6.46 2.99 
Mean 5.85 6.42 3.72 
Standard 
Deviation 3.62386 1.92884 0.913488 
Standard 
Error of 
the Mean 1.81193 0.96442 0.456744 
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Percent Relaxation of Contraction with 10-6 M 5-Hydroxytryptamine 
Tissue Control Vehicle 
Soybean 
Oil 
Fish 
Oil 
1 1.03 2.16 3.69 6.13 
2 2.20 4.48 6.30 4.12 
3 1.46 2.21 2.58 6.15 
4 1.40 1.56 2.19 7.44 
5 2.87 4.55 4.32 21.31 
6 5.11 3.98 9.13 
7 1.35 
8 18.50 
9 7.47 
Mean 1.79 2.99 3.82 9.03 
Standard 
Deviation 0.73 1.41 1.63 6.96 
Standard 
Error of 
the Mean 0.33 0.63 0.73 3.11 
 
 
Percent Relaxation of Contraction with 10-7 M 5-Hydroxytryptamine 
Tissue Vehicle 
Soybean 
Oil Fish Oil 
1 1.87 6.69 3.62 
2 -1.57 1.73 3.00 
3 -0.63 5.10 -2.24 
4 2.20 -0.78 0.94 
5 0.57 6.28 
6 1.08 4.49 
7 4.98 4.30 
Mean 1.21 3.19 2.91 
Standard 
Deviation 2.13 3.36 2.79 
Standard 
Error of 
the Mean 0.80 1.68 1.05 
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